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A Actin  alpha actin 
 
AdoMet   adenosylmethionine 
 
Alu a short DNA stretch originally defined by the action of Alu restriction 
endonuclease; one of the most abundant mobile  primate genome 
elements 
 
CGI   CpG island 
 
CpG   CG dinucleotide 
 
DMR   differentially methylated region 
 
DNMT   DNA methyltransferase 
 
Dpc   day post coitum 
 
Ed   embryonic day 
 
H19   a gene for non-coding RNA, expressed from maternal allele only 
 
H3Lys9  3rd histone lysine position 9 
 
HDAC   histone deacetylase 
 
IAP   intracisternal A particle 
 
 9 
ICF immunodeficiency, centromere instability, facial anomalies 
syndrome 
ICR   imprinting control region 
 
IGF 2   insulin growth factor 2 
 
LINE-1  LINE-1, long interspersed elements 
 
LFA-1   Lymphocyte function-associated antigen 
 
Lit1   long intronic transcript 
 
mC   methyl cytosine 
 
MyLC   myosin light chain 
 
NESP55  neuroendocrine secretory protein 55 
 
ORF   open reading frame 
 
Peg3   paternally expressed gene 3 
 
PGC   primordial germ cells 
 
SAH   S-adenosylhomocysteine 
 
Snrpn DMR1 small nuclear ribonucleoprotein polypeptide differentially methylated 
region 1, alternatively Snrpn D1 
 
SVA   a composite repetitive element named after its constitutive elements 
SINE, VNTR and ALU 
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TSS   transcription start site 
 
Xa   active X chromosome 
 





Es sind zum Teil erhebliche Unterschiede der DNS-Methylierung an einzelnen Loci und 
repetitiven Elementen beim Menschen in verschiedenen Zellen und Geweben 
beobachtet worden.  
Es wurde ebenfalls über mehrere inter-und intrafragmentäre Korrelationsfälle des DNS-
Methylierungsmusters berichtet. Um das Ausmaß und die Reproduzierbarkeit solcher 
Korrelation zu untersuchen analysierten wir die Korrelation der Methylierung zwischen 
sieben verschiedenen Loci in neun verschiedenen Geweben in einer Population von 100 
gesunden sieben Wochen alten CD1 Mäuse. Wir haben hochquantitative Methoden zur 
genauen Messung der Methylierung bei zwei einzelnen Loci in Promoter des Alpha-
Aktin und der leichten Myosin-Kette, an drei unterschiedlich methylierten Regionen der 
Peg3, SNRPN und LIT1-Genen mit imprinted Loci, und an zwei repetitiven Elementen in 
den LINE-1 und IAP-LTR-Genen in den verschiedenen Geweben eingesetzt. 
In dieser Mäusepopulation haben wir geschlechtsabhängige Methylierungsmuster 
sowie intergewebliche Korrelation an mehreren Loci im Gehirn und Milz beobachtet. Da 
die Korrelation zwischen Geweben bisher selten beschrieben wurde, haben wir die 
Ergebnisse durch erneute Analyse unter Verwendung von SIRPH und 
Pyrosequenzierung für Milz (intergewebliche Korrelation) und Zungenmuskulatur 
(geschlechtsassozierte Korrelation) bestätigt, die Korrelationsmuster konnten auch mit 
diesen Methoden nachgewiesen werden. Diese Experimente sind hier ausführlich 
geschildert.  
Bei ähnlichen Messungen drei Monate später und mit einer anderen, unter 
ähnlichen Bedingungen gezüchteten Mäusepopulation, konnten keine gewebs- oder 
geschlechtsabhängige Korrelationsmuster nachgewiesen werden. Hinsichtlich der 
Größe und Variabilität des Epigenoms sind hier zusätzliche Untersuchungen, die eine 
größere Anzahl von Loci und eine größere Population umfassen, erforderlich, um 




Waddington first described epigenetics in 1942, advancing the idea that genotype 
programs phenotypic changes (Feinberg, 2007). Later, many other ideas and 
experimental evidence began to emerge from it, cleaving the original idea into multiple 
fields of research. At present, epigenetics defines the broad category of information 
heritable through cell divisions, and possibly between generations (Rakyan et al., 2001), 
which is independent of the DNA sequence. What is truly remarkable in the cell, is that 
over a meter of DNA is not only packed into a nucleus, but this compaction mechanism 
also allows some areas to be transcribed, while at the same time repressing others 
(Ducasse and Brown, 2006). 
Two main mechanisms known so far to achieve this state of functional compaction are 
histone modifications and DNA methylation. Histones are instrumental in forming the 
chromatin structure by winding DNA onto their octamers. Various histone modifications, 
such as methy-, acety-, phosphorylation, SUMOylation ADP-ribosylation change the 
structure of the nucleosome and recruit various regulatory complexes (Jenuwein, Allis, 
2001; Strahl, Allis, 2000)  
The focus of this work is DNA methylation at specific loci in different tissues in a 
relatively small outbred mice population. Discovered in 1950 in calf thymus (Hotchkiss, 
1948), DNA methyation is the covalent attachment of a methyl group to the 5th position 
of the pyrimidine ring of a cytosine or adenine residue (Fig.1). In eukaryotes it is limited 
almost exclusively to cytosines, and mammal DNA in somatic cells is methylated mainly 
in the context of CpG dinucleotides. (Weber and Schuebeler, 2007). The methyl group 
comes from s-adenosylmethionine, a major methyl group donor that modifies 
macromolecules (DNA, RNA, proteins) and is a precursor to many vital molecules 
(dopamine, norepinephrine) (Brosnan et al., 2007). The reaction itself is catalyzed by 
DNA methyltransferases, or DNMT's. Four are known to date (Brosnan et al., 2007; Katz 
et al., 2003; listed in more detail in section 1.2.2, page 9). This gives us a source of the 
process – adenosylmethionine (AdoMet) ; the target – cytosine in a CpG dinucleotide; 
and the means – DNMT's (Figures 1, 2). 
A process usually results in a functional outcome, and in this case the outcomes are a 
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rainbow of functions, including but not limited to: 
 Gene imprinting (Feinberg, 2007),  
 Silencing of foreign DNA (Jaenisch and Bird, 2003),  
 Repression of gene expression (Feinberg, 2007),  
 
All the above processes link directly to such fundamental themes as ontogenesis, 
ageing, cancer diagnostic and therapy, the basis of interindividual phenotype differences 
despite very close genotype and vast intraindividual differences between cells and 
tissues of the same organism, where genotype is identical. 
Yet much more work is still needed to achieve a systemic understanding of how 
epigenetics influences genesis and phenotype in a given organism, and to determine the 
degree of influence of various environment factors (Jirtle and Skinner, 2007). 
 
1.2 Methylation – substrates and enzymes 
 
1.2.1 S-Adenosylmethionine (SAM) 
 
Adenosylmethionine, or AdoMet, is the methyl group donor for DNA methylation. The 
dietary precursors to synthesis of S-adenosylmethionine are B group vitamins, folate, 
vitamin B-12, choline and methionine, generally referred to as lipotropes. The whole 
synthesis process is part of one-carbon metabolism, in which S-AdoMet serves as a 
carbon-group donor in more than 80 reactions; of greater importance are two major 
reaction groups, namely those of nucleotide synthesis and those of methylation, not only 
genomic DNA but also proteins, phospholipids, RNA and viral DNA. (Brosnan et al., 
2007) 
The synthesis of S-adenosylmethionine is facilitated by AdoMet synthetase; the 
adenosyl portion of ATP is transfered to methionine, as schematically shown in Fig.1. 
(Percipalle and Visa, 2006). AdoMet exists in two stereoisomeric forms, (S,S)-AdoMet 
and (R,S)-AdoMet. The S,S enantiomer is biologicaly active, while R,S is an inhibitor of 
methylases; it constitutes about 3 % of all AdoMet in mouse liver (Percipalle and Visa, 
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2006). Upon donating the methyl group, S-AdoMet becomes S-adenosylhomocysteine 
(SAH) (Brosnan et al., 2007). SAH, in turn, acts as an inhibitor for its own synthesis. 
That is why S-AdoMet:SAH ratio can be used to evaluate the methylation capability of a 










Fig. 1: Simplified scheme of adenosylmethionine synthesis  
 
1.2.2 DNMT's, DNA methyltransferases 
 
Three DNMT's are known in mammals: DNMT1, DNMT2, and DNMT3, named so by 
discovery timing; all share a number of conserved domains (Weber and Schuebeler, 
2005; Attwood et al., 2002).  
The first eukaryotic DNA methyltransferase, DNMT1, has been discovered in 1988 and 
shares a similarity with bacterial methyltransferases. The protein is 1620 amino acids 
long and has a number of functional domains. Among these, some have been identified 
that facilitate the protein's import into the  nucleus and some that are needed for its 
association with DNA (Weber and Schuebeler, 2005; Attwood et al., 2002; Goll and 
Bestor 2005). Since then, many more methyltransferases have been discovered by 
sequence similarity, in a number of organisms - mice, frogs, and bees to name some.  It 
has been shown that DNMT1 exhibigted 5 to 30 fold greater affinity for hemimethylated 
DNA, and it was therefore ascribed the maintenance methyltransferase activity. The 
activity of DNMT1A on unmethylated substrates exceeds that of DNMT3A and 
DNMT3B, which are supposed to be the main de novo DNA methyltransferases.  
DNMT1 is degraded in G0 phase; it also tends to be more concentrated in cycling cells. 
S-Adenosylmethionine S-Adenosylhomocysteine 
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Oocytes are an exception, in that they contain high concentrations of DNMT1 in its 
shortened and degradation-resistant form, the 118 amino acid shorter DNMT1o. This 
form is bound by annexin V, a phospholipid binding protein, and retained in the 
cytoplasm of the oocyte and early embryo (Goll and Bestor, 2005). A truncated form of 
DNMT1 also exists in male germ cells. There have been suggestions DNMT1o is 
needed to maintain imprinted loci methylation at the eight cell preimplantation stage 
(Howell et al., 2001).  
DNMT2, also discovered by sequence similarity, is found in all organisms that have 
members of the DNMT1 and DNMT3 families. The protein with all characteristic catalytic 
methyltransferase motifs is  expressed in most mammalian tissues. DNMT2 has been 
shown to methylate tRNA and also have some weak activity on DNA. Its biological 
significance is unclear, as both insect and animal knockouts remained viable and 
without obvious defects (Jeltsch et al., 2006; Goll and Bestor, 2005).  
The DNMT3 family has an affinity for unmethylated CG dinucleotdes, which identifies 
them as de novo DNMTs. Their structural differences led some authors to suggest that 
DNMT3A is distributive, while 3B is processive (Gowher and Jeltsch, 2002 ). Knockout 
experiments have reavealed that DNMT3A null mice live up to four weeks, then die with 
signs of aganglionic megacolon and azoospermia in males. DNMT3B null exhibited 
developmental arrest between ED 14.5 and 18.5, and mice defficient in both 3A and 3B 
underwent developmental arrest at between ED 8.5-9.5 (Okano et al., 1999). Another 
experiment led to conclude that mice mutant for DNMT3B die at about 9.5 dpc (Chen et 
al., 2002). 
 Point mutations in DNMT3B cause ICF syndrome (immunodeficiency, centromere 
instability, facial anomalies) (Xu et al., 1999). In ICF, demethylation of satelite DNA on 
chromosomes 1,9, and 16 causes multiple long chromosomal arms; this instability is 
best observed in T  lymphocytes, and accompanied by immunodeficiency – as a result, 
most patients die of infectious diseases at an early age.  
DNMT3L (DNMT3-like) is expressed specifically in germ cells. (Aapola et al., 2000). It 
participates in establishment of maternal imprints in the oocyte and methylation of 
dispersed repeated sequences the prospermatogonia. DNMT3L knockouts are viable, 
but sterile in both sexes. Although DNMT3L has not been shown to participate in DNA 
methylation directly, its role as as an enhancer of DNMT3A and 3B activity has been 
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backed by experimental evidence (Fraga and Esteller 2007). DNMT3L is expressed in 
oocytes after meiotic recombination and prospermatogonia. Its absence does not 
interfere with oogenesis or early embriogenesis (if the male genome portion is 
DNMT3L+); male germ cells defficient in DNMT3L proceed to apoptosis via abnormal 
synapsis or asynapsis. It seems essential for male meiosis, while female meiosis occurs 
normally in its absence. (Bour'chis and Bestor, 2004).  
The reason for male germ cell instability without DNMT may be the awakening and 
expression of normally silent transposons, such as Line-1 and Iap, which in turn causes 
chromosomal assymetry and synaptic instability. DNMT3L knockout experiment results 
are also sex dependent. In females, its deletion results in the absence of maternal 
methylation imprints, leaving retrotransposons methylated. This leads to biallelic 
expression of normally silenced genes and eventual embryonic development failure with 
death until mid-gestation. In males, the methylation of retrotransposons is lost, resulting 
in their expression, especially Line-1(long interspersed elements) and Iap (intracisternal 
A particle), which then led to synapsis failure at meiotic prophase and apoptosis before 
pachytene (Fraga and Esteller, 2007). The paternally methylated DMRs (differentialy 
methylated regions, often associated with gene promoters and imprinting) stayed 
methylated, while retrotransposons were not properly inactivated.  
DNMT3L and 3A seem to be cooperating in the germ cell line, their function being de 
novo methylation, namely the establishment of paternal imprints (Kaneda et al., 2004; 
Chedin et al., 2002).  
DNMTs also bind to histone deacetylases (HDACs), and can target them to regions of 
gene silencing. Histone deacetylation at lysine tails that stick out of the DNA-histone 
chain is one of the molecular mechanisms associated with silencing. Transcription 
corepressors, HDACs and chromatin remodeling proteins bind to hypermethylated DNA 




1.2.3 CpG - quantity; standalone and distribution 
 
The target of methylation in mammalian DNA is cytosine residue at its 5' position. Most 
mC in mammals is also in the context of 5'CpG3', and enzymatically maintained in this 
state during cell divisions.  
CpG dinucleotides are found in the mouse genome at a frequency which is less than 
statistically expected. They are found at about 20 % of expected frequency. This could 
be explained by the tendency of methylcytosine to be deaminated to thymine, a 
mismatch which is consequently repaired to form a TpG dinucleotide (CpA on 
complementary strand). At some areas, however, the C and G nucleotide content is 
about 64 %, while the genome average is 42 %. These areas are known as CpG islands 
(CGIs). CGIs can be classified according to their position, as associated with a promoter 
at the 5' end of a gene, and not asociated with known promoters. The two groups are 
not strictly separated, as about 5 % of promoter-associated CGIs are also due to Alus. 
Ca. 60 % of human genes are associated with CGI, including all housekeeping genes 
and about half of tissue-specific genes. In mouse, about 88 % of imprinted genes are 
associated with CGIs (Attwood et al., 2001). A CGI is usually about 1 kb long,  and 
found at the 5' end of the gene it regulates; it is found in the context of transcriptionally 
active chromatin. Since their discovery 20 years ago, CpG islands have been a reliable 
indicator for gene promoters. The CpG islands make up to 2 % of the whole genome. 
They are associated with promoters and are less methylated than the “loose” non-
clustered CG dinucleotides, which are associated with transposable elements (LINE-1 
and Alu, for example) - these are largely methylated. Notably, the housekeeping genes 
are associated with CGI's, while only one out of four tissue-specific genes has one CGI 
overlapping with its transcription start site (TSS). (43). CpG-islands are originaly defined 
as an area with a length of more than 200 bp, including a CG-content over 50 % and a 
ratio of at least observerd CpG/expected CpG ObsCpG/ExpCpG x 0.6. The ratio was 







(Gardiner-Garden et al., 1987). This definition has the drawback that it makes it difficult 
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to distinguish between CpG-islands and the approximately 1,000,000 Alu copies per 
haploid genome. The current criterion requires a DNA sequence of at least 500 bp, a 
GC-content of 55 % and an ObsCpG/ExpCpG ratio higher or equal to 0.65, respectively 

















Fig. 2: DNA bases and the relative quantity of methylated cytosines in the genome 
(Mouse genome database, http://www.informatics.jax.org/, accessed 2011.03.11) 
Cytosine  - 29.5 
% 
Thymine - 19.8 % 
Adenine - 29.3 % 








The dynamics of methylation are different between sexes. Prospermatogonial DNA is de 
novo methylated during the perinatal period, while oocyte DNA methylation occurs 
shortly before ovulation; methylation pattern is then quickly erased in the PGCs of the 
next generation. Paternal germ cell line must thus keep methylation stable through many 
numbers of divisions, possibly leading to greater epigenetic mutational load in germ cell 
genomes of older males. This in turn may be associated with greater disease incidence 
in the resulting offspring. Shortly after fertilization demethylation of the paternal genome 
is occurs. It is an active process. Maternal genome is then demethylated at a slower 
pace. Remethylation begins at the blastocyst stage and is different in the embryonic 
layers (Siedlecki and Zielenkiewicz 2006; Cervoni et al., 1999; Bestor, 2000). 
 
1.3.2 Gene imprinting 
 
In mammals, most autosomal genes are expressed from both paternal and maternal 
alleles. Imprinting is the process whereby one of the two copies is repressed while the 
other remains active, as shown by experiments of nuclear transfer in mouse (McGrath 
and Solter, 1984; Surani et al., 1984), which revealed that same genes behave 
differently depending upon their parental origin (Bestor, 2004; Doerfler, 2004). Imprinted 
genes are involved in controlled restriction processes during fetal development, where 
they are especially important in placental development and growth. Some are suspected 
to influence behavior, including binding patterns and maternal care. Although a number 
of lone imprinted genes are known, the majority are clustered and under the control of a 
single imprinting control region (ICR) (Bestor, 2001; Bird, 2002). The ICR acquires 
differential methylation in the germ cell stage, and is able to control the expression of all 
the genes in its cluster. For the standalone-imprinted genes, their promoter is also their 
ICR. The methylation of imprinted regions is known to be resistant to the genome-wide 





Fig. 3: Mechanism of DNA methylation pattern maintenance. DNMT is only able to 







1.3.3 Gene repression 
 
One of the best examples on the repression role of DNA methylation is the Xist 
locus.The locus that initiates the random X chromosome inactivation, Xist, produces the 
RNA that inactivates one of the two X chromosomes. On the active chromosome, Xist is 
not expressed as it is extensively methylated at the 5' region. On the male X, the pattern 
of Xist methylation is the same as on Xa of females, thus keeping it open to 
transcription. In essence, methylation has no direct role in establishing X inactivation, 
but it directly protects the one X chromosome that needs to stay active from it. It also 
keeps the genes on Xi inactive (Fraga and Esteller, 2007).  
Cytosine methylation may inhibit transcription factors from binding to promotors directly, 
or could influence the binding of macromolecular complex of transcription repressor 
mSin3a and histone deacetylases, thus possibly influencing chromatin structure, i.e. 
triggering its condensation. DNA methylation and histone deacetylation display synergy 
in silencing genes; this silent state is then maintained by dense CpG island 





Fig. 4: Silencing of active DNA is mediated by DNA-methyltransferase (DNMT), methyl-
CpG binding proteins (MBP) and histone deacetylase (HDAC) (Lee, 1999) 
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1.4 Known variability 
 
A number of works indicate that DNA methylation varies depending on gene expression 
intensity and numerous other conditions, such as specific cancers and other diseases.  
 
1.4.1 Differences in health and pathology  
 
Methylation differences have been shown to exist in various pathologic conditions. Rett 
syndrome, a neurological disorder with early onset, has been traced to mutations in 
methyl-CpG binding protein 2 gene, which is transcriptional repressor. Its mutations 
have been identified in up to 90 % sporadic cases of the disease. Also, Dnmt1 levels are 
high in neurons but it is almost absent in glia. Experimental mice methyl CpG binding 
protein knockout models showed adverse effects on survival after birth. Microscopic 
studies of a cell model system revealed methylation to be important for neurite 
outgrowth. Interestingly, mouse models have reproduced most aspects of the syndrome, 
including also the special hand wringing behaviors (in this case forepaws) (Shahbazian 
and Zoghbi, 2002). 
 
Prader-Willi and Angelman syndromes are associated with several genes located on the 
chromosome 15q11-q13; five of them are expressed only from the paternal 
chromosome, loss of their function through deletion, uniparental disomy, or imprinting 
errors causes Prader-Willi syndrome, a neurological disorder with mild developmental 
delay in association with hyperphagia and obesity later in the course of life. Another two 
genes are expressed from the maternal chromosome, and loss of their function through 
one of the mechanisms mentioned above causes Angelmann syndrome with lack of 
speech, seizures and severe mental retardation. Exact mechanisms of epigenetic 
regulation factors here is still unknown, however, it is clear that the region can exist in 
two mutually exclusive states, paternal and maternal, and that these states have 
markedly different methylation patterns (Buiting et al., 2003; Xin et al., 2001). 
 
Beckwith-Wiedemann syndrome, a congenital condition associated with pre- and 
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postnatal overgrowth, macroglossia, and anterior abdominal wall defects, has been 
linked to the chromosomal region 11p15.5, with most common among other causes 
being an imprinting defect in DMR-Lit1 with loss of methylation on its maternal copy. The 
locus is an imprinting control region for the subdomain containing about 12 genes. 
Normally, the maternally derived allele should stay methylated and thus silent. This 
allele also shows histone H3Lys9 methylation, indicating it as a mechanism for changes 
on the chromosomal level (El-Maarri et al., 2007). 
 
Complete hydatidiform moles are abnormal pregnancies with embryo absence and 
degeneration of villi. Mostly only the paternal, or androgenic genome is observed, 
however one fifth of them show biparental contribution with abnormal hypomethylation in 
two paternally expressed genes, Snrpn and Peg3, together with hypermethylation of 
maternally expressed genes NESP55 and H19. Familial studies showed that these 
defects are traceable to the grandparental generation maternally, possibly pointing to 
faulty epigenetic reprograming during either oogenesis or postzygotic development (El-
Maarri et al., 2003). 
 
In cancer, overall genomic DNA hypomethylation is observed, while certain CpG rich 
regions tend to be hypermethylated (Fraga and Esteller, 2007; Toyota and Issa, 1999). 
Global hypomethylation is associated with genomic instability, while regional 
hypermethylation may lead to loss of gene expression (Eden et al., 1994; Lengauer et 
al., 1997). Some examples include the estrogen receptor gene in colon mucosa, which 
becomes increasingly methylated with progressing age and is close to 100 % 
methylated in colonic cancer, and insulin-like growth factor 2, which is one of the 
regulating factors in growth of both benign and malignant tissues; its methylation also 
tends to grow with age and is found to be greater in tumors (Toyota and Issa, 1999).  
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1.4.2 Gender dependent differences 
 
Probably the most evident difference between sexes is the inactivation of the X 
chromosome, which accounts for a significant global methylation difference between 
male and female embryos. At 7,5 days post coitum, female mice embryos were 
observed to be less methylated than their male counterparts (Prissette et al., 2001) 
.Even in an individual embryo, paternal and maternal genomes take a dynamically 
different methylation and demethylation courses (Fig.4) Global analysis data has shown 
the male genome to be more methylated (Fuke et al., 2004 ; Shimabukuro et al., 2006). 
The inactive X chromosome is specifically hypermethylated at CpG islands at gene-rich 
regions while being generally hypomethylated at gene poor regions; the active one is in 
contrast hypermethylated not at the specific promoter-associated CpG islands but at the 
bodies of genes. The question deserves deeper and more thorough analysis, as the 
studies to date differed much on the number of individuals studied, number and sort of 
tissues taken into account (Eckhardt et al., 2006; El-Maarri et al., 2007; Sandovici et al., 
2005).  
Differences between male and female lymphocytes have been observed in a study of 
four different autosomal loci in 134 males and 157 females (Sarter et al., 2005). Three 
out of four loci were more methylated in males, while the fourth had been observed to be 
uniformly unmethylated in both sexes.  Difference may lie at the very beginning of tissue 
differentiation, with a study showing female derived ES cells being generally less 
methylated than male ES cells (Zvetkova et al., 2005).  
There are also differences in primordial germ cells, where imprinted regions are more 
methylated in XY than in XX cells (Durcova-Hills et al., 2004; 2006).
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1.4.3 Tissue dependent variation 
 
Same loci are methylated differently in various tissues. Repetitive fragments tend to be 
methylated more in most tissues.  
  
 
1.4.4 Age dependent variation 
 
Although some genes become more methylated with age, the general trend of the 
genome is hypomethylation as cellular divisions accumulate. Immortalized cells also 
show hypermethylation of some genes. Dnmt1, the main maintenance 
methyltransferase, also decreases in expression with age. A good example of age 
dependent hypermethylation is the estrogen receptor gene in colonic mucosa, which 
steadily accumulates methylation with age and is frequently hypermethylated in cancer. 
Insulin growth factor 2, or IGF2 gene, acquires methylation on the allele that is normally 
not methylated with age, thus possibly silencing not only the meant to be quiet, but also 
the necessary active allele. The gene regulates tissue growth and development. Many 
adult tumors display increased methylation of both alleles, while in young individuals 
only one of the two is methylated (Lopatina et al., 2002; Toyota and Issa, 1999). 
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2.Workflow chart. 
Tissue samples were used to extract DNA with a standard Qiagen kit, the extracted 
DNA consequently undergoing bisulfite treatment, PCR and single nucleotide extension 






































This work aims at comparing the level of methylation at different loci in different tissues 
in a population of 100 outbred mice (50 male and 50 female) grown under the same 
conditions. More specifically the aims could be stated as: 
1- Determine the accurate methylation levels by a highly quantitative assay at the 
promoters of two single loci (alpha actin and myosin light chain), three differentially 
methylated regions associated with imprinted loci (Lit1 DMR, SNRPN DMR1 and Peg3 
DMR) and two repetitive sequences (Iap and LINE-1) in different mice organs (brain, 
tongue, skin, lungs, spleen, bone marrow, muscle, testes, and heart);  
2- Determine the sex influence on methylation levels 
3- Compare the methylation at the above loci between male and females derived 
samples. 
4- Compare the methylation levels between different tissues.  
5- Investigate correlation in the level of methylation between different loci in the same 
tissue (Intra – tissue correlation). 
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One hundred outbred CD1 mice, 50 male and 50 female, 7 weeks old, have been used 
for this study.  
The following tissue samples and whole organs were taken and frozen immediately in 
liquid nitrogen: brain, tongue, skin specimen (ears), lungs, spleen, liver, kidney, bone 
marrow (washed out from lumen of femur with 0.9 % NaCl solution), bone (metaphysis 
of femur), muscle ( femoral extensor and flexor groups, one paw of each individual), 
testes, and heart. 
 
4.2 Fragments investigated 
 
4.2.1 Single loci 
4.2.1.1 Murine MLC1V gene, MyLC 
 
Exon 1 encoding myosin alkali light chain, muscle slow (ventricular) isoform on 
chromosome 9. (accession n. X12972); Fig.5. 
Myosin is the main protein in the contractile apparatus. A myosin molecule consists of 
four chains, two light and two heavy. Proportions and sort of the heavy and light chain 
isoforms define the mechanical velocity and power effect of the muscle, which may be 
as different as balistic jump, run or throw motion or constant postural support. The light 
chains have a molecular weight of 17000 to 21000 kDa. Both heavy and light chains are 
subject to tissue and developmental stage specific polymorphisms. (Young et al., 1986). 
There are a number of different myosin proteins with variety of functions; they differ 
mostly in their heavy chain. There are three main myosin light chain isoforms, resulting 
from alternative splicing of its gene and present in various proportions in smooth, 
skeletal and cardiac muscle; different types of body muscles express different myosin 
isoforms dependent on their function.  
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mRNA start 
Bisulfite forward primer 
SNuPE primer 1 
SnuPE primer 2 
Bisulfite reverse primer 
 
A) Original sequence ( accession n. X12972): 
  1141 acatacacaC Gtggagcaac tcttctgcac aataaatttg gacaggtaaa ggttagaaaa 
     1201 gtgtgtacca catgctatac accatagtag gggctggaat gaccaaaggg tCGttcttga 
     1261 ataacttCGc acctgggtgg cccaggtccc ctgatta[aga gCGaggggtg gtaggatctg 
     1321 tgttgaggca ccttttcaag tagggagggt ccctggctgt gtgcatggtg ggaggtctct 
     1381 ggacatttgt atgcattgtc tggtgtCGct gttcagggcc tgtcagtgcc ccagctgggt 
     1441 ctaggggaag aggctgtCGt gtgtcttgtc tctgtggtcc CGtttcCGgg tgttcacatt 
     1501 catgtatgtc tgtgtgggtc tgagtgagtg tctgtatatt tatgtctggg tgtttgtatg 
     1561 cactagtgta tgagtgtctg gatacagcag gcagctgcag tccactcaca gggtcccagg 
     1621 gtctccagga acaccccaag cacaCGtggc actccctCGa ggactgtcct ccagactagt 
     1681 tcaacaggct ccttttacaa aactcctaag actagtgtct caggttttac acacccacac 
     1741 tCGcacaCGC GCGcacacac acacacatgt gtgcacacac acatacatac acactggatt 
 
B) Sequence after bisulfite treatment with pirmer annealing sites, yellow markings 
showing the binding sites of bisulfite primers, red markings indicating the sites of single 
nucleotide extension primers:  
 
 1141 atatatataC Gtggagtaat ttttttgtat aataaatttg gataggtaaa ggttagaaaa 
 1201 gtgtgtatta tatgttatat attatagtag gggttggaat gattaaaggg tCGtttttga 
     1261 ataatttCGt atttgggtgg tttaggtttt ttgattaaga gCGaggggtg gtaggatttg 
     1321 tgttgaggta tttttttaag tagggagggt ttttggttgt gtgtatggtg ggaggttttt 
     1381 ggatatttgt atgtattgtt tggtgtCGtt gtttagggtt tgttagtgtt ttagttgggt 
 1441 ttaggggaag aggttgtCGt gtgttttgtt tttgtggttt CGttttCGgg tgtttatatt 
     1501 tatgtatgtt tgtgtgggtt tgagtgagtg tttgtatatt tatgtttggg tgtttgtatg 
     1561 tattagtgta tgagtgtttg gatatagtag gtagttgtag tttatttata gggttttagg 
     1621 gtttttagga atattttaag tataCGtggt attttttCGa ggattgtttt ttagattagt 
     1681 ttaataggtt ttttttataa aatttttaag attagtgttt taggttttat atatttatat 
     1741 tCGtataCGt gCGtatatat atatatatgt gtgtatatat atatatatat atattggatt 
 
Fig. 5: Myosin light chain exon 1, original sequence and sequence after bisulfite 
processing 
SNuPE primer 2 → 
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4.2.1.2 Alpha-actin gene  
 
Mouse skeletal alpha actin gene (accession n. M12347) (Fig.6). Encodes for a 
ubiquitous protein in all eukaryotic cells. First discovered as actomyosin by Kuhne in 
1861, isolated by Straub, Bonga and Szent-Gyorgyi in 1939-1942. Around 1970, its 
existence in non-muscle cells has been proven (Pederson and Aebi, 2005). In recent 
years there has been increasing proof for actin existing in mono- and polymeric forms 
not only in the cytoplasm, but also in the nucleus of the cells, being closely associated 
with RNA polymerases. It is a small compact protein of around 43 kDa. In muscles, actin 
is the rail on which myosin complexes move. In non-muscle cells, it has a variety of 
functions, including support and stabilization of nuclear matrix and lamina, chromatin 
remodeling, and being in complex with the known three types of RNA polymerase 
(Pederson and Aebi 2003). Actin can adopt a great number of forms, such as filaments, 
sheets, tubes, which makes it the scaffold, roof and floor of many cellular processes 
such as transcription, chromatin formation, cellular shape, motility, adhesion. Actin is 
phylogenetically very old, being found in comparable forms among such long diverged 
species as mammals and fungi (Goodson and Hawse, 2002). Actin defects lead to one 
of three major forms of myopathy; it is one of the five genes so far linked to
 the disorder (Clarkson et al., 2004).
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mRNA start 
Bisulfite reverse primer 
Bisulfite forward primer 
SNuPE primer 2 SNuPE primer 1 
A) Original sequence (accession n. M12347:) 
 
 361 ggcaggtcag caatCGtgtg tccaggtggg cagatctggg gagacctttc aaacaggtaa 
      421 atcttgggaa gtacagacca gCGgtcaaag cagtgacctt tggcccagca cagcccttcC 
      481 Gtgagccttg gagccagttg ggaggggcag acagctgggg atactctcca tataCGgcct 
      541 ggtcCGgtcc tagctacctg ggccagggca gtcctctcct tctttggtca gtgcaggaga 
      601 ccCGggCGgg acccaggctg agaaccagcC Gaaggaaggg actctagtgc cCGacaccca 
      661 aatatggctt gggaagggca gcaacattct tCGgggCGgt gtggggagag ctccCGggac 
      721 tatataaaaa cctgtgcaag gggacaggCG gtc[acaCGga CGtaagcctc acttcctacc 
      781 ctCGgcaccc agggcagagt cagagcagca ggtagggtgg aggtggggag ggtgacctgg 
      841 agacccagca aagaaagcta ttgagccttg gttgtattta gcactgagtt ctggaaattt 




B) Sequence after bisulfite treatment with pirmer annealing sites, yellow markings 
showing the binding sites of bisulfite primers, red markings indicating the sites of single 
nucleotide extension primers:  
 
  
 361 ggtaggttag taatCGtgtg tttaggtggg tagatttggg gagatttttt aaataggtaa 
      421 attttgggaa gtatagatta gCGgttaaag tagtgatttt tggtttagta tagttttttt 
      481 gtgagttttg gagttagttg ggaggggtag atagttgggg atatttttta tataCGgttt 
      541 ggttCGgttt tagttatttg ggttagggta gttttttttt tttttggtta gtgtaggaga 
      601 ttCGggCGgg atttaggttg agaattagtC Gaaggaaggg attttagtgt tCGatattta 
      661 aatatggttt gggaagggta gtaatatttt tCGgggCGgt gtggggagag ttttCGggat 
      721 tatataaaaa tttgtgtaag gggataggCG gttataCGga CGtaagtttt attttttatt 
      781 ttCGgtattt agggtagagt tagagtagta ggtagggtgg aggtggggag ggtgatttgg 
      841 agatttagta aagaaagtta ttgagttttg gttgtattta gtattgagtt ttggaaattt 
      901 ttttaaattt atatttagtt tattttgtga ttgggtattt aggatatgtt tgggggtttg 
 
Fig. 6: A fragment of alpha actin gene, original sequence and sequence after bisulfite 
processing 
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4.2.2 Differentially methylated regions (DMRs) at imprinted genes 
 
4.2.2.1 Paternally expressed gene 3 (Peg3) 
 
PEG3 is located on chromosome 7, - (Mus musculus, exon 1. Accession n. AF105262; 
Fig. 7) 
and belongs to a group of genes in which loss of methylation has been associated with 
various neoplastic diseases (Feinberg, 2007). Its human homologue is located on 
chromosome 19. Peg3 consists of nine exons. A number of repeats and a CpG island is 
located in its 5' region. The nine-exon transcript is 8.7 kb, ORF contains exons 3 to 9 
and is 4.7 kb.  It encodes a zinc finger protein, and some experiments indicate its role as 
a tumour suppressor. During embryogenesis, it is expressed in mesodermal tissues; in 
adult individuals, a high expression rate is observed in the central nervous system and 
hypothalamus. Peg3 knockout female mice demonstrate impaired maternal behaviour 
(Kohda et al., 2001). The gene is expressed in mesodermal tissues of early somites, 
and later in the gut and hypothalamus. Other tissues with strong expression include 
tongue and cranial skeleton vertebral cartilage. Less expression occurs in heart and 
neural tissue (Kuroiwa et al., 1996). In humans, the pattern is completely different, the 
highest expression occurring in placenta, testes and ovary, while pancreas, prostate, 
intestine and heart show low expression (Kim et al., 1997). Lack of Peg3 results in 
growth retardation in affected embryos. Experiments with embryos that had only the 
paternal genome showed death before gestational day 10, with poor extraembryonic 
tissue, retarded growth and trophoblast proliferation (Obata et al., 1998). 
34 
mRNA start 
SNuPE primer 1 
Bisulfite forward primer 
Bisulfite reverse primer 
SNuPE primer 2 
A) Original Sequence 
 
     2641 GtcaactcCG tgccttggCG ccaagctgtt gccttgacaa cagcagtctg attggcaggg 
     2701 tgtgggaggC Gtggtgaggg cccaaagCGg ggaatggggt cttggattgg ttagagagga 
     2761 agctcCGcct ctgcagagga ccctgacaag gaggtgtccC Gc[agcccttg ctgcagaCGc 
     2821 tggggagtca ggagtCGCGg gaggaCGagc atCGgaggag aagCGgagag atgtccaccc 
     2881 tgggctggtg gCGcCGcCGg gCGccCGgtt cagtgtgggt gcactagact gcCGaccctg 
     2941 gtCGgggtgt gtgCGtagag tgctgtgctc CGggaggtga gtcagcCGgc cacctggctg 
     3001 ctctgcagca tgcaccctct tagatacCGt ctgcagagtt cagatggtgt ttggggtgCG 
     3061 ttgcCGCGgg ccaggggCGg cagaccatat caCGgctccc aagggtaact gacaaggctg 
     3121 cagactgCGc cttCGggaag ggggaatcac caCGgagCGg cCGtgttgcC Gcagggatgc 




Sequence after bisulfite treatment with pirmer annealing sites, yellow markings showing 
the binding sites of bisulfite primers, red markings indicating the sites of single 
nucleotide extension primers:  
 
        
 2641 gttaatttCG tgttttggCG ttaagttgtt gttttgataa tagtagtttg attggtaggg 
     2701 tgtgggaggC Gtggtgaggg tttaaagCGg ggaatggggt tttggattgg ttagagagga 
     2761 agtttCGttt ttgtagagga ttttgataag gaggtgtttC Gtagtttttg ttgtagaCGt 
     2821 tggggagtta ggagtCGCGg gaggaCGagt atCGgaggag aagCGgagag atgtttattt 
     2881 tgggttggtg gCGtCGtCGg gCGttCGgtt tagtgtgggt gtattagatt gtCGattttg 
     2941 gtCGgggtgt gtgCGtagag tgttgtgttt CGggaggtga gttagtCGgt tatttggttg 
     3001 ttttgtagta tgtatttttt tagatatCGt ttgtagagtt tagatggtgt ttggggtgCG 
     3061 ttgtCGCGgg ttaggggCGg tagattatat taCGgttttt aagggtaatt gataaggttg 
     3121 tagattgCGt tttCGggaag ggggaattat taCGgagCGg tCGtgttgtC Gtagggatgt# 
 
Fig. 7: Fragment of paternally expressed gene 3, original sequence and sequence after 
bisulfite processing 
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4.2.2.2 Small nuclear ribonucleoprotein N (Snrpn) gene  
 
Snrpn D1 (Mus musculus small nuclear ribonucleoprotein N) gene differentially 
methylated region1, on chromosome 7, accession n.AF332579, promoter region); Fig.8. 
Microdeletions and other alterations in this region are observed in patients with Prader–
Willi and Angelman syndromes, also in cases of Albright hereditary 
pseudohypoparathyroidism and osteodystrophy type IA. (Feinberg, 2007) The protein is 
ribosome associated, found in the spliceosome (Glenn et al., 1997) and responsible for 
gene splicing, thus having a direct impact on the synthesis of brain proteins, particularly 
those that function in the hypothalamus (Cassidy et al., 2000). The Snrpn associated 
DMRs are unmethylated in mice spermatozoa but completely methylated in mature 
oocytes. The gene contains two differentially methylated regions; - the first DMR 
includes part of the promoter and transcription start site, and is postulated to inherit a 
maternal-specific imprint. In mice, this DMR is completely methylated in metaphase II 
oocytes and unmethylated in sperm. Experiments indicate that oocyte methylation 
occurs in transition between the non-growing oocyte and  metaphase II oocyte, at which 
stage it is complete.  
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mRNA start 
Bisulfite forward primer 
Bisulfite reverse primer 
SNuPE primer 1 
SNuPE primer 2 
A) Wild type sequence 
 67681 aaaaatctgt gtgatgcttg caatcacttg ggagcaattt ttttaaaaaa ttaaatgtat 
    67741 ttagtaatag gcaattatat ccattattcc agattgacag tgattttttt tttttaatac 
    67801 aCGctcaaat ttcCGcagta ggaatgctca agcattcctt ttggtagctg ccttttggca 
    67861 ggacattcCG gtcagaggga cagagacccc tgcattgCGg caaaaatgtg CGcatgtgca 
    67921 gccattgcct gggaCGcatg CGtagggagc CGCGCGacaa acctgagcca ttgCGgca[ag 
    67981 actagCGcag agaggagagg gagcCGgaga tgccagaCGc ttggttctga ggagtgattt 
    68041 gcaaCGcaat ggagCGagga aggtcagctg ggcttgtgga ttctagtagt gaaagtgcat 
 
 
B) Sequence after bisulfite treatment with pirmer annealing sites, yellow markings 
showing the binding sites of bisulfite primers, red markings indicating the sites of single 
nucleotide extension primers:  
 
    67681 aaaaatttgt gtgatgtttg taattatttg ggagtaattt ttttaaaaaa ttaaatgtat 
    67741 ttagtaatag gtaattatat ttattatttt agattgatag tgattttttt tttttaatat 
    67801 aCGtttaaat tttCGtagta ggaatgttta agtatttttt ttggtagttg ttttttggta 
    67861 ggatatttCG gttagaggga tagagatttt tgtattgCGg taaaaatgtg CGtatgtgta 
    67921 gttattgttt gggaCGtatg CGtagggagt CGCGCGataa atttgagtta ttgCGgtaag 
 
    67981 attagCGtag agaggagagg gagtCGgaga tgttagaCGt ttggttttga ggagtgattt 
    68041 gtaaCGtaat ggagCGagga aggttagttg ggtttgtgga ttttagtagt gaaagtgtat 
 
Fig. 8: Snrpn fragment, original sequence and sequence after bisulfite processing 
4.2.2.3 Mus musculus Lit1 
 
Lit1, or Mus musculus partial Kcnq1 gene encoding for voltage gated potassium channel 
protein, (accession n.AJ271885, Fig.9) is an antisense-transcript of Kvlqt1, expressed 
paternally while maternally methylated throughout the developmental stages. Lit1 locus 
corresponds to a highly conserved region between mouse and human. Loss of maternal 
allele methylation at its location correlates with Beckwith-Wiedemann syndrome (Yatsuki 
et al., 2000) 
.
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Bisulfite forward primer 
Bisulfite reverse primer 
SNuPE primer 1 
SNuPE  primer 2 
A) Wild type sequence 
 
    45901 gaacattcCG aaCGgagccc ctcactctca gcattaaaac agctaccaca taacaacaCG 
    45961 tactccactc actaccttgg tgctggccac acCGggctac aaagctcagg ggtctccaga 
    46021 ccCGattCGg tttcagctcc agtgCGttct gactCGgccC Ggggtttaga atcCGaaggc 
    46081 ctgagcCGgt gtcctaggcc actcaccttg ggactCGacC GacctCGggg ctcaaagggc 
    46141 ctcaagacca cccctgcttc tgtaagcctg ggccacaaag atggggaCGt ggaCGcaaaa 
    46201 taCGagaact gagccaCGgc CGtgaaaCGa ggacCGgcCG tgaaaCGagg acCGagcCGt 
    46261 aactgcaaaa CGaataCGga gccactgCGg caaaaCGaag atggagccca gcCGCGaaag 
    46321 CGCGgcaCGa atcacctctg cttctggcCG tgagtgcttg cCGCGaggag ggggaggcta 
    46381 tgatgagCGC GgccaCGCGg acttgCGact tgtgcCGtgc tgactcagag aagaaaccCG 
    46441 CGctgagaaa aaaaccatac ctaggagaac catgcCGaga aaaagaagCG ctgggaacca 
    46501 agctgaacag aaaagctctc caagtagaat cacacagagg gaaaagaagC Gtgttgaaga 
 
B) Sequence after bisulfite treatment with pirmer annealing sites, yellow markings 
showing the binding sites of bisulfite primers, red markings indicating the sites of single 
nucleotide extension primers:  
 
    45901 gaatatttCG aaCGgagttt tttattttta gtattaaaat agttattata taataataCG 
    45961 tattttattt attattttgg tgttggttat atCGggttat aaagtttagg ggtttttaga 
    46021 ttCGattCGg ttttagtttt agtgCGtttt gattCGgttC Ggggtttaga attCGaaggt 
    46081 ttgagtCGgt gttttaggtt atttattttg ggattCGatC GatttCGggg tttaaagggt 
    46141 tttaagatta tttttgtttt tgtaagtttg ggttataaag atggggaCGt ggaCGtaaaa 
    46201 taCGagaatt gagttaCGgt CGtgaaaCGa ggatCGgtCG tgaaaCGagg atCGagtCGt 
    46261 aattgtaaaa CGaataCGga gttattgCGg taaaaCGaag atggagttta gtCGCGaaag 
    46321 CGCGgtaCGa attatttttg tttttggtCG tgagtgtttg tCGCGaggag ggggaggtta 
    46381 tgatgagCGC GgttaCGCGg atttgCGatt tgtgtCGtgt tgatttagag aagaaattCG 
    46441 CGttgagaaa aaaattatat ttaggagaat tatgtCGaga aaaagaagCG ttgggaatta 
    46501 agttgaatag aaaagttttt taagtagaat tatatagagg gaaaagaagC Gtgttgaaga 
    46561 aaaattgaga gaatttagta ggttaaaaaa aaatgttgag aagttaagtg gatCGCGtta  
 




4.2.3 Repetitive elements 
 
4.2.3.1 LINE-1 repetitive element  
 
Mus musculus LINE-1 repetitive element (LINE-1 ), (accession n. D84391; Fig.10). 
Multiple sequences of retroviral origin, together with Iap responsible for a large part of 
the genomic retroviral load. Failure to silence them results in abnormal chromatin 
structure and early apoptosis. Long interspersed elements (Lines) are mobile genetic 
sequences that have over time accumulated in the genomes of higher eukaryotes via 
germline transposition. Lines are a major source of insertional mutagenesis in humans, 
being involved in both germinal and somatic mutant phenotypes. What makes them 
particularly interesting, these elements are capable not only of own transposition, but 
may also take fragments of other genes with them, thus possibly serving as a genome 
remodeling agent. They are a source of insertional mutagenesis. LINE-1 elements were 
active throughout mammalian evolution and 17 % of the human genome consists of 
recognizable copies of LINE-1. Active copies still retropose in the human genome, 
cause insertional inactivation of human genes and seem to stimulate genomic 
recombinogenic breaks. LINE-1s also transpose other elements in trans, such as 
processed pseudogenes, Alu elements and probably also SVA, which are both short 
interspersed nuclear elements (SINEs) (Weinhold, 2006).  
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Bisulfite forward primer 
Bisulfite reverse primer 
SNuPE primer 1 SNuPE primer 2 
A) Sequence 
      421 tCGccatctt ggtcCGggac cCGcCGaact taggaaatta gtctgaacag gtgagagggt 
      481 gCGccagaga acctgacagc ctctggaaca ggcagaagca cagaggggct gaggcagcac 
      541 cctgagtggg cCGgggacag cCGgccacct tcCGgacCGg aggacaggtg ccCGccCGgc 
      601 tggggaggCG acctaagcca cagcagcagC GgtCGccatc ttggtcCGgg accCGcCGaa 
      661 cttaggaaat tagtctgaac aggtgagagg gtgCGccaga gaacctgaca gcttctggaa 
      721 caggCGgaag cacagaggCG ctgaggcagc accctgCGtg ggcCGgggac agcCGgccac 
      781 cttcCGgacc agaggacagg tgcccaccCG gctggggagg CGgcctaagc cacagcagca 
      841 gCGgtCGcca tcttggtcCG ggaccCGcCG aacttaggaa attagtctga acaggtgaga 
      901 gggtgCGcca gagaacctga cagcttctgg aacaggcaga agcacagagg ggctgaggca 
      961 gcaccctgtg tgggcCGggg acagcCGgcc accttcCGga cCGgaggaca ggtgcccacc 
     1021 CGgctgggga ggCGgcctaa gccacagcag cagCGgtCGc catcttggtc cCGggactcc 
     1081 aaggaactta ggaatttagt ctgcttaagt gagagtctgt accacctggg aactgccaaa 
     1141 gcaacacagt gtctgagaaa ggtcctgttt tgggccttct tcttCGgcca ggaggaggtc 
 
B) Bisulfite Sequence after bisulfite treatment with pirmer annealing sites, yellow 
markings showing the binding sites of bisulfite primers, red markings indicating the 
sites of single nucleotide extension primers:  
 421 tCGttatttt ggttCGggat tCGtCGaatt taggaaatta gtttgaatag gtgagagggt 
 481 gCGttagaga atttgatagt ttttggaata ggtagaagta tagaggggtt gaggtagtat 
      541 tttgagtggg tCGgggatag tCGgttattt ttCGgatCGg aggataggtg ttCGttCGgt 
      601 tggggaggCG atttaagtta tagtagtagC GgtCGttatt ttggttCGgg attCGtCGaa 
      661 tttaggaaat tagtttgaat aggtgagagg gtgCGttaga gaatttgata gtttttggaa 
      721 taggCGgaag tatagaggCG ttgaggtagt attttgCGtg ggtCGgggat agtCGgttat 
      781 ttttCGgatt agaggatagg tgtttattCG gttggggagg CGgtttaagt tatagtagta 
      841 gCGgtCGtta ttttggttCG ggattCGtCG aatttaggaa attagtttga ataggtgaga 
      901 gggtgCGtta gagaatttga tagtttttgg aataggtaga agtatagagg ggttgaggta 
 961 gtattttgtg tgggtCGggg atagtCGgtt atttttCGga tCGgaggata ggtgtttatt 
 1021 CGgttgggga ggCGgtttaa gttatagtag tagCGgtCGt tattttggtt tCGggatttt 
 1081 aaggaattta ggaatttagt ttgtttaagt gagagtttgt attatttggg aattgttaaa 
 1141 gtaatatagt gtttgagaaa ggttttgttt tgggtttttt ttttCGgtta ggaggaggtt 
 
Fig. 10: Mouse LINE-1 repetitive element, original sequence and sequence after 
bisulfite processing 
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4.2.3.2 Intracisternal A-particle gag protein gene, IAP.  
 
Mus musculus clone MIA14 full-length intracisternal A-particle gag protein gene (Iap), 
accession n. M17551; Fig.11. 
Intracisternal A particle - repetitive elements of retroviral origin, found in the whole 
genome, normaly in silenced state. In mice, its an aggressive retrovirus, normally 
heavily methylated. Its reactivation causes transcript levels that are 50 to 100-fold higher 
in compared to normal controls. During global demethylation wave in the preimplantation 
embryo, the methylation of Iap persists. Specific dynamic paterns of Iap methylation 
correlate closely with DNMT1 expression (Walsh et al., 1998). There are some division 
stages at the primordial germ cell level, where genome is both demethylated and 
dividing. Male germ cells are subject to a few such divisions around embryonic day 13; 
further divisions are already in the form of densely methylated spermatogonia; these can 
divide 100 to 150 times; this would be consistent with the idea that methylation is the 
specific mechanism keeping the retrovirus silent.  
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Bisulfite forward primer 
Bisulfite reverse primer 
SNuPE primer 1 
SNuPE primer 2 
A)Sequence 
 
 1 tgttgggagc CGCGcccaca ttCGcCGtta caagatggCG ctgacagctg tgttctaagt 
       61 ggtaaacaaa taatctgCGc atatgcCGag ggtggttctc tactccatgt gctctgcctt 
      121 cccCGtgaCG tcaactCGgc CGatgggctg cagccaatca gggagtgaca CGtcctaggC 
      181 Gaaatataac tctcctaaaa aagggaCGgg gtttCGtttt ctctctctct tgcttcttac 
      241 actcttgctc ctgaagatgt aagcaataaa gttttgcCGc agaagattct ggtctgtggt 
      301 gttcttcctg gcCGggCGtg agaaCGCGtc taataacaat tggtgacCGa attcCGggaC 




B) Sequence after bisulfite treatment with pirmer annealing sites, yellow markings 
showing the binding sites of bisulfite primers, red markings indicating the sites of 




 1  tgttgggagt CGCGtttata ttCGtCGtta taagatggCG ttgatagttg tgttttaagt 
 61 ggtaaataaa taatttgCGt atatgtCGag ggtggttttt tattttatgt gttttgtttt 
 121 tttCGtgaCG ttaattCGgt CGatgggttg tagttaatta gggagtgata CGttttaggC 
 181 Gaaatataat ttttttaaaa aagggaCGgg gtttCGtttt tttttttttt tgttttttat 
 241 atttttgttt ttgaagatgt aagtaataaa gttttgtCGt agaagatttt ggtttgtggt 
      301 gttttttttg gtCGggCGtg agaaCGCGtt taataataat tggtgatCGa atttCGggat 




Fig. 11: IAP, original sequence and sequence after bisulfite processing 
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4.3 DNA extraction 
 
Qiagen Dneasy blood and tissue kit was used according to the manufacturer’s 
specifications. Tissue specimens were homogenized in 1,5 ml Eppendorf tubes using a 
handheld homogenizer. The concentration of DNA was then measured by 
spectrophotometer. 
Approx. 10 mg of spleen and 25 mg of other tissues from each individual were placed 
into 1.5 ml microcentrifuge tube and suspended in 180 µl buffer ATL, then homogenized 
with a single use plastic handheld mortar for each sample by grinding until no particles 
were seen. For more mechanically resistant tissues (bone, cardiac muscle) an electric 
homogenizer was used.  
Then, 20 µl proteinase K was added and the mixture vortexed for 5 to 10 seconds, 
followed by an overnight-incubation step at 56º C.  
As the lysis is complete, the lysate was vortexed for 15 seconds, then 200 µl buffer AL 
was added and again mixed by vortexing, followed by 200 µl 96 % ethanol.  The mixture 
is then pipeted (including precipitate if present) into a DNeasy Mini spin column, where it 
has to be  centrifuged at ≥6000 g (8000 rpm) for 1 minute. Then, flow-through and 
collection tube were  discarded.  
The column was then placed into a new collection tube, and washed with 500 µl buffer 
AW1, followed by further centrifugation step at ≥6000 g (8000 rpm) for 1 minute, after 
which the flow-through and collection tube were again discarded, the column placed into 
a new collection tube and washed with 500 µl buffer AW2. 
The resulting liquid was subjected to centrifugation for 3 min at 20000 g (14000 rpm), 
after which the collection tube with the flow-through were discarded, the column 
transferred into the final 1.5 ml microcentrifuge tube and  200 µl buffer AE was pipeted 
onto the membrane, incubated for 1 min at room temperature and centrifuged at ≥6000 
g (8000 rpm) for 1 minute. This step was in some cases repeated twice for maximum 
DNA yield. DNA concentration was then measured and standard concentration working 
aliquots prepared. 
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4.4 Bisulfite conversion 
 
Bisulfite conversion is a multistep reaction that leads to the conversion of cytosine 
residues to uracil in the presence of sodium bisulfite. Three steps are involved in the 
reaction, namely sulfonation, deamination and desulfonation. First, cytosines are 
reversibly sulfonated to cytosine-6-sulfonate. Second, cytosine-6-sulfonate is irreversibly 
deaminated to form uracil-6-sulfonate; third, uracil-6-sulfonate is then reversibly 
desulfonated to uracil. Under the right conditions for each step (step 1- low pH and low 
temperature, step 2 - higher temperature and sodium bisulfite concentration, and step 3 
at higher pH), the reaction is highly selective for non-methylated cytosines, and 5-
methylcytosines remain unconverted (El Maarri et al., 2004). 
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  (5´)a-- GTTCTGC-------CG--CmG-----GCTTCCA-- 
  (3´)b-- CAAGACG-------GC--GCm-----CGAAGGT-- 
 
       Denaturation 
  (5´)a-- GTTCTGC-------CG--CmG-----GCTTCCA-- 
  (3´)b-- CAAGACG-------GC--GCm-----CGAAGGT-- 
 
       Bisulphite treatment 
  (5´)a-- GTTUTGU-------UG--CG-----GUTTCCA-- 
  (3´)b-- UAAGAUG-------GU--GC-----UGAAGGT-- 
 
       Strand specific DNA amplification 
  (5´)a-- GTTTTGT-------TG--CG-----GTTTTTA--   Upper 
  (3´)a-- CAAAACA-------AC--GC-----CAAAAAT--   strand 
 
  (3´)b-- TAAGATG-------GT--GC-----TGAAGGT--   Lower  
  (5´)b-- ATTCTAC-------CA--CG-----ACTTCCA--   strand 
Fig. 12: Bisufite conversion scheme (El Maarri et al., 2004) 
 
The buffers for the bisulfite conversion and bisulfite mix were prepared as per 
information provided by the manufacturer. The bisulfite mix was reconstituted with 800 µl 
RNAse free water. The reaction mixture was then prepared as follows: 5 µl of 200 ng/µl 
DNA, diluted with 15 µl RNAse-free water, 85 µl Bisulfite mix and 35 µl DNA protect 
buffer. The reaction mixture was then vortexed until it turned blue. Then, the bisulfite 



































1. Denaturation at 99 °C for 5 min 
2. Incubation at 60 °C for 25 min 
3. Denaturation at 99 °C for 5 min 
4. Incubation at 60 °C for 85 min 
5. Denaturation at 99 °C for 5 min 
6. Incubation at 60 °C for 175 min 
7. 20 °C pause. 
 
The bisulfite converted product then had to be cleaned from remaining DNA-aggressive 
reagents.  
For this, the PCR tubes were centrifuged briefly, the ensuing supernatant then being 
transferred to 1.5 ml Eppendorf tubes. 
560 µl buffer BL was added. The original protocol calls for additional carrier RNA at this 
step, however, RNA may be skipped if more than 100 ng DNA is used. Then the 
reaction mix was vortexed and centrifuged briefly, before transfering it into Epitect spin 
columns and centrifuging at max speed for 1 min. The flowthrough was then discarded, 
columns placed back into collection tubes.  
Next, 500 µl buffer BW was added and the mixture was centrifuged at max speed for 1 
min.  Filtrate was again discarded and columns placed back into collection tubes. Then 
500 µl buffer BD was added, lids closed, and the reaction mix incubated at ambient 
temperature for 15 min, followed by centrifugation at max speed for 1 min. Flowthrough 
again discarded and columns placed back into the tubes.  
500 µl buffer BW was then added and centrifuged at max speed for 1 min. Filtrate 
discarded, columns placed back into tubes. This washing step was repeated twice.  
Columns were then placed into new 2 ml collection tubes and centrifuged at max speed 
for 1 min.  
Finally, columns were placed into 1.5 ml microcentrifuge tubes, 20 µl buffer EB (elution 
step) was added to the center of the membrane, then centrifuged at approx. 15000 g 
(12000 rpm) for 1 min. The elution step can be repeated with further 20 µl buffer EB to 
maximize DNA yield. 
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4.4 Amplification of fragments from bisulfite converted DNA 
 
 Reaction buffer B, ready to use as supplied (SolisBiodyne, Tartu, Estonia) 
 MgCl2 100 mM (SolisBiodyne) 
 dNTPs (stock concentration 100 mM, working solution 2.5 mM) (Fermentas, 
Lithuania) 
 DNA polymerase (HotFirePol) (SolisBiodyne) 
 Molecular biology grade water.  
 Primers, stock solution 100 pM, working solution 14 pM (MWG) 
 Bisulfite converted DNA. 
 
 PCR amplification: the fragments were amplified in a Biometra T3 thermocycler 
as follows:  
Step 1: incubate at 95 °C for 15 min  
Step 2: incubate at 92 °C for 30 sec 
Step 3: incubate at X °C for 30 sec (where X is annealing, given in table N.1 with 
primers used for amplification)  
Step 4: incubate at 72 °C for 1 min; repeat steps 2 to 4 for 34 cycles. 
Step 5: incubate at 72 °C for 10 min for a final elongation step. 
Step 6: incubate at 4 °C until use.  
 
Bisulfite treatment will convert all non-methylated cytosine residues into uracil, the 
sequence selectivity and specificity for primer annealing is therefore reduced. For this 
reason, additional precautions concerning primer design and annealing locations need 
to be made. In designing the primers, care should be taken that the primers do not 
overlap with CpG dinucleotides. Thus, amplification is independent from the conversion 
efficiency and methylation status at CpG sites. Primer length should be 25 to 30 
nucleotides to insure a robust yet specific annealing. To ensure selective amplification of 
converted DNA, primers should when possible be located in an originally cytosine-rich 
region (but not CpGs). Extensive T and A stretches, common for converted DNA, should 
be avoided in primers to minimize the risk of primer dimere formation. Recommended 
length of the product is 300 to 500 bp, as DNA depurination and fragmentation occurs. 
47 
 





A master mix* of all reagents except the DNA was prepared, using the following 
reagent quantities for each sample: 16.4 µl of water, 2.5 µl reaction buffer B, 0.63 µl 
100 mM MgCl2, 2.5 µl dNTPs  solution, DNA polymerase (the optimal polymerase 
quantity waried depending on the batch and was adjusted for each batch), 14 pM 
primer solution, 1 µl.  
  
The ready mix was briefly vortexed, then distributed to PCR strips, followed by addition 
of 62 ng bisulfite converted DNA, in our case a volume of 2.5 µl. (End volume in each 
tube  was  ca. 25 µl), then cycled under the following conditions: 
 
Step 1: 95 °C 15 min  
Step 2: 92 °C 30 sec 
Step 3: X °C 30 sec (where X is annealing, given in table N.1 together with 
amplification primer sequences)  
Step 4: 72 °C 1 min, then back to step 2 for 34 cycles. 
Fragment Forward and reverse primers Product, BP 
F: 5'-ATA TTA TAG TAG GGG TTG GAA TGA TTA AAG-3' 410
R: 5'-CCT ATT AAA CTA ATC TAA AAA ACA ATC CTC-3'
F: 5'-GGG GTA GAT AGT TGG GGA TAT TTT T-3' 257
R: 5'-CCT ACT ACT CTA ACT CTA CCC TAA ATA-3'
F: 5'-TTG ATA ATA GTA GT TGA TTG GTA GGG TGT-3' 395
R: 5'-ATC TAC AAC CTT ATC AAT TAC CCT TAA AAA-3'
F: 5'-AAA TTT GTG TGA TGT TTG TAA TTA TTT GGG-3' 310
R: 5'-TTT ACA AAT CAC TCC TCA AAA CCA A-3'
F: 5'-GGG TTA TAA AGT TTA GGG GTT TTT AGA TT-3' 470
R: 5'-AAA CTT TTC TAT TCA ACT TAA TTC CAA AC-3'
F: 5'-GTT AGA GAA TTT GAT AGT TTT TGG AAT AGG-3' 620
R: 5'-TCA AAC ACT ATA TTA CTT TAA CAA TTC CCA-3'
F: 5'-TTG ATA GTT GTG TTT TAA GTG GTA AAT AAA-3' 210
R: 5'-AAA ACA CCA CAA ACC AAA ATC TTC TAC-3'
MyIC at 51°C
Alpha Actin  at 58°C 
PEG3 at 54°C





Step 5: 72 °C 10 min, final elongation. 
Step 6: 4 °C and pause.  
 
4.5 Amplification product cleanup (exociap) 
 
The amplification products had to be cleaned from all remaining nucleotides and 
excess primers as these would have interfered with the subsequent single 
nucleotide extension reaction. An enzyme-based approach was used as 
described below.  
E.Coli exonuclease (ExoI, Fermentas) 
Calf intestine alkaline phosphatase (CIAP, Fermentas) 
10x EXO-CIAP buffer (Fermentas) 
Molecular biology grade water 
PCR product from step 3. 
 
PCR product cleanup was done in standard 200 µl PCR tubes using E.Coli 
exonuclease (ExoI, Fermentas), calf intestine alkaline phosphatase (CIAP, 
Fermentas), and 10x EXO-CIAP buffer (Fermentas) according to the following 
procedure:  
  First, 1.175 µl water was added to the tube, then 0.125 µl EXO, followed by 0.5 
µl CIAP and 0.2 µl EXO-CIAP buffer and 5 µl of bisulfite converted DNA; then the 
samples were incubated as follows in a thermal cycler: 30 min at 37 °C, 20 min at 
85 °C, pause at 4 °C.  
This method is more expensive than agarose gel based purification of the 
product, yet enzymatic treatment is more convenient when processing large 
numbers of samples. However, a highly specific product is a prerequisite for an 
enzymatic cleanup, whereas in a gel-based purification method it is possible to 
purify the needed specific band fraction from unwanted unspecific products. 
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4.6 Single nucleotide primer extension (SNuPE) 
 
 10x reaction buffer C, supplied ready (SolisBiodyne, Tartu, Estonia) 
 TermiPol (SolisBiodyne, Tartu, Estonia) 
 ddCTP&ddTTP, 20mMstock, 15 pM working solution. (Fermentas)  
 Molecular biology grade water 
 MgCl2 25 mM (Solis) 
 Exo/CIAP cleaned PCR product from step 4.  
 
Single nucleotide primer extension, (SNuPE) is a prerequisite for HPLC analysis of a 
given CpG dinucleotide. It is a modification (El-Maarri et al., 2007) of the original method 
developed by Gonzalgo and Jones (Gonzalgo and Jones, 1997). An oligo just flanking 
the 5' end of a CpG site, is extended by either a ddCTP or ddTTP, depending on the 
methylation status of the template. An unmethylated CpG is extended by ddTTP, a 
methylated CpG by ddCTP. This way the relative content of C and T at a given position 
can be determined. 
The SNuPE reaction was done using primers and temperatures as listed in table 2. 
Procedure: 
A master mix was prepared with the following reagents (using approx 10 % more 
volume than needed due to pipeting error): 
 
 Reaction buffer C   2 µl 
 ddCTP&ddTTP (1 mM mix, i.e. 5 µl from stock solution of each  
diluted by 490 µl water)  2 µl 
 Water -    8 µl 
 MgCl2  25mM -   2 µl 
 TermiPol -    0.2 µl 
 Primer  15 pM -   2 µl each; end volume 18 µl without DNA. 
 
The master mix was then distributed into PCR strips, followed by addition of 2 µl DNA 
from the cleaned bisulfite product into each, and the mix was subjected to thermal
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 cycling under the following conditions:  
 
 Step1: incubation at 94 °C for 2 min 
Step2: incubation at 92 °C for 30 sec 
Step3: incubation at 40 °C for 30 sec 
Step4: incubation at 52 °C for 1 min, then back to step 2 for 70 times.  
Step4: incubation at 4 °C indefinitely.   
The product could then be used directly for  HPLC analysis or frozen at -20 °C. 
 
 
Tab.2: Primers used for the single nucleotide extension step 
 
Fragment Primer 
MyIC 1: 5'-GTA TTG TTT GGT GT -3'
2: 5'-GTG TTT TGT TTT TGT GGT TT-3'
A Actin 1: 5' – GGG ATT TTA GTG TT-3'
2: 5'- TTT ATT TAG GTT GAG AAT TAG T – 3'
PEG3 1: 5'-GGG GAG TTA GGA GT-3'
2: 5'-TTT TTT TGT ATT AGA TTG-3'
SNRPN D1 1: 5'-TAG TTA TTG TTT GGG A -3'
2: 5'-TAG TTG TTT TTT GGT AGG ATA TTT-3'
LIT1 1: 5'- AGA ATT GAG TTA -3'
2: 5'- ATT ATT TTT GTT TTT GGT – 3'
L1 1: 5'-GTA TTT TGT GTG GGT-3'
2: 5'-TTT TTT GAG GAT AGG TGT TTA TT-3'
IAP 1: 5'-TAA TTA GGG AGT GAT A-3'
2: 5'-TAA TTT TTT TAA AAA AGG GA-3'
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4.7 HPLC analysis: 
 
 Wave system from Transgenomic, IP RP HPLC column; DNASep (cat. no.DNA 
99-3510, Transgenomic), where the stationary phase is alkylated nonporous 
polystyrene-divinylbenzene-2 µm beads (cat.no.PS/DVD-C18) 
 TEAA (triethylamoniumacetate) buffer - ion pairing reagent. (Cat.no.553303) 
 Acetonitril (Roth Art.8825.2) 
 HPLC-grade water (Merck, cat.no. 1.15333.2500)  
 
High-performance liquid chromatography (HPLC). The SNuPE reaction product was 
separated and quantified using ion-pair reverse phase HPLC (SNuPE-IP RP HPLC or 
SIRPH). The original method used radioactively labeled nucleotides and subsequent 
electrophoresis; the modification used here is based on the possibility to separate 
different extensions of the same oligo based on retention times for different sequences.  
This method gives a reliable methylation estimate at selected CpG sites. The extended 
product is directly loaded on a Wave DNA Analysis System from Transgenomic. As 
ddTTP is more hydrophobic, it has a longer retention time than ddCTP. If the primers 
are well optimized, it is possible to quantify multiple CpG site methylation on the same 
HPLC injection (figure 13). Measuring the height of the peaks and calculating their 
percentage ratios allows to estimate the methylation percentage at a given CpG site. 
 
Procedure:  
20 µl of the SNuPE product from the previous step was used for each injection on the 
HPLC machine (Wave, Transgenomic), with the oven temperature set to 50 °C, and the 














Calculation of the proportion of methylated CpGs was done according to the following 
formula: M=[C/(C+T)]*100, where C and T are respectively the peak heights of the 
ddCTP and ddTTP extended oligonucleotides. Peak heights are then calculated by the
 Wavemaker software (Fig.13) 
Step Time (minutes) %A (0.1M TEAA) %B (0.1M TEAA, 25% Acetonitril)
Loading 0.0 90 10
Start gradient 0.1 90 10
Stop gradient 8.1 50 50
Start clean 8.20 0 100
Stop clean 8.7 0 100
Start equilibrate 8.8 90 10
Stop equilibrate 9.3 90 10
Where the start percentage of buffer B in the elution buffer will steadily increase over an 8-
min period to reach the “stop gradient” step. 
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     5’gatg aaaattagag ttttT* 
     5’gatg aaaattagag ttttC 









Fig. 13: Scheme of the SNuPE product quantification using HPLC.  
 










Fig. 14: The reaction could also be multiplexed with up to three primers. Here an 



















 dNTPs: GE Healthcare, 25 mM each. 
 RT-enzyme: SuperScript III, Invitrogen. 
 Platinum-Taq: Invitrogen 
 Rox reference dye: Invitrogen 
 Primers: listed in table 4 
 Magnesium chloride, 50 mM. 
 10x PCR buffer.  
 Real-time cycler: Applied biosystems (ABI) Sequence detection system (SDS) 
7700. 
 
Tab.4: Real-time PCR primers used for RNA expression analysis.  
 
Real-time PCR is based on the detection of fluorescent signals of the amplification. 
Quantity of the PCR product determines signal strength. For this purpose, an ABI 
Prism® 7700 SDS machine was used. 
 
Cycling conditions were as follows:  
Primer Sequence
Taq-muAactin-F 5'-CTG CCT GAC GGG CAG GT-3'
Taq-muAactin-R 5'-CCG CAG ACT CCA TAC CGA TAA-3'
Taq-muAactin-P-Fam 5'-CGT TTC CGT TGC CCG GAG AC -3'
Taq-muMyIc-F 5'-GCT GCA TCA ACT ATG AAG CGT-3'
Taq-muMyIc-R 5'-CTG GGC TTC CTG AGA GGC-3'
Taq-muMyIc-P-Fam 5'-TGT GAA GCA TAT CAT GGC GAG CTG-3'
Taq-muPBGD-F 5'-CGG CCA CAA CCG CGG AAG AA-3'
Taq-muPBGD-R 5'-GTC TCC CGT GGT GGA CAT AGC AAT GA-3'
Taq-muPBGD-R-Joe 5'-TCG AAT CAC CCT CAT CTT TGA GCC GT-3'
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 Incubation at 50˚C for 20 min. 
 Incubation at 95˚C for 15 min 
 Incubation at 94˚C for 30 sec. 
 Incubation at 60˚C for 60 sec. 
 Repeat previous steps for 40 cycles.  
 
 
4.9 Statistical analysis 
 
Pearson correlation and t-test analysis were performed based on the generated 
methylation data. T-tests were performed to compare differences between males and 
females at different loci and in different tissues. Uncorrected P values below 0.05 were 
considered to be significant (α level of 0.05). To correct for multiple testing, Bonferoni 
correction was used  
The Pearson coefficient r was computed for all pairs of methylation variables within one 
tissue and in the two gender groups separately using the proc corr function from SAS 
software package (SAS for Windows, v9.1.,SAS Institute Inc.,Cary, NC, USA; 
http://www.sas.com).  
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5. Results  
 
5.1 DNA quantification and quality test: 
 
The DNA used in the experiments was extracted from the 9 organs mentioned 
previously (brain, tongue, skin (ear lobe), lungs, spleen, bone marrow (from lumen of 
femur), skeletal muscle (from femoral extensor and flexor groups), testes, and heart of 
100 mice (50 males, 50 females). A total of 900 units of DNA stock solution were 
generated. The aliquots were initially loaded on a 1.5 % agarose gel, thus testing the 
possible level of genomic DNA degradation. An example of this can be seen in Fig.7 








Fig. 15: Genomic DNA samples (extracted from bone marrow) on a 1,5 % agarose gel: 
 
5.2 PCR amplification  
 
The genomic DNA was then subjected to bisulfite treatment (described in detail on p.39-
41), and consequently amplified with the region-specific bisulfite primers (Tab. 2, 
conditions and amplification protocol on p.42-43). Amplification product samples are 
shown on Fig.8 below. As seen in Fig.8, some products, especially the repetitive 
elements Iap and LINE-1, have unspecific amplification bands present in the product. 
This problem was solved by using the second set of primers, namely in the single 
nucleotide primer extension step (SNuPE), which are highly specific for the sequences 
targeted. 






























Fig. 16: Bisulfite treated DNA amplification product samples on a 1,5 % agarose gel. 
257 bp 
a) Alpha actin  
410 bp 
b) Murine MLC1V gene 
392 bp 




5.3 HPLC chromatograms  
 
The bisulfite amplification product was then subjected to the single nucleotide primer 
extension protocol (SNuPE; primers listed on Tab.3, reaction conditions listed on p. 45-
47). Figure 16 shows some examples of the HPLC chromatograms, the peak height of 
which is our actual data and mirrors the percentage of CpGs methylated at the given 
CpG site. Not all CpG sites have been successfully analyzed by HPLC due to multiple 
preparation steps, each of which could not be performed with 100 % efficiency. The 
numbers of sites with readable HPLC chromatogram peaks and their raw data (peak 
height) plus the calculated ddCTP to ddTTP ratio are fully listed in Appendix 2.  
As seen in chromatogram examples in figure 16 below, not all chromatograms 
demonstrated same sharpness of peak separation and distinctive peak height or shape. 
The peak separation distance is dependent on the sequence of the SNuPE primer used, 
as different sequences have slightly different melting properties and will therefore react 



































Fig. 17: HPLC chromatogram samples. a) Murine MLC1V gene, MyLC; b) Alpha actin; 














Myosin light chain, MyLC  
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5.4 The influence of sex on methylation levels: male/female differences 
 
A) Single loci 
 
Two CpG sites have been investigated in myosin light chain gene and two in alpha actin, 
of 100 mice, 9 organs from each, generating a total of 900 chromatograms and 1800 
single cytosine methylation readings. Readable peaks have been obtained for 1696 
CpG sites in myosin light chain and 1540 in alpha actin.  
 
 Myosin  
The CpG sites investigated were located after nucleotide positions 1406 and 1480, 
accession n.X12972.  Initial data indicated males being more methylated in lungs, brain, 
tongue, and heart. After Bonferoni correction, which was done for the first CpG site in 
every region studied, none of them were significant enough (Table 5). 
 
 Alpha actin   
Raw data showed a tendency towards greater methylation in males in lungs , tongue, 
and muscle, while females tended to be more methylated in brain. After statistical 
analysis and Bonferoni correction, only the difference in tongue remained significant. 
(Tab.5-7). 
B) Imprinted genes 
 
 Peg3  
Initial trend showed greater methylation in males in skin, tongue, and muscles, while 
females were more methylated in brain. Statistical analysis after Bonferoni correction left 
males to be signifficantly more methylated in skin and tongue (Tab.5-7).
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  Snrpnd1,  
Initial trend indicated greater methylation in males in lungs, tongue, and heart, while 
females leaned toward greater methylation in spleen and bone marrow. Data after 
bonferoni correction showed males were statistically more methylated in the CpG sites 
at nucleotide positions 57858 and 57934, accession n.AF332579, in lungs and tongue, 
and less methylated at position 57858 in bone marrow (Tab. 5-7). 
 Lit1,  
Initial tendency was greater mehylation in males in spleen, lungs, skin, and tongue, 
while females were more methylated in brain and bone marrow. After Bonferoni 
correction, males remained more methylated in lungs, tongue and skin, less methylated 




CpG sites at nucleotide positions 170 and 206, accession n. M17551. Uncorrected data 
suggested males were more methylated in spleen and bone marrow, less methylated in 
lungs, skin, brain, and heart. After Bonferoni correction, males remained significantly 
more methylated in bone marrow, but less in lungs and skin (Tables 5 a-c).  
 
 LINE-1.  
The CpG sites investigated were located at nucleotide positions 965 and 1001, 
accession n. D84391. Initial results showed males to be more methylated in brain, 
females in bone marrow, tongue, and heart. After Bonferoni correction, difference 
remained signifficant in tongue and skeletal muscle (Tables 5 a-c)
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Tab. 5: Level of methylation in spleen, lung and skin tissue samples plus male/female T-
test and Bonferoni correction; correction shown only for the first positions (first pair of 
HPLC peaks) analyzed.  
 
Tissue Spleen Lungs Skin






ci Regions Pos. 1406 Pos. 1480 Pos. 1406 Pos. 1480 Pos. 1406 Pos. 1480
MyLC males 74 80 47 52 66 72
Acc. n. X12972 females 72 80 45 51 67 71
T-Test 0.07348109 0.59254373 0.00469404 0.32702893 0.18036824 0.05886483
Bonferroni correction: 1.00E+00 2.96E-01 1.00E+00
Pos. 441 Pos. 529 Pos. 441 Pos. 529 Pos. 441 Pos. 529
A actin males 37 50 27 34 26 35
Acc. n.  M12347 females 37 48 25 32 24 34
T-Test 0.258 0.244 0.002 0.037 0.058 0.641










s Pos. 2835 Pos. 2922 Pos. 2835 Pos. 2922 Pos. 2835 Pos. 2922
PEG3 males 43 49 39 50 45 53
Acc. n. M12347 females 44 49 38 48 43 50
T-Test 0.06163219 0.05904186 0.33776207 0.05705342 0.00001064 0.00003568
Bonferroni correction: 1.00E+00 1.00E+00 6.70E-04
Pos. 57835 Pos. 57934 Pos. 57835 Pos. 57934 Pos. 57835 Pos. 57934
SNRPN D1 males 42 50 44 56 44 52
Acc. n. AF332579 females 42 51 41 53 44 50
T-Test 0.43737012 0.03877697 0.00000000 0.00049491 0.12466367 0.06769482
Bonferroni correction: 1.00E+00 1.23E-07 1.00E+00
Pos. 45216 Pos. 45348 Pos. 45216 Pos. 45348 Pos. 45216 Pos. 45348
LIT1 males 47 39 44 36 46 42
Acc. n.  AJ271885 females 47 38 42 35 43 38
T-Test 0.01570943 0.00418357 0.00000041 0.14552654 0.00000000 0.00000002
Bonferroni correction: 9.90E-01 2.58E-05 4.13E-09




ts IAP males 78 84 77 79 64 60
Acc. n. M17551 females 77 82 79 81 66 60
T-Test 0.17646157 0.00001424 0.00000055 0.00000300 0.00000160 0.43046263
Bonferroni correction: 1.00E+00 3.47E-05 1.01E-04
Pos. 965 Pos. 1001 Pos. 965 Pos. 1001 Pos. 965 Pos. 1001
L1 males 80 84 84 87 85 87
Acc. n. D84391 females 79 84 84 87 85 88
T-Test 0.49695 0.90907 0.27722 0.58366 0.59721 0.74366
Bonferroni correction: 1.00E+00 1.00E+00 1.00E+00
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Tab. 6: Level of methylation in brain, bone marrow, and testicular tissue samples plus 
male/female T-test and Bonferoni correction; correction shown only for the first positions 
(first pair of HPLC peaks) analyzed. 
Tissue Brain Bone marrow Testes






ci Regions Pos. 1406 Pos. 1480 Pos. 1406 Pos. 1480 Pos. 1406 Pos. 1480
MyLC males 70 80 66 76 72 74
Acc. n. X12972 females 69 80 65 76
T-Test 0.00894007 0.28580020 0.39208895 0.99844120
Bonferroni correction: 5.63E-01 1.00E+00
Pos. 441 Pos. 529 Pos. 441 Pos. 529 Pos. 441 Pos. 529
A actin males 46 54 33 39 59 63
Acc. n.  M12347 females 50 57 34 39
T-Test 0.056 0.004 0.598 0.698










s Pos. 2835 Pos. 2922 Pos. 2835 Pos. 2922 Pos. 2835 Pos. 2922
PEG3 males 44 51 40 47 20 29
Acc. n. M12347 females 47 54 41 47
T-Test 0.00100214 0.00187294 0.08743775 0.16564843
Bonferroni correction: 6.31E-02 1.00E+00
Pos. 57835 Pos. 57934 Pos. 57835 Pos. 57934 Pos. 57835 Pos. 57934
SNRPN D1 males 45 59 42 54 18 24
Acc. n. AF332579 females 45 61 43 55
T-Test 0.72186344 0.22192811 0.00006885 0.09708330
Bonferroni correction: 1.00E+00 4.34E-03
Pos. 45216 Pos. 45348 Pos. 45216 Pos. 45348 Pos. 45216 Pos. 45348
LIT1 males 44 38 39 38 20 28
Acc. n.  AJ271885 females 46 41 42 39
T-Test 0.00013058 0.00000817 0.00001037 0.05728803
Bonferroni correction: 8.23E-03 6.53E-04




ts IAP males 89 75 81 73 63
Acc. n. M17551 females 90 73 82
T-Test 0.00116926 0.00008632 0.09224869
Bonferroni correction: 5.44E-03
Pos. 965 Pos. 1001 Pos. 965 Pos. 1001 Pos. 965 Pos. 1001
L1 males 88 85 72 79 73 71
Acc. n. D84391 females 88 84 72 80
T-Test 0.36289 0.01975 0.07199 0.03683
64 
Tab. 7: Level of methylation in tongue, skeletal muscle, and heart muscular tissue 
samples plus male/female T-test and Bonferoni correction; correction shown only for the 
first positions (first pair of HPLC peaks) analyzed.  
Tongue Muscles Heart






ci Regions Pos. 1406 Pos. 1480 Pos. 1406 Pos. 1480 Pos. 1406 Pos. 1480MyLC 66 75 65 75 51 58
Acc. n. X12972 68 71 66 75 49 56
0.01676302 0.00000000 0.19318411 0.66041539 0.05675236 0.02870041
Bonferroni correction: 1.00E+00 1.00E+00 1.00E+00
Pos. 441 Pos. 529 Pos. 441 Pos. 529 Pos. 441 Pos. 529
A actin 27 37 21 29 27 35
Acc. n.  M12347 23 31 20 30 26 35
0.000 0.001 0.008 0.515 0.804 0.598










s Pos. 2835 Pos. 2922 Pos. 2835 Pos. 2922 Pos. 2835 Pos. 2922
PEG3 65 80 51 57 46 58
Acc. n. M12347 0.00000000 67 48 55 47 57
3.16E-08 0.00002850 0.00145772 0.10246896 0.72458959 0.34578413
Bonferroni correction: 9.18E-02 1.00E+00
Pos. 57835 Pos. 57934 Pos. 57835 Pos. 57934 Pos. 57835 Pos. 57934
SNRPN D1 50 63 65 75 44 54
Acc. n. AF332579 43 55 66 75 43 54
0.00000000 0.00000000 0.58944354 0.98802868 0.04240597 0.28364517
Bonferroni correction: 6.61E-25 1.00E+00 1.00E+00
Pos. 45216 Pos. 45348 Pos. 45216 Pos. 45348 Pos. 45216 Pos. 45348
LIT1 57 47 40 35 34 35
Acc. n.  AJ271885 47 39 41 36 34 35
0.00000000 0.00000000 0.37497445 0.28398094 0.78698771 0.99382305
Bonferroni correction: 4.46E-13 1.00E+00 1.00E+00




ts IAP 82 88 62 60 81 88Acc. n. M17551 82 88 60 61 80 89
0.90602758 0.86625529 0.16220050 0.64959605 0.30722528 0.03667537
Bonferroni correction: 1.00E+00 1.00E+00 1.00E+00
Pos. 965 Pos. 1001 Pos. 965 Pos. 1001 Pos. 965 Pos. 1001
L1 85 83 86 81 85
Acc. n. D84391 86 84 86 82 86
0.00000000 0.07970 0.02044 0.00016803 0.00013
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5.5 Methylation variability at  
specific loci in different organs 
 
In this part, we investigated the organ specific methylation variations at the studied loci. 
Complete values and standard deviation are given in Appendix 1. 




Fig. 18: Alpha actin. Among tissues studied in both sexes, in males, alpha actin was 
most methylated in brain (46 %), least methylated in skeletal muscle (21 %). Of all the 
tissues, testis showed the highest methylation level, reaching 59 %. In females, same 
tendency was observed (brain 49 %, skeletal muscle 20 %). 
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Fig. 19: Myosin light chain: Males are most methylated in spleen (74 %), least 
methylated in lungs (47 %). Females are also most methylated in spleen (72 %), least 
methylated in lungs (45 %). Considering that methylation is inversely proportional to 
gene expression, these results are logical in that if skeletal muscle expresses myosin 
light chain gene in a high level it should be less methylated there. The relatively low 
methylation in lungs cannot be simillarly explained. 
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Fig. 20: Peg3: Among the tissues studied, males showed heaviest methylation in tongue 
(65 %), least methylation in bone marrow (41 %); females were most methylated in 
tongue (56 %), least methylated in lungs (38 %). Testes showed a signifficant reduction 
in methylation at this locus due to the imprinting process that leaves it unmethylated in 
male gametes.  
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Fig. 21: Snrpn-D1: In males, most methylated in skeletal muscle (65 %) , least 
methylated in spleen and bone marrow (42 %). In females, most methylated in skeletal 
muscle (66 %), least in bone marrow (32 %). Again, testis showed very low methylation 
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Fig. 22: Lit1: In males, most methylated in tongue (57 %), least methylated in heart 
muscle (34 %). In females, it is also most methylated in tongue (47 %), least in heart 
muscle (34 %). Low methylation in testis would again correlate with the imprinting status 
of this locus.
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Fig. 23: Iap: highly methylated in most of the tissues analysed. In both males and 
females, most methylated in brain (89 % and 90 %, respectively), least methylated in 
skeletal muscle (62 % and 60 %). 
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Fig. 24: LINE-1: In males, most methylated in brain (88 %), least methylated in bone 
marrow (72 %). In females, the same trend is observed, with brain at 87 %, and bone 
marrow at 73 %. It is to be expected that parasitic repeats are silenced to a significant 
degree in all tissues.  
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5.6 Correlation between methylation and RNA expression levels 
 
Quantitative RNA expression analysis was done for the two single copy genes, alpha 
actin and myosin light chain, in 9 tissues. Liver and kidney have been additionally 
included in this section. Expression data is presented in the following section. These are 
different measurements than those presented in sections 4.4 and 4.5; they are, 
however, comparable. The results presented in the two graphs below are the averages 
















Fig. 25: Relative RNA expression intensity in a given tissue for alpha actin. Methylation 
is given in percent, expression is relative pyrosequecing data  
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These results show methylation and expression do not correlate directly. This may be 
due to the possibility that the expression switch may be programmed on a much larger 
scale and consist not only of DNA methylation, but also of other factors. Skeletal muscle 
(femoral and tongue muscles), however, show markedly higher expression; and also 
selectively lower methylation levels. In tissues with highest methylation levels, testis and 
brain, no detectable expression was observed. Males show relatively higher expresion in 
all tissues. 
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Fig 26: Relative RNA expression intensity in a given tissue for myosin light chain. . 
Methylation is given in percent, expression is relative pyrosequecing data 
 
Myosin light chain is expressed at high levels in cardiac muscle. Once again, and as at 
the alpha actin locus, there is no strict correlation between methylation and expression 
of myosin light chain. The expression of various myosin isoforms and their methylation 
in heart may be considered more in-depth in the future, as the pattern observed 
markedly differs from that of other tissues. It is to be noted that highest expression was 
observed in cardiac muscle, which also shows relatively lower methylation levels. 
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5.7 Correlation of methylation between different loci within one tissue 
 
Here, we measured DNA methylation values at 6 different loci in 9 different organs of 
about 100 male and female mice. The methylation data presented below was 
reanalysed to answer the question if correlation exists between different loci in a given 
tissue in the level of DNA methylation. For this purpose we used the SAS package 
program. Several instances of signifficant correlation have been observed; the detailed 
results are listed in appendix 3. However not all correlations were observed in both male 
and female group. We consider the strong 'true' correlations are the ones that are 
detected in both sexes as these are two different groups of samples that could serve as 
independent replicate for each other; this does not necessary mean that other 
correlations found in only one sex are not true, as gender specific effects cannot be 
excluded. 
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Bone Marrow:  
In bone marrow, a strong positive correlation was observed between Myc and LINE-1 in 
both male and female samples (appendix II).  
Fig 27: Scatter plot of correlation between SN1 in myosin ligt chain and long 
interspersed elements in male mice bone marrow, y = 0.4918x+39.036 and R2 = 0.334 
 
Fig 28: Scatter plot of correlation between SN1 in myosin ligt chain and long 
interspersed elements in female mice bone marrow, y = 1.0838x-12.221, R2=0.6538 








58 60 62 64 66 68 70 72








67 68 69 70 71 72 73 74 75 76
77 
Heart: 
Significant correlation was observed in males between Peg3 and Snrpn-D1 loci (at the 
second CpG: SN2); A positive significance between the same two loci was observed in 
female samples. 
Fig 29: Scatter plot of correlation between SN2 in small nuclear ribonucleoprotein 
polypeptide differentially methylated region 1, and paternally expressed gene 3 in male 
mice heart, y = 0.2857x+37.564, R2 = 0.3729 
Fig 30: Scatter plot of correlation between SN2 in small nuclear ribonucleoprotein 
polypeptide differentially methylated region 1, and paternally expressed gene 3 in female 
mice heart, y =0.2758x+37.824, R2=0.2665 
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In brain tissue, significant correlation could be observed between alpha actin and Peg3 
at the second CpG site in both males and females. Similarly significant positive 
correlation was observed between Peg3 and Snrpn-D1 at the first CpG site (SN1). 
Fig 31: Scatter plot of correlation between SN2 in paternally expressed gene 3 and 
alpha actin in male mice brain, y = 0.5271x+23.041, R2=0.5829 
Fig 32: Scatter plot of correlation between SN2 in paternally expressed gene 3 and 
alpha actin in male mice brain, y =0.5416x+20.878, R2=0.5227 
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In spleen tissue samples, the highest degree of correlation was observed simultaneously 
in males and females. The correlation showed positive significance and are as follows: 
between Myc and IAP at first CpG site; between Myc and LINE-1 at both studied CpGs; 
between Snrpn-D1 and IAP at first CpG; between Snrpn-D1 and LINE-1 at first CpG and 

















Fig 33: Scatter plot of correlation between SN1 in intracisternal A particle gene and 
myosin light chain in male mice spleen, y=0.3836x+49.188, R2=0.8098 
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Fig 34: Scatter plot of correlation between SN1 in long interspersed elements and 
myosin light chain in male mice spleen, y=0.7092x+27.215, R2=0.6786 
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Fig 35: Scatter plot of correlation between SN1 in long interspersed elements and 
myosin light chain in female mice spleen, y=0.6383x+33.413, R2=0.8169 
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Fig 36: Scatter plot of correlation between SN2 in long interspersed elements and 





Recent methylome studies have shown that DNA methylation exists not only in the CpG 
context. This is especially true for pluripotent cells (Goodson and Hawse, 2002). 
However, in this presented work, only methylation in CpG content was investigated. The 
material consisted of differentiated tissue, with the partial exception of testes, and only 
CG sites were specifically analyzed in the used approach.  
 
There are differences between somatic tissues. They are comprised of varying 
proportions of cells in various differentiation states, so that the results are tissue specific 
patterns of expression and also tissue specific DNA methylation. The questions we raise 
here are: 1) are there methylation differences between these somatic tissues that are 
gender specific? 2) Are there methylation differences at CpG sites between different 
somatic tissues in the same gender? What we are presenting here is a relatively small 
study as both the number of animals and of gene fragments investigated are limited. 
However, it comprises genes of some key traits: structural protein encoding genes 
(myosin and alpha actin), imprinted genes (PEG3, SnrpnD1 and Lit1), and two repetitive 
elements (LINE-1 and IAP) that are used as surrogate methylation markers to reflect on 
the overall genome methylation trends.  
 
A) Structural protein encoding genes 
 
Myosin is the main protein in the contractile apparatus. A myosin molecule is composed 
of two heavy and two light chains. Proportions and sort of the heavy and light chain 
isoforms define the mechanical velocity and power effect of the muscle. The light chains 
have a molecular weight of 17 to 21 kDa. Both heavy and light chains are subject to 
tissue and developmental stage specific isoform changes. There are multiple myosin 
light chain isoforms, resulting from alternative splicing of its gene and present in various 
proportions in smooth, skeletal and cardiac muscle; different types of body tissues 
express different myosin isoforms dependent on their function. The myosin region 
investigated in this study is the murine MLC1V gene for myosin alkali light chain, exon 1, 
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a ventricular/slow muscle isoform (Feng 2008; Leoni et al., 2005; Redowicz 2002). 
The CpG sites investigated were located after nucleotide positions 1406 and 1480, 
accession n.X12972 (coding sequence starts at 1365, mRNA at 1298). Initial data 
indicated males being more methylated in lungs, brain, tongue, and heart. However, 
after Bonferoni correction for multiple testing, which was done for the first CpG site in 
every region studied, none of them were significant enough (Table 5). These, then, are 
but trends, limited by the size of the study. 
 
The difference in heart and tongue between sexes (Tab.5-7) seems clear enough, as 
these are both muscle tissue dominated organs and both consist of striated muscle. We 
can well assume that there is a sex dependent difference, as androgen concentration 
affects myosin subtype predominance, and possibly enacts quantitative changes in the 
musculature (Redowicz 2002). The difference may exist, however, it may be necessary 
to discern between individual muscle fiber subtypes to be able to see a more detailed 
DNA methylation picture. This picture should be dynamic, showing what exactly 
happens to this methylation as individual cells progress from totipotency to the fully 
differentiated muscle fibers. 
 
We see there that lungs use myosin in cilia movement. It could well be that there are sex 
dependent differences in the respiratory pathway epithelium structure, only they were 
not to be observed with a given method and limited investigated regions. We also have 
to take into account the heterogeneity of the cells in the probe, not only epithelial. 
Assuming that CpG methylation reflects repression, muscles responsible for epithelial 
cilia motion may express this particular myosin isoform. Lungs do stand out between 
other tissues in myosin, with their value of just 47 %, while other tissues varies between 
65 % and 75 % (again, see comparison on page 58).  
 
In addition to the gender differences, the tissues also exhibit distinct differences in 
myosin methylation. Considering that methylation at these promoter regions is inversely 
correlated with expression, one would expect higher methylation in tissues where 
myosin would be less needed. Surprisingly, the least methylation is observed in lungs, 
while one would expect them to be so in striated muscle dominated tissue, such as 
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skeletal muscle, heart, and tongue. A gap of ca. 20 % in methylation separates lungs 
from these tissues. The presence of cardiac, skeletal and tongue muscle on the less 
methylated side is not surprising. The lungs raise questions in this context-whether this 
CpG methylation is an isolated random finding, or whether a particular myosin subtype 
is more actively expressed in the lung, again, possibly in the ciliated epithelial surfaces, 
as asserted by previous works (Feng 2008). There is also a notable difference between 
skeletal and cardiac muscle, the latter being almost 20 % less methylated than the 
former. One has also to consider that methylation at the specific investigated CpGs may 
not be directly linked to the expression as would be expected.  
 
Summarizing the results, we may say that there are methylation differences in this 
housekeeping gene, not as evident between sexes, but quite distinct between tissues. 
For greater functional significance, these results need to be complemented with studies 
involving a larger sample number, and wider evaluation of larger sequence, not limited 
to methylation at few CpG sites. A more accurate picture may be possibly obtained by 
studying not only complete tissues, but also their individual homogeneous sub-cellular 
populations. These could then possibly be differentiated by expression of specific 
proteins, in conjunction with their methylation assessment.  
 
Alpha actin gene encodes a small compact protein of around 43 kDa. CpG sites 
investigated were located directly after nucleotide positions 441 and 529, accession n. 
M12347 (coding sequence starts at 1785, mRNA at 754). In muscles, actin is the rail on 
which myosin complexes move. In non-muscle cells, it has a variety of functions, 
including support and stabilization of nuclear matrix and lamina and chromatin 
remodeling (McGrath and Solter 1983). Actin can adopt a great number of forms, as 
filaments, sheets, or tubes, which makes it the scaffold of many cellular processes such 
as transcription, chromatin formation, cellular shape, motility, and adhesion. It is also 
phylogenetically very old, being found in comparable forms among such long diverged 
species as mammals and fungi (Derks et al., 2008).  
 
In alpha actin, raw data showed a tendency towards greater methylation in males in 
lungs, tongue, and muscle, while females tended to be more methylated in brain, 
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although this was only seen in one of the two investigated sites (Tab.5-7). After 
statistical analysis and Bonferoni correction for multiple testing, only the difference in 
tongue remained significant. (Tab.5-7). RNA expression analysis in alpha actin revealed 
that in those fragments where its promoter was comparatively less methylated, there 
was also higher expression, such as tongue and skeletal muscle, whereas stronger 
methylation correlated with less expression (for example, brain; see alpha actin, brain, 
primer/site 2 in Tab. 5-7). 
 
We may assume, keeping in line with the hypothesis that greater methylation means 
less expression, that there are structural differences between male and female tongue 
muscle. These may be related to the male hormone induced muscle quantitative 
differences (Redowicz 2002). Though not confirmed, the brain methylation trend 
remains interesting, showing the possibility of structural differences in the cellular 
composition of the brain between sexes. This data could have been influenced, as in 
other tissues, by percentage distribution of different types of cells in the tissue sample. 
In the brain, this would be for example glial and vascular cells. The difference therefore 
could be a product of different proportions of these cells between the sexes, while the 
qualitative cell structure could be identical. Other studies have shown that expression of 
housekeeping genes, among them also an actin subtype, differs depending on brain 
area sampled (Wolfrum et al., 1998). Thus, greater uniformity, along with increased 
accuracy, is needed in the sampling to come to conclusions (Wolfrum et al., 1998). In 
our work, though brain area sampled was random, there is a trend towards general 
difference between the sexes.  
 
As we set the sex differences aside and only consider the differences between tissues, 
the differences of methylation at given sites may be as high as 40 % between testis and 
skeletal muscle, or 30 % between skeletal muscle and brain, as seen in graph of section 
4.5, methylation variability, part c, repeats, on page 62. These results do show, as 
expected, less methylation and would predict greater expression activity of actin in 
muscle tissues, such as heart, skeletal muscle and tongue. The skin may fit in this 
context due to its mechanical properties, which may be traced to actin at the molecular 
level, being a very basic structural protein. 
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B) Imprinted genes 
 
In mammals, most autosomal genes are expressed from both paternal and maternal 
alleles. Imprinting is the process whereby one of the two inherited copies is repressed 
and the other stays active. This has first been shown in mouse nuclear transfer 
experiments (Bestor and Bourc'his 2006; Surani and Barton 1983), which showed that 
same genes might behave differently depending upon their parental origin. (Doerfler 
2005; Otsuka et al., 2009). Imprinted genes are involved in controlled growth restriction 
processes during fetal development, where they are especially important in placental 
development, and growth in general. Of roughly 30.000 genes expressed in humans, an 
estimated 74 are imprinted (Ying-Chun et al., 2006).  
The functions associated with imprinting to date include tumor suppression, brain 
development and apoptosis (El-Maarri et al., 2005; Ying-Chun et al., 2006), nurturing 
behavior and maternal resource availability in mammals (Dvo Kim et al., 2007).  
 
PEG3; paternally expressed gene 3. Two CpG sites in exon 1 were investigated, at 
nucleotide positions 2835 and 2922 (accession n. AF105262, mRNA starts at 2803). 
PEG3 consists of nine exons and is ca. 26 kb long. The gene is located on mouse 
proximal chromosome 7, its human homologue on human chromosome 19. It encodes a 
zinc finger protein, and some experiments indicate its role as a tumour suppressor 
(Lucifero et al., 2002). The gene is expressed in mesodermal tissues of early somites, 
and later in the gut and hypothalamus (Kuroiwa et al., 2009). Later development shows 
ubiquitous expression in tissues, with predominant expression in brain, testis, ovary and 
placenta. (El-Maarri et al., 2005). PEG3 has been implicated in regulating development 
of some brain parts through apoptotic pathways (Broad et al., 2009). PEG3 deficient 
mice are growth impaired (Meyne and Legator 1980), which also fits to its involvement in 
numerous cancer lines, including endometrial, ovarial, cervical cancers and glioma (El-
Maarri et al., 2005).  
 
Initial trend showed greater methylation in males in skin, tongue, and muscles, while 
females were more methylated in brain (procentual data plots, page 59). Statistical 
analysis after Bonferoni correction left males to be significantly more methylated in skin 
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and tongue (Tab.5-7). Concerning the inter-tissue differences and in accordance to 
previous works, testes showed less methylation and thus possibly greater expression 
(El-Maarri et al., 2005); the methylation results from brain tissue, however, were not 
much different from those of other tissues, for example, the difference between brain, 
muscle, heart and lung was less than 10 % in the data plot on page 59, while the 
difference between brain and testes was over 20 %.  
 
Snrpn D1; small nuclear ribonucleoprotein N gene differentially methylated region 1. We 
analyzed two CpG positions in this gene, nucleotide positions 57858 and 57934 
(accession n.AF332579, coding sequence starts at 68049, mRNA at 67979). Initial trend 
indicated greater methylation in males in lungs, tongue, and heart, while females leaned 
toward greater methylation in spleen and bone marrow. Data after Bonferoni correction 
showed males were more methylated in the CpG sites at both positions in lungs and 
tongue, and less methylated at position 57858 in bone marrow (Table 5). In males, 
skeletal muscle is the most methylated tissue (65 %), spleen and bone marrow are least 
methylated (42 %). In females, skeletal muscle is most (66 %), and bone marrow least 
methylated (32 %). Testis showed very low methylation levels, as imprinting leaves this 
locus unmethylated in spermatozoa. Overall impression is that skeletal muscle tissue is 
relatively highly methylated with over 60 % at both loci observed, testes is strongly 
hypomethylated, with next relatively low methylation tissue being the spleen, and other 
tissues are relatively even at about 45 %. 
 
The gene is found on chromosome 7 in mouse (Chromosome 15 in humans, (Glenn et 
al., 1996)). It encodes the Snrpn protein involved in RNA splicing (Rodriguez-Jato et al., 
2005). The core gene has 10 exons, transcribes into a 1.4 kb mRNA. Exons 1-3 encode 
the SNURF protein, 4-10 encode the Snrpn splicosomal protein. Besides the two 
proteins, the gene also contains a ca. 460 kb long RNA transcript, which results in 
numerous small RNAs due to variuos splicing. (Suzuki et al., 2009). The Snrpn region 
contains two alternative upstream promoters and some non-coding exons. There are 
multiple untranslated upstream exons of unknown function and at least two alternative 5' 
start sites (Glenn et al., 1997). The sequence is also host to multiple small nucleolar 
RNAs encoded in the region. The protein has a direct impact on the synthesis of brain 
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proteins, particularly those that function in the hypothalamus, due to its splicing function 
(Feinberg 2007). The gene contains two differentially methylated regions and 23 known 
methylation sites. The first DMR includes part of the promoter and transcription start 
site, and is postulated to inherit a maternal-specific imprint.  
 
The function of the gene is complex. Experimental deletion data from mouse model 
shows that a deletion from SNRPN to UBE3A causes hypotonia, growth retardation and 
partial lethality (Glenn et al., 1997). Loss of these small nucleolar RNAs contributes to 
Prader-Willi syndrome. Their target molecules remain unknown. SNRPN transcription 
sense and adhering UBE3A (linked to Angelman syndrome) antisense units serve as 
host genes for small nucleolar RNAs encoded within them (Glenn et al., 1997).  
 
Lit1, The genomic region of Lit1 corresponds to a highly conserved region between 
mouse and human. It is an imprinted locus, participating in the expression regulation of 
KCNQ1a voltage-gated potassium channel protein. CpGs investigated in this region 
were located at nucleotide positions 45216 and 45348, accession n.AJ271885. Initial 
tendency was greater mehylation in males in spleen, lungs, skin, and tongue, while 
females were more methylated in brain and bone marrow. After Bonferoni correction, 
males remained more methylated in lungs, tongue and skin, less methylated in brain 
and bone marrow. 
 
LIT1, or long QT intron transcript, codes for an antisense RNA in the region of KvLQT1, 
a gene encoding a voltage-gated potassium channel. It is transcribed in the opposite 
direction to the channel gene (Fig.1) The channel gene is about 300 kb long and is 
expressed from the maternal allele. (Fig.2) The heart is an exception to this, as both 
paternal and maternal gene copies are expressed (Gaston et al., 2001). Another 
interesting observation is that in described cases of loss of imprinting of LIT1, 
demethylation of the maternal allele was always complete. There was also no tumour 
risk associated with demethylation of LIT1 only, where neighbouring imprinting centres 
were not affected. However, in tumour tissues, mosaic demethylation patterns have 
been observed (DeBaun et al., 2002). Our data possibly indicates a more active 
metabolism in the male brain and bone marrow, pointing to a possible more active 
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production of the said potassium channel in these tissues. Slight, yet statistically reliable 
difference in skin and lungs can indicate a slower cellular change rate there in the 
males, or simply a different cell/connective tissue ratio in the probes. This pilot work 
provides limited data for few methylation sites of each studied gene, which makes it 
difficult to reach definitive conclusions. 
 
Imprinted genes are involved in controlled growth restriction processes during fetal 
development, where they are especially important in placental development, and growth 
in general. Of roughly 30.000 genes expressed in humans, an estimated 74 are 
imprinted (Ying-Chun et al., 2006).  
The functions associated with imprinting to date include tumor suppression, brain 
development and apoptosis (, El-Maarri et al., 2005; Ying-Chun et al., 2006), nurturing 
behavior and maternal resource availability in mammals (Dvo Kim et al., 2007).  
 
PEG3. In paternally imprinted gene 3, two CpG sites in exon 1 were investigated, at 
nucleotide positions 2835 and 2922 (accession n. AF105262, mRNA starts at 2803). 
PEG3 consists of nine exons and is ca. 26 kb long. The gene is located on mouse 
proximal chromosome 7, its human homologue on human chromosome 19. It encodes a 
zinc finger protein, and some experiments indicate its role as a tumour suppressor 
(Lucifero et al., 2002). The gene is expressed in mesodermal tissues of early somites, 
and later in the gut and hypothalamus (Kuroiwa et al., 2009). Later development shows 
ubiquitous expression in tissues, with predominant expression in brain, testis, ovary and 
placenta. (El-Maarri et al., 2005). PEG3 has been implicated in regulating development 
of some brain parts through apoptotic pathways (Broad et al., 2009). PEG3 deficient 
mice are growth impaired (Meyne and Legator 1980), which also fits to its involvement in 
numerous cancer lines, including endometrial, ovarial, cervical cancers and glioma (El-
Maarri et al., 2005).  
 
Initial trend showed greater methylation in males in skin, tongue, and muscles, while 
females were more methylated in brain (procentual data plots, page 59). Statistical 
analysis after Bonferoni correction left males to be significantly more methylated in skin 
and tongue (Tab.5-7). Concerning the inter-tissue differences and in accordance to 
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previous works, testes showed less methylation and thus possibly greater expression 
(El-Maarri et al., 2005); the methylation results from brain tissue, however, were not 
much different from those of other tissues, for example, the difference between brain, 
muscle, heart and lung was less than 10 % in the data plot on page 59, while the 
difference between brain and testes was over 20 %.  
 
Snrpn D1; small nuclear ribonucleoprotein N gene differentially methylated region 1. We 
analyzed two CpG positions in this gene, nucleotide positions 57858 and 57934 
(accession n.AF332579, coding sequence starts at 68049, mRNA at 67979). Initial trend 
indicated greater methylation in males in lungs, tongue, and heart, while females leaned 
toward greater methylation in spleen and bone marrow. Data after Bonferoni correction 
showed males were more methylated in the CpG sites at both positions in lungs and 
tongue, and less methylated at position 57858 in bone marrow (Table 5). In males, 
skeletal muscle is the most methylated tissue (65 %), spleen and bone marrow are least 
methylated (42 %). In females, skeletal muscle is most (66 %), and bone marrow least 
methylated (32 %). Testis showed very low methylation levels, as imprinting leaves this 
locus unmethylated in spermatozoa. Overall impression is that skeletal muscle tissue is 
relatively highly methylated with over 60 % at both loci observed, testes is strongly 
hypomethylated, with next relatively low methylation tissue being the spleen, and other 
tissues are relatively even at about 45 %. 
 
The gene is found on chromosome 7 in mouse (Chromosome 15 in humans, (Glenn et 
al., 1996)). It encodes the Snrpn protein involved in RNA splicing (Rodriguez-Jato et al., 
2005). The core gene has 10 exons, transcribes into a 1.4 kb mRNA. Exons 1-3 encode 
the SNURF protein, 4-10 encode the Snrpn splicosomal protein. Besides the two 
proteins, the gene also contains a ca. 460 kb long RNA transcript, which results in 
numerous small RNAs due to variuos splicing. (Suzuki et al., 2009). The Snrpn region 
contains two alternative upstream promoters and some non-coding exons. There are 
multiple untranslated upstream exons of unknown function and at least two alternative 5' 
start sites (Glenn et al., 1997). The sequence is also host to multiple small nucleolar 
RNAs encoded in the region. The protein has a direct impact on the synthesis of brain 
proteins, particularly those that function in the hypothalamus, due to its splicing function 
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(Feinberg 2007). The gene contains two differentially methylated regions and 23 known 
methylation sites. The first DMR includes part of the promoter and transcription start 
site, and is postulated to inherit a maternal-specific imprint.  
 
The function of the gene is complex. Experimental deletion data from mouse model 
shows that a deletion from SNRPN to UBE3A causes hypotonia, growth retardation and 
partial lethality (Glenn et al., 1997). Loss of these small nucleolar RNAs contributes to 
Prader-Willi syndrome. Their target molecules remain unknown. SNRPN transcription 
sense and adhering UBE3A (linked to Angelman syndrome) antisense units serve as 
host genes for small nucleolar RNAs encoded within them (Glenn et al., 1997).  
 
Lit1, The genomic region of Lit1 corresponds to a highly conserved region between 
mouse and human. It is an imprinted locus, participating in the expression regulation of 
KCNQ1a voltage-gated potassium channel protein. CpGs investigated in this region 
were located at nucleotide positions 45216 and 45348, accession n.AJ271885. Initial 
tendency was greater mehylation in males in spleen, lungs, skin, and tongue, while 
females were more methylated in brain and bone marrow. After Bonferoni correction, 
males remained more methylated in lungs, tongue and skin, less methylated in brain 
and bone marrow. 
 
LIT1, or long QT intron transcript, codes for an antisense RNA in the region of KvLQT1, 
a gene encoding a voltage-gated potassium channel. It is transcribed in the opposite 
direction to the channel gene (Fig.1) The channel gene is about 300 kb long and is 
expressed from the maternal allele. (Fig.2) The heart is an exception to this, as both 
paternal and maternal gene copies are expressed (Gaston et al., 2001). Another 
interesting observation is that in described cases of loss of imprinting of LIT1, 
demethylation of the maternal allele was always complete. There was also no tumour 
risk associated with demethylation of LIT1 only, where neighbouring imprinting centres 
were not affected. However, in tumour tissues, mosaic demethylation patterns have 
been observed (DeBaun et al., 2002). Our data possibly indicates a more active 
metabolism in the male brain and bone marrow, pointing to a possible more active 
production of the said potassium channel in these tissues. Slight, yet statistically reliable 
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difference in skin and lungs can indicate a slower cellular change rate there in the 
males, or simply a different cell/connective tissue ratio in the probes. This pilot work 
provides limited data for few methylation sites of each studied gene, which makes it 
difficult to reach definitive conclusions.   
 
LIT1 is transcribed from centromere to telomere and is expressed from the paternal 
chromosome. In most patients of BWS, LIT1 expression is abnormal from both alleles, 
while some demonstrate biallelic expression, indicating relaxation of imprinting 
(Beckwith 1963). Loss of imprinting in LIT1 correlated completely with its biallelic 
expression. It is not the only, but the most frequent genetic alteration in BWS, making it 
a key component in the pathogenesis.  
 
LIT1 methylation abnormalities have been associated with overgrowth and birth defects 
(Arima et al., 2005). Moreover, other pathologies based on the potassium channel 
defects are the long QT syndrome, a cardiac muscle defect inherited in a dominant way, 
and Jervell-Lange-Nielson syndrome, characterized by deafness and cardiac conduction 
abnormalities (Yatsuki et al., 2000). Another described pathological feature is the 
midline abdominal wall defect with a frequency of 69 % in patients with abnormal LIT1 
methylation (Higashimoto et al., 2003). All this could be related to the LIT1 being in the 
proximity of a potassium ion channel gene, and the cardiac conductive system running 
through the septum. Our work also showed LIT1 to be less methylated in cardiac muscle 
most likely due to more active expression of the region due to its role in ion conduction. 
LIT1 methylation in BWS patients is also reliably associated with macrosomia (53 % are 
associated while only 18 % are not)– as potassium channels are some of the more 
elementary molecular blocks in all cells, their function changes would affect most other 
cellular processes down the line, which rely on osmosis and ion concentrations for the 
proper conformation and function of their components. 
LIT1 is transcribed in the direction of the telomere and is paternaly expressed. LIT1 is 
transcribed in the direction of the telomere and is paternaly expressed. LIT1 is 
transcribed in the direction of the telomere and is paternaly expressed. In most patients 
of BWS, LIT1 expression is abnormal from both alleles, while some demonstrate biallelic 
expression, indicating relaxation of imprinting (Beckwith 1963). Loss of imprinting in LIT1 
 92 
correlated completely with its biallelic expression. It is not the only, but the most frequent 
genetic alteration in BWS, making it a key component in the pathogenesis.  
 
LIT1 methylation abnormalities have been associated with overgrowth and birth defects 
(Arima et al., 2005). Moreover, other pathologies based on the potassium channel 
defects are the long QT syndrome, a cardiac muscle defect inherited in a dominant way, 
and Jervell-Lange-Nielson syndrome, characterized by deafness and cardiac conduction 
abnormalities (Yatsuki et al., 2000). Another described pathological feature is the 
midline abdominal wall defect with a frequency of 69 % in patients with abnormal LIT1 
methylation (Higashimoto et al., 2003). All this could be related to the LIT1 being in the 
proximity of a potassium ion channel gene, and the cardiac conductive system running 
through the septum. Our work also showed LIT1 to be less methylated in cardiac muscle 
most likely due to more active expression of the region due to its role in ion conduction. 
LIT1 methylation in BWS patients is also reliably associated with macrosomia (53 % are 
associated while only 18 % are not)– as potassium channels are some of the more 
elementary molecular blocks in all cells, their function changes would affect most other 
cellular processes down the line, which rely on osmosis and ion concentrations for the 




Fig. 37: Location of LIT1 within KvLQT1 (Lister et al., 2000)
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C) Repetitive elements 
 
IAP, intracisternal A particle gag protein gene, CpG sites at nucleotide positions 170 and 
206 (coding sequence starts at 594), accession n. M17551. Raw data suggested males 
were more methylated in spleen and bone marrow, less methylated in lungs, skin, brain, 
and heart. After Bonferoni correction, males remained more methylated in bone marrow, 
less in lungs and skin (Table 5). The general impression is that as a once active 
retrovirus, IAP is relatively highly methylated in most tissues, which is not much 
dependent on the sex of the individual. Comparing to other fragments, such as Snrpn 
and Lit1, where methylation is mostly under 50 %, IAP reaches heights of well over 70 
%, and, in brain, even 90 %.  
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The mouse genome has up to 1000 copies of IAP. The IAP sequence itself is about 7 kb 
long (Mays-Hoopes et al., 1983). Although the particle is in some aspects similar to 
retroviruses (they are collinear with the retroviral RNA and have long terminal repeats), 
there is no known extracellular form, i.e. no free virus. Therefore, both the version of 
intracellular evolution to present status and an infectious entry in the past remains 
possible. The IAP genes present in the mouse genome are not identical, though they 
are highly homologous.  
 
An experiment as early as 1983 (Feenstra et al., 1986) has shown that the CCGG 
sequences in the IAP gene are methylated in most tissues (CmCGG) and unmethylated 
in myeloma, where it is expressed (CCGG), although even myeloma cells do not show 
full demethylation. Plasmocytoma in the mouse also shows higher IAP expression than 
other lymphocytes (Dupresoir and Heidmann, 1996). This has little direct relation to our 
work, as the individuals investigated had no known tumors. IAP is, just as other 
elements, markedly demethylated in testes. Again, this is proof of epigenetic 
reprogramming in germ cells and also a link to its possible positive function as a driving 
factor behind mutagenesis. It would be interesting to see mouse ovary in comparison, 
whether its results would be similar to testes or whether a lower number of 
reprogrammed cells would lead to a high methylation levels characteristic of somatic 
tissues.  
 
Due to the functional properties of the repeat, it can be inactivated by methylation of a 
few sites; this has been shown in a 1986 experiment (Falzon and Kuff, 1991). Further 
work indicated that methylation of specific sites had a summation effect in the IAP 
inactivation. These sites were located in the protein bonding DNAse and endonuclease 
domains (Lueders et al., 1993).  
 
Due to the nature of the IAP particles, their transcription level controls their 
transposition, as there is a RNA intermediate. It has also been hypothesized that IAP 
can become randomly active and cause mutagenesis at the germ cell level during the 
demethylation waves in their maturation, while staying relatively silent in the grown-up 
organism (Argeson et al., 1996). This silence is then again in accord with our data 
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showing high IAP methylation in all examined tissues. IAP expression directly depends 
on the cellular proliferation rate. This could explain the high IAP methylation in brain and 
the striking difference between testis and all other tissues. It does not explain well the 
relatively high methylation levels in kidney and liver, especially the later, which is known 
for its cellular regeneration abilities. In the testis, IAP expression is limited to specific 
developmental stages and diminish with further differentiation; the pattern repeated itself 
over multiple generations and thus seems to be stable (Argeson et al., 1996). Off-time 
and cell type IAP CpG methylation could be successfully induced with 5-azacytidine, a 
demethylating agent. The ability of IAP to be activated in specific developmental stages 
of germ cells might indicate its function, which once a retrovirus acquired to coexist with 
the host genome, giving it a possibility to generate heritable genetic diversity. Normally, 
the transposable elements are strictly methylated and their expression either 
physiologically limited to the given germ cell stages or only achievable by demethylating 
agents or direct gene manipulation (Gaudet et al., 2004). Demethylating agents in 
themselves represent a rather clumsy tool, as much more than a single specific target 
locus is affected. In this, further analysis, understanding and development of exact 
molecular tools are necessary.  
 
LINE-1: Long interspersed elements (Lines, or LINE-1) are endogenous mobile genetic 
elements. The CpG sites investigated were located at nucleotide positions 965 and 1001 
(coding sequence starts at 1343), accession n. D84391. Initial results showed males to 
be more methylated in brain, females in bone marrow, tongue, and heart. After 
Bonferoni correction, difference remained reliable in tongue and cardiac muscle, both for 
Primer 1  (Table 5). Overall impression is that these elements are strongly inhibited even 
in tissues where demethylation is genome-wide and systematic, testis reaching a level 
of over 70 %, more than any other element in our study.  
A full LINE-1 element is about 6 kb long, contains two ORF's, first encoding a RNA – 
binding protein, and second of them encoding a reverse transcriptase (Florl et al., 1999, 
Takai et al., 2000). ORF1 is a RNA-binding protein functioning as a nucleic acid 
chaperone; ORF2 is a reverse transcriptase and endonuclease (Cotton et al., 2009). 
LINE-1 element has a CpG – rich promoter at its 5' end. 
Line-1s have accumulated in the eukaryote genome via germline transposition. About 17 
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% of the human genome consists of LINE-1's, counting roughly 516000 copies in 
haploid genome, thus making it a very convenient tool for evaluation of quantitative 
genome methylation at a given site, organ or cell group (R.Scott Hansen, 2003). 
Greatest portion of them are degenerate and non-functional. Some 30 to 100 of these 
elements, having assessed their completeness and methylation status, could be active 
(Takai et al., 2000, Tsutsumi, 2000). Even elements that have lost both reading frame 
expressional capacity may still function as possible promoter sites, altering the function 
of genes around them. Again, our data gives only indirect hints to this, as all individuals 
studied had no known pathological conditions. Only in testes, where the hottest DNA 
changes of all studied tissues were taking place, was LINE-1 significantly less 
methylated than in other tissues. This could indirectly be compared to the rapid cellular 
multiplication in tumors. Microscopic examination showed that uncontrolled LINE-1 
transposition results in unstable branched DNA structure (Takai et al., 2000). Active 
LINE-1s are transcribed into RNA, then reverse-transcribed into cDNA and integrated at 
another location.  
 
 
If promoter methylation contributes to the silencing of expression, as seen in previous 
examples of IAP, this would fit the general higher methylation of repetitive elements. 
What is interesting is also a statistically reliable sex difference in the methylation of 
different fragments in the tongue, which could be confirmed despite a rather small 
population sample. Therefore, we confirmed that differences between sexes exist at 
given loci. As methylation is not the only epigenetic regulation mechanism and the 
number of CpG sites investigated was limited, we can only say that differences exist, 
and leave their exact mapping to further studies.  
 
On the carcinogenic potential of LINE-1: consistent diet deficient in methyl group donors, 
or choline deficient diet, has been shown to be linked to LINE-1-hypomethylation and 
the induction of hepatic cancer in rodent experiments (Oki et al., 2008). LINE-1 
hypomethylation has been observed as an early change preceding elimination of cancer 
cell clones in leukemia, a study testing demethylating agent decitabine (Choi et al., 
2007). LINE-1 elements have been shown to be transcribed in human teratocarcinoma 
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cells and to be significantly hypomethylated in urothelial carcinoma cells, with higher-
grade tumors displaying a trend towards a more complete demethylation. LINE-1 
demethylation has been proved in hepatocellular carcinomas, while it was absent in 
surrounding liver cirrhosis (Tsutsumi, 2000).  
 
LINE-1 is less methylated in neuroendocrine tumours (p=0.04); it was more pronounced 
in carcinoid than in neuroendocrine tumors. There also were tissue dependent 
variations, for example, showing that haematologic neoplasia tends to be less 
hypomethylated than intestinal (Ostertag et al., 2007). The only abdominal organ 
present was spleen. It does show a tendency towards relatively less methylation, when 
compared to other tissues (see Line-1 methylation graph under 4.5, Methylation 
variability at specific loci in different organs). In intestinal neoplasia, LINE-1 
hypomethylation is associated with shorter survival times among patients with colon 
cancer (Srinivasan et al., 2008). Possible mechanisms of this are the genomic instability 
associated with global genome hypomethylation, transcriptional instability, activation of 
oncogenes, dormant endogenous viruses and mobile elements, also inflammatory 
mediators and increased oxidative stress (Srinivasan et al., 2008).  
In prostate cancer, LINE-1 hypomethylation has been demonstrated to occur in the early 
stages of tumoral development, while global hypomethylation followed at a much later, 
metastatic disease stage, along with even more pronounced LINE-1 hypomethylation 
(Figueiredo et al., 2009). This insinuates a role of LINE-1 hypomethylation as a possible 
trigger event. In bladder tumours, hypomethylation of a certain LINE-1 promoter has 
been proved to induce the transcription of MET-oncogene (a hepatocyte growth factor 
receptor) in tumour itself and the entire urothelium of the affected bladder (Kuff et al., 
1981). This gene is known to exist in a few truncated forms, being active in breast, 
prostate, colorectal and lung carcinomas. Furthermore, specific LINE-1 element can be 
targeted by placing one amplification promoter in the element and another in a targeted 
gene (Kuff et al., 1981). Figures 3 and 4.  
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Summary on tissue and sex influence on methylation 
 
The end result showed that most of the fragments were less methylated in testes; this 
coincides with the intensive expression there due to the high cell replication rate. We 
took the complete organ; were it possible to separate the germ cell population only, 
these results would be even more different from those of other organs. Brain, where cell 
division happens at a much slower tempo, displayed higher methylation in most 
fragments. What we see though is mixture of different cells type like glial and neural 
tissues together. Neurons and glia would likely demonstrate a different methylation 
pattern if studied separately.  
 
A good functional correlation can also be seen with alpha actin and muscular tissue; its 
promoter is comparatively less methylated in tongue, skeletal muscle and heart, where 
one would also await higher expression. Since these tissue specific differences exists at 
most loci, it was possible by principle component analysis (using these limited studied 
loci) to clearly separate most tissues in tissue specific clusters, in both males and 
females, (figures 18 A and B). 
 
In general, sex has a clear influence on methylation, males appear to be more 
methylated in muscular tissue, for unclear reasons statistically reliably so only in the 
tongue, and less methylated in bone marrow. Male hematopoesis may be generally 
faster than female in mice, which would then correlate with this. Lungs and skin may 
have to do with different expression levels, male skin being structurally more ”rugged” 
and lungs having greater volume, and probably slightly different mechanical properties, 
than their female counterparts. Brain methylation differences between sexes need to be 
considered in more anatomical and molecular detail. Although differences exist, two 
CpG sites of one gene are much too little ground to start speculating about general 
differences. However the sex influence was not equally seen in all tissues, this is clearly 
illustrated by principle component analysis and non-supervised hierarchical clustering 
were only tongue and to less extent lung and skin could see a separate clustering of 




The genome is subject to many regulatory mechanisms, of which methylation is only 
one. This work serves to show that significant differences exist between closely related 
organisms, and that sex is one of the determining factors in every organisms particular 
methylation pattern. We also see that same genes are differently methylated in different 
organs. Organs are collections of many different cell populations, and greater exactness 
could be achieved by isolating homogeneous cell populations, which is technically 
challenging. We also know at this point that DNA methylation pattern of an individual 
changes during its life. To determine these dynamics, a work of much larger scale is 
required, involving greater numbers of individuals, DNA from more than one time point in 
their lives and, as said before, more exact isolation of cell populations. This shall also 
require methods capable of analyzing multiple CpG sites rapidly and from lesser DNA 
amounts. The complexity of the problem is further shown by the fact that sex specific 
methylation results could not be reproduced in another mice population – but were still 
reproducible in the tissue samples used in the original work. This shows that methylation 
patterns are possibly dependent on the environmental influences, seasonal variability 
and other factors. The first group of mice were raised in August/September, the second 
in December/January; though conditions were close, they may have not been fully 
identical. The exact CO2 concentration used to kill the mice to harvest tissue samples 
was not measured; the pathological anaerobic metabolism prior to stop of vital functions 
may have been different in both groups; exposure to CO2 results in a decrease in alpha-
ketoglutarate, which is a cofactor in transforming 5-methylcytosine into 5-
carboxylcytosine; between these are the oxidation products which are the intermediate 
steps in demethylation process. Thus, different levels of CO2 could possibly have 
caused different methylation product concentration in tissues with active circulation, 
such as spleen and brain. The SIRPH technique used was very accurate and sensitive, 
but covered only few methylated spots in the genome. A technique capable of broader 
analysis and a larger cohort of experimental animals would be needed to visualize 
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Tab. 8: Alpha actin methylation data, section 1 
Run orderMouse No.Spleen Lungs Skin
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
1 M1 33.29 28.59 39.73
11 M2 35.61 46.00 27.74 34.62 45.30
21 M3 35.53 50.28 25.85 42.52
31 M4 37.88 49.14 28.42 35.36 20.65
41 M5 39.89 51.91 29.36 39.25 32.00
51 M6 42.74 49.37 27.92 39.73 27.41
61 M7 37.74 51.54 29.39 33.79 24.68
71 M8 37.99 50.51 27.42 36.77 31.09
3 M9 35.12 27.74 36.32
13 M10 43.35 28.24 35.54 25.81
23 M11 35.26 48.33 26.97 33.40 26.34 41.77
33 M12 35.35 28.05 19.64
43 M13 31.94 26.36 33.39 24.14
53 M14 34.35 51.14 21.39 22.07
63 M15 34.74 52.35 27.04 30.74 20.00
73 M16 36.94 45.60 27.93 29.73 25.92
5 M17 36.84 52.43 20.89 25.66 32.75
15 M18 38.64 49.55 38.40 37.81 26.76
25 M19 32.84 48.41 24.96 29.26 35.68
35 M20 40.46 60.65 30.19 32.41 24.04
45 M21 43.60 30.12 37.80
55 M22 34.28 55.61 22.94 32.04
65 M23 37.36 32.42 34.87 26.77
75 M24 40.41 51.75 31.49 37.26 26.64 38.17
7 M25 36.55 50.60 25.85 30.10 26.54 42.31
17 M26 35.07 50.77 24.92 30.43 28.58
27 M27 32.76 54.71 28.51 32.91 24.03 37.24
37 M28 39.12 53.70 29.14 34.40 28.22
47 M29 32.77 51.70 28.31 31.27 25.86
57 M30 37.10 27.58 30.65 21.06
67 M31 38.08 51.24 27.00
77 M32 32.78 46.91 31.59
9 M33 39.32 51.21 33.85
19 M34 34.38 26.07
29 M35 38.33 51.28 29.52
39 M36 43.32 25.13
49 M37 40.98 21.28




Tab. 8: Alpha actin methylation data, section 2 
Run order Mouse No. Brain Bone marrow Testes
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
1 M1 42.35 52.46 32.30 34.25 65.86 69.96
11 M2 42.49 52.42 42.77 46.66
21 M3 43.48 51.52 25.22 47.68 66.62 70.32
31 M4 42.52 49.83 31.92 38.35 64.57 68.74
41 M5 46.02 54.03 33.47 40.41 60.08 63.92
51 M6 46.94 56.15 38.23 39.37 50.68 52.09
61 M7 42.33 50.48 32.26 36.71 25.13 25.23
71 M8 46.01 51.46 29.96 42.55 52.63 57.00
3 M9 50.20 57.86 30.37 36.55 60.31 64.24
13 M10 45.28 53.79 34.92 39.05 59.56 63.51
23 M11 45.38 54.42 30.06 34.26 62.46 65.52
33 M12 43.91 51.23 30.38 38.41 64.47 66.47
43 M13 66.77 65.00 28.74 34.51 61.90 65.76
53 M14 62.28 65.55 30.82 36.50 63.02 65.69
63 M15 45.15 54.83 31.52 35.25 60.80 64.23
73 M16 43.92 54.42 33.65 33.93 59.60 64.96
5 M17 45.25 54.32 34.73 38.52 63.39 66.39
15 M18 70.62 69.16 33.81 41.43 60.88 66.93
25 M19 41.37 50.79 30.69 36.45 64.71 68.53
35 M20 43.60 53.49 36.51 43.45 66.08 69.53
45 M21 41.26 48.98 35.99 36.68 61.81 65.40
55 M22 43.76 51.20 33.75 43.20 57.18 61.35
65 M23 44.94 50.77 34.27 38.46 63.38 67.05
75 M24 36.56 39.36 65.61 68.30
7 M25 46.83 53.36 36.05 40.74 63.76 68.05
17 M26 67.90 62.65 36.45 40.51 60.10 65.56
27 M27 53.83 58.01 30.69 36.94 22.44 24.00
37 M28 38.52 42.68 65.16 68.45
47 M29 42.38 49.67 31.35 38.99 65.65 68.52
57 M30 41.48 49.31 31.26 35.76 65.34 70.18
67 M31 45.30 51.39 33.94 39.31 67.53 71.59
77 M32 39.78 46.27 30.06 34.30 62.29 69.37
9 M33 44.41 51.81 35.62 40.01 64.93 67.17
19 M34 40.50 49.41 32.33 37.04 68.66 71.33
29 M35 45.72 53.84 32.98 42.22 61.85 65.05
39 M36 37.75 43.64 64.57 67.38
49 M37 43.73 52.18 31.38 36.66 71.62 72.72




Tab.8: Alpha actin methylation data, section 3 
Run orderMouse No.Tongue Muscles Heart
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
1 M1 35.89 17.79 24.34 25.50
11 M2 28.42 18.76 24.95 26.44
21 M3 31.66 19.87 29.33 27.01
31 M4 24.88 20.43 26.07 29.82
41 M5 27.30 39.68 22.62 29.75 27.00 36.04
51 M6 33.72 24.77 33.32 27.68 32.57
61 M7 36.94 18.93 25.88 27.54 34.69
71 M8 23.35 42.47 18.84 28.02 26.96
3 M9 17.47 23.43 25.62 32.05
13 M10 25.69 22.10 24.49 25.43 36.26
23 M11 28.43 20.26 25.95 26.76 29.47
33 M12 22.28 47.98 20.27 24.37 24.09 34.99
43 M13 28.21 20.01 26.46 26.65
53 M14 17.34 23.49 31.01 26.59 37.01
63 M15 18.70 20.26 27.01 23.21 34.24
73 M16 22.62 32.08 22.81 25.31
5 M17 29.41 36.31 25.19 26.80 37.11
15 M18 31.50 22.95 33.65 29.65 35.66
25 M19 23.16 20.91 27.87 40.02
35 M20 31.27 19.14 38.56 26.86 35.33
45 M21 24.79 23.52 30.72
55 M22 24.39 19.75 30.29
65 M23 27.47 25.66 29.76
75 M24 27.00 42.45 22.68 28.53
7 M25 26.07 31.24 27.60 30.97
17 M26 22.24 31.61 18.57 28.53 22.38
27 M27 21.91 35.36 20.36 100.00 26.10
37 M28 31.16 26.83
47 M29 20.18 25.23
57 M30 16.76 25.22
67 M31 29.23 26.38 35.01 27.14
77 M32 22.68 16.19 26.47
9 M33 23.26 34.68 23.98 38.09 32.61 39.87
19 M34 23.08 20.49 28.46 23.39
29 M35 25.98 24.31 20.52
39 M36 27.02 18.08 24.71
49 M37 23.67 39.56 22.81 23.14




Tab.8: Alpha actin methylation data, section 4 
Run orderMouse No.Spleen Lungs Skin
69 M39 Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
79 M40 44.27 54.68 25.82 32.95 44.583
81 M41 40.05 50.15 23.59 32.46 43.6842
82 M42 39.80 48.55 38.38 29.33 45.2819
83 M43 35.43 44.48 42.21 22.79 44.9322
84 M44 31.33 45.75 51.30 24.61 47.9727
85 M45 35.58 46.44 36.99 26.29
86 M46 29.05 43.34 38.38 22.92 44.9621
87 M47 31.44 46.09 34.95 23.89 41.6809
88 M48 33.17 44.62 32.70 25.28 33.27 44.513
89 M49 33.75 46.87 26.52 23.85 31.15
90 M50 29.79 42.46 24.72 22.81 42.6045
2 F1 30.94 42.50 26.21 20.46 28.59 33.5301
12 F2 38.63 22.28 28.13 21.88 29.99 65.2991
22 F3 33.45 22.61 30.08 26.58 41.5771
32 F4 21.46 25.63 24.66 56.2994
42 F5 39.06 52.20 23.55 28.05 24.62 67.6637
52 F6 40.50 48.96 23.72 29.76 24.97 23.1718
62 F7 44.80 53.55 25.12 29.45 26.31 56.7696
72 F8 46.39 30.28 35.85 26.37 34.81 46.2235
4 F9 33.95 49.10 21.34 19.89 61.0876
14 F10 39.39 22.36 26.60 36.85 44.5277
24 F11 38.07 28.43 32.49 26.02 36.29 43.2226
34 F12 32.47 50.10 24.94 31.68 26.76 34.70 41.8955
44 F13 38.73 56.01 23.29 23.46 46.6374
54 F14 38.46 27.15 27.67 66.0003
64 F15 23.24 32.68 24.90 42.5319
74 F16 36.67 24.48 18.28 45.0674
6 F17 40.25 31.19 31.62 21.74 56.9827
16 F18 35.04 45.46 25.47 33.88 44.1769
26 F19 38.64 47.63 24.40 35.77 23.70 39.4936
36 F20 23.84 36.95 26.04 38.73 43.8469
46 F21 46.42 24.73 31.76 23.38 46.5218
56 F22 32.28 50.33 20.34 28.77 22.32 38.758
66 F23 42.64 28.24 32.21 21.38 35.53 44.2945
76 F24 34.91 24.53 23.88 33.35 43.2441
8 F25 33.70 21.45 30.29 19.84 30.51 40.172
18 F26 36.94 28.29 68.2387
28 F27 36.46 26.57 41.94 28.19 37.82 46.2426
38 F28 39.0625 28.6761 28.0521 43.5899 66.9201




Tab.8: Alpha actin methylation data, section 5 
Run orderMouse No. Brain Bone marrow Testes
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
69 M39 44.58 50.43 39.17 40.02 34.89 37.35
79 M40 43.68 51.33 37.19 38.48 60.20 63.70
81 M41 45.28 51.68 37.57 42.23 69.64 75.67
82 M42 44.93 49.97 34.84 38.90 63.52 69.48
83 M43 47.97 53.71 35.41 49.82 29.37 32.77
84 M44 37.12 44.61 29.03 31.48
85 M45 44.96 50.77 31.89 42.81 50.30 52.89
86 M46 41.68 59.99 32.53 36.96 69.23 71.22
87 M47 44.51 56.68 66.69 70.56
88 M48 29.98 44.58 68.60 71.90
89 M49 42.60 50.33 30.78 64.80 66.29 70.32
90 M50 33.53 56.03 65.13 66.59
2 F1 65.30 66.00 31.84 40.11
12 F2 41.58 52.20 31.85 36.48
22 F3 56.30 58.38 30.23 40.32
32 F4 67.66 64.88 36.71 40.90
42 F5 23.17 32.05 34.09 37.84
52 F6 56.77 59.95 37.49 40.01
62 F7 46.22 54.33 39.54 41.58
72 F8 61.09 61.10 30.80 34.79
4 F9 44.53 56.24 34.59 38.57
14 F10 43.22 56.71 33.73 38.31
24 F11 41.90 52.34 30.24 37.30
34 F12 46.64 55.81 34.57 39.30
44 F13 66.00 62.60 36.83 41.29
54 F14 42.53 54.73 33.35 35.86
64 F15 45.07 53.44 33.87 35.81
74 F16 56.98 59.72 38.50 41.35
6 F17 44.18 61.08 32.66 40.24
16 F18 39.49 61.54 36.11 38.69
26 F19 43.85 50.99 32.39 36.29
36 F20 46.52 51.72 40.30 47.93
46 F21 38.76 53.55 26.74 40.23
56 F22 44.29 51.56 39.36 39.30
66 F23 43.24 48.80 35.14 41.39
76 F24 40.17 68.58 30.24 34.29
8 F25 68.24 67.27 34.36 42.49
18 F26 46.24 54.47 36.46 39.41
28 F27 66.9201 66.5016 32.9109 37.6258




Tab.8: Alpha actin methylation data, section 6 
Run order Mouse No. Tongue Muscles Heart
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1
69 M39 39.18 19.67 35.13 25.80
79 M40 20.44 40.42 23.76 27.83
81 M41 22.56 18.17 25.29
82 M42 26.34 19.08 28.12
83 M43 41.39 22.15 27.11
84 M44 29.67 20.58 23.71
85 M45 26.60 32.29 27.10 28.66
86 M46 25.29 20.55 27.46
87 M47 35.99 22.62 25.54
88 M48 31.30 22.47 31.40
89 M49 24.76 18.55 21.20
90 M50 34.99 26.77 25.49
2 F1 19.76 34.12 20.22 34.97 22.23
12 F2 23.42 28.07 27.88 25.98
22 F3 24.78 30.67 13.09 24.19
32 F4 27.40 37.28 14.80 27.97
42 F5 20.64 30.86 21.85 30.20
52 F6 25.23 27.39 23.15 27.30
62 F7 29.98 34.01 19.35 32.88 26.38
72 F8 20.42 21.36 24.66 27.49
4 F9 23.41 25.05 17.67 19.56
14 F10 27.54 21.84 27.50 27.00
24 F11 20.93 26.40 21.74 41.06
34 F12 22.81 27.40 26.63 40.29 46.91
44 F13 25.33 37.51 22.68 28.92 28.75
54 F14 25.23 29.52 23.28 27.39
64 F15 17.76 28.61 21.93 37.04 24.26
74 F16 22.95 28.11 22.84 28.28 24.85
6 F17 20.22 27.23 20.97 30.28 31.41
16 F18 20.97 34.77 20.20 29.71 24.27
26 F19 23.49 29.62 19.36 30.84 27.06
36 F20 24.27 33.93 21.74 27.76
46 F21 18.01 36.08 14.74 25.46 21.26
56 F22 21.59 24.53 18.76 27.74 25.30
66 F23 21.33 21.40 28.57 29.09
76 F24 24.97 31.35 17.53 26.36 23.72
8 F25 22.50 16.06 21.74
18 F26 23.25 16.00 28.64
28 F27 20.582 30.0203 15.4463 25.1551 28.8001




Tab.8: Alpha actin methylation data, section 7 
 
Run order Mouse No. Spleen Lungs Skin
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
48 F29 38.19 30.70 22.56
58 F30 41.17 23.56 28.92 22.42
68 F31 36.39 44.28 26.08 33.65 21.17
78 F32 35.51 48.23 27.85 35.03 25.05 28.04
10 F33 24.03 28.73 33.52
20 F34 35.26 21.62 32.49 21.82
30 F35 37.31 48.90 31.49 32.74 23.04 28.35
40 F36 37.64 51.74 24.21 30.41 22.45
50 F37 40.72 30.88 32.69 21.40
60 F38 42.71 51.26 25.10 22.51 28.27
70 F39 36.39 52.85 28.77 32.79 25.03
80 F40 34.23 49.08 28.74 29.32 23.82
91 F41 38.48 40.67 22.48 23.19 34.25
92 F42 32.01 41.38 25.22 33.45 25.97 35.88
93 F43 36.58 43.70 27.11 29.70 25.63 31.95
94 F44 34.06 44.43 29.82 33.67 24.87 35.15
95 F45 20.65 29.99 25.33 31.76
96 F46 39.46 27.40 27.67 23.35 35.27
97 F47 30.34 24.45 31.44 20.84 39.91
98 F48 38.18 43.77 24.55 30.68 26.19
99 F49 32.82 52.65 23.79 38.59 26.28 36.00
100 F50 34.72 44.91 26.36 37.42 25.06 29.58
Mean males 36.55 49.54 29.66 33.90 26.92 35.06
SD Males 3.75 5.83 5.57
Mean females 37.05 47.55 25.46 32.09 24.18 34.31
SD Females 4.38 2.88 3.74
Mean both 36.79 48.77 27.35 32.79 25.54 34.55
Control M 27.51 37.44 26.00 26.00 31.00




Tab.8: Alpha actin methylation data, section 8 
 
Run order Mouse No. Brain Bone marrow Testes
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
48 F29 50.93 54.45 36.42 40.70
58 F30 45.27 53.34 30.58 36.69
68 F31 47.23 55.30 33.41 37.92
78 F32 40.25 48.35 30.99 41.96
10 F33 50.64 53.82 32.62 40.60
20 F34 67.86 65.73 25.12 32.40
30 F35 31.87 38.68
40 F36 46.08 54.22 34.59 36.58
50 F37 62.23 63.53 30.73 37.33
60 F38 50.62 59.86
70 F39 69.73 72.12 34.37 38.71
80 F40 45.80 55.39 31.92 35.24
91 F41 38.00 44.97 35.76 36.14
92 F42 48.11 55.60 32.96 36.86
93 F43 43.87 52.69 37.68 39.55
94 F44 47.81 54.62 35.97 41.01
95 F45 43.97 51.06 33.58 38.84
96 F46 44.24 54.96 33.84 38.20
97 F47 42.32 51.31 27.45 38.66
98 F48
99 F49 55.59 62.49 35.78 42.84
100 F50 36.62 51.23 39.07 48.16
Mean males 46.16 53.59 33.40 39.92 59.12 62.61
SD Males 7.23 3.00 11.72
Mean females 49.02 56.42 33.74 39.11
SD Females 10.14 3.31
Mean both 47.62 55.04 33.57 39.51
Control M 26.00 32.00 29.00 32.00




Tab.8: Alpha actin methylation data, section 9 
 
Run order Mouse No. Tongue Muscles Heart
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
48 F29 18.33 30.36 20.60 25.98
58 F30 21.09 15.40 28.33
68 F31 19.72 21.32 54.01 25.66
78 F32 21.61 31.21 19.31 27.47
10 F33 26.88 16.71 21.99 32.92
20 F34 20.40 32.82 25.22
30 F35 28.88 19.17 31.02 38.67
40 F36 18.96 38.23 19.18 32.59 29.90
50 F37 21.97 14.30 26.52
60 F38 22.68 31.75 20.88 27.11 27.01 35.11
70 F39 20.97 19.10 33.13 27.24
80 F40 24.15 38.83 20.05 26.74
91 F41 24.42 18.00 26.18 27.10 31.93
92 F42 40.92 21.72 30.68 30.43 36.86
93 F43 25.57 15.08 30.65
94 F44 23.63 24.09 29.36 29.94
95 F45 23.79 16.61 24.36
96 F46 25.34 16.77 26.62
97 F47 25.17 21.43 26.99 23.38
98 F48 24.44 18.61 27.43
99 F49 20.99 38.18 20.98 27.60
100 F50 29.96 21.96 32.67 25.74
Mean males 27.19 37.40 21.37 32.25 26.58 35.37
SD Males 5.30 2.83 2.51
Mean females 23.46 31.45 19.69 31.11 27.15 34.68
SD Females 3.83 3.23 4.46
Mean both 25.29 33.21 20.52 31.68 26.87 35.15
Control M 37.00 24.00 30.00 27.00




Tab.9: Snrpn D1 methylation data, section 1 
 
Run orderMouse No.Spleen Lungs Skin
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
1 M1 41.91 48.72 45.16 46.54
11 M2 41.79 49.15 43.95 44.75
21 M3 39.97 51.31 47.83 43.10 53.11
31 M4 41.06 48.31 43.46 40.92
41 M5 42.35 50.81 44.77 42.02
51 M6 43.72 51.35 44.48
61 M7 41.30 48.56 42.74 45.97 52.67
71 M8 43.30 50.86 45.16
3 M9 41.27 48.31 46.19 45.50
13 M10 43.05 50.55 43.30 43.42
23 M11 41.45 48.78 44.92 44.43 52.30
33 M12 41.93 49.50 43.87 47.67
43 M13 41.47 48.82 43.72 56.06 45.24
53 M14 41.55 48.80 45.62 46.48 54.29
63 M15 40.48 47.72 43.09 55.81 43.82 48.26
73 M16 47.95 42.87 55.27
5 M17 41.65 48.66 44.94 43.22 53.57
15 M18 43.24 50.78 43.93 47.21
25 M19 42.03 49.82 44.37 46.09
35 M20 43.35 50.48 44.27 56.81 44.07
45 M21 43.17 50.86 44.43 57.33
55 M22 42.29 49.96 42.86 54.17
65 M23 43.91 52.41 42.99 55.92 47.46
75 M24 43.69 51.14 42.99 43.86 51.61
7 M25 42.50 49.19 44.08 42.07
17 M26 44.24 51.26 43.34 39.30
27 M27 41.28 48.83 42.15 53.85 42.55 51.85
37 M28 42.01 49.16 44.39 46.53
47 M29 41.76 48.78 42.86 55.82 42.78 52.01
57 M30 42.34 49.74 42.75 43.11 51.76
67 M31 42.64 50.24 39.74 48.50
77 M32 42.07 49.75 45.99
9 M33 42.58 48.81 43.45
19 M34 41.80 48.06 45.59
29 M35 40.08 49.04 44.71
39 M36 41.26 50.57 45.50
49 M37 48.02 58.94 42.42




Tab.9: Snrpn D1 methylation data, section 2 
 
Run order Mouse No. Brain Bone marrow Testes
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
1 M1 42.54 61.78 41.24 54.31 16.12 21.16
11 M2 46.32 29.11 40.46
21 M3 15.68 18.95
31 M4 44.62 41.32 13.61 19.92
41 M5 44.97 16.52 22.11
51 M6 46.35 43.51 24.91 31.55
61 M7 44.28 40.76 34.82 48.55
71 M8 46.83 19.47 32.48
3 M9 15.49 19.95
13 M10 42.92 60.06 40.96 17.18 19.18
23 M11 45.35 40.17 50.78 15.66 21.23
33 M12 45.13 42.03 52.14 16.52 20.23
43 M13 54.51 70.95 42.05 16.11 23.90
53 M14 47.25 63.42 41.10 56.88 14.07 21.46
63 M15 45.56 40.84 14.66 21.38
73 M16 45.49 40.52 56.14 15.83 22.49
5 M17 44.07 41.09 53.45 15.31 21.46
15 M18 53.82 41.73 55.05 15.62 19.54
25 M19 43.27 60.56 42.00 13.80 19.51
35 M20 44.86 40.61 56.09 14.38 17.64
45 M21 43.20 61.07 40.46 53.38 19.39 23.97
55 M22 43.68 60.77 42.93 21.42 23.62
65 M23 44.85 40.07 57.76 13.71 18.05
75 M24 40.57 53.48 13.00 19.28
7 M25 46.38 40.47 54.13 14.66 18.33
17 M26 46.12 61.36 42.73 16.29 19.20
27 M27 41.00 51.18 41.39 51.63
37 M28 41.11 55.38 12.86 15.11
47 M29 41.80 58.61 38.34 12.38 16.46
57 M30 45.05 59.89 38.92 52.22 12.08 17.13
67 M31 43.74 59.16 39.69 57.51 11.58 15.82
77 M32 43.74 39.12 50.96 13.84 18.29
9 M33 42.88 56.52 43.57 53.24 14.53 19.70
19 M34 43.91 57.91 43.15 50.79 10.54 15.33
29 M35 43.43 53.51 43.72 56.15 14.10 20.53
39 M36 41.54 51.15 13.86 19.52
49 M37 42.72 55.77 42.77 53.66 10.83 15.87




Tab.9: Snrpn D1 methylation data, section 3 
 
Run order Mouse No. Tongue Muscles Heart
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
1 M1 53.11 66.07 65.99 76.46 43.31 51.48
11 M2 73.71 61.59 64.04 76.16 42.38 52.54
21 M3 56.39 70.27 63.70 74.48 43.36 52.06
31 M4 50.11 66.19 66.50 74.64 44.29 53.07
41 M5 51.52 64.37 64.89 76.47 44.65 52.36
51 M6 52.72 66.13 76.70 44.14 51.99
61 M7 52.96 64.90 68.08 79.54 43.76 51.46
71 M8 55.69 69.86 63.94 75.68 44.52 54.67
3 M9 63.67 73.48 44.78 52.54
13 M10 53.99 65.88 68.78 79.16 44.78 54.14
23 M11 50.90 66.74 66.82 78.16 44.62 52.50
33 M12 51.30 68.85 77.80 44.39 51.89
43 M13 45.76 66.54 74.38 43.87 52.75
53 M14 48.31 62.10 65.83 76.18 44.51 54.39
63 M15 48.11 61.01 63.64 75.69 44.44 53.18
73 M16 48.44 63.49 64.06 66.10 44.51 53.13
5 M17 52.23 65.10 61.20 75.08 44.41 52.19
15 M18 50.51 62.15 64.53 81.66 45.43 53.40
25 M19 48.44 63.52 44.71 53.22
35 M20 53.13 66.71 64.54 74.80 45.62 53.68
45 M21 48.85 45.26 54.42
55 M22 50.83 63.99 76.13 44.77 57.75
65 M23 47.36 62.90 64.11 70.79 45.64 55.96
75 M24 47.48 59.96 64.50 64.86 45.31 56.92
7 M25 51.27 66.08 43.97 54.83
17 M26 50.00 62.21 65.24 75.37 44.44 54.05
27 M27 46.74 62.69 44.93 54.68
37 M28 52.70 64.92 73.87 44.41 54.38
47 M29 47.27 61.04 75.74 42.96 58.25
57 M30 62.05 40.40 54.55
67 M31 47.10 60.63 66.01 76.64 42.30 54.63
77 M32 45.30 60.05 40.96 53.59
9 M33 50.20 65.38 42.94 50.57
19 M34 58.06 63.69 76.49 42.72 51.92
29 M35 54.88 70.77 73.18 42.39 54.57
39 M36 51.04 63.88 64.66 69.01 42.39 53.85
49 M37 44.48 57.26 62.58 43.79 54.07




Tab.9: Snrpn D1 methylation data, section 4 
 
Run order Mouse No. Spleen Lungs Skin
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
69 M39 42.92 51.64 43.40
79 M40 43.09 50.76 43.71 49.67
81 M41 41.02 51.14 44.81 51.48
82 M42 44.01 48.42 46.19
83 M43 42.53 50.09 43.22 48.21
84 M44 41.66 48.51 44.35
85 M45 42.49 49.03 45.26 52.75
86 M46 41.65 49.38 44.15
87 M47 42.64 50.27 52.57 48.55 55.77
88 M48 42.23 50.61 44.39 51.23
89 M49 42.40 50.49 44.25
90 M50 39.13 48.84 43.57 53.53
2 F1 41.94 50.39 42.19 41.29
12 F2 40.95 47.49 41.62 44.69
22 F3 43.87 51.61 42.04 44.20
32 F4 40.70 47.88 41.99 43.16
42 F5 41.86 50.88 42.20 43.62
52 F6 43.62 51.05 41.04 46.85
62 F7 41.93 49.88 41.34 54.80 42.41
72 F8 39.46 49.19 41.67 46.23
4 F9 42.46 50.40 42.19 43.50
14 F10 40.53 47.04 42.03 55.11 44.28
24 F11 42.60 51.65 42.01 43.93
34 F12 42.12 49.83 41.81 54.83 42.71
44 F13 52.27 51.66 43.79 46.63
54 F14 44.28 59.68 43.03 43.69 51.58
64 F15 49.28 51.66 47.21 43.70
74 F16 39.42 49.11 40.57 54.31 43.15 51.22
6 F17 41.32 48.79 46.59
16 F18 44.76 53.36 43.51 39.04
26 F19 46.26 42.46
36 F20 43.91 51.61 42.70 43.19
46 F21 40.20 50.38 42.06 42.46
56 F22 43.79 41.50 40.76 45.65
66 F23 38.41 51.14 44.41 43.25 48.23
76 F24 44.72 51.97 42.61 43.86 50.45
8 F25 42.41 50.79 43.49 44.37
18 F26 42.75 54.38 43.20 45.23
28 F27 43.2009 56.8504 40.7569 44.6255 54.4763





Tab.9: Snrpn D1 methylation data, section 5 
 
Run order Mouse No. Brain Bone marrow Testes
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
69 M39 43.12 57.06 41.72 34.99 44.80
79 M40 44.36 46.58 18.39 22.96
81 M41 43.82 59.12 43.14 52.46 10.22 16.88
82 M42 41.79 59.64 45.13 55.05 11.35 18.52
83 M43 44.90 59.59 39.45 49.05
84 M44 39.88 49.06
85 M45 43.06 60.28 25.28 31.93
86 M46 40.30 50.61 12.81 19.33
87 M47 17.14 24.77
88 M48 15.27 20.22
89 M49 12.17 16.93
90 M50 15.34 20.58
2 F1 47.65 42.24 51.52
12 F2 46.08 43.08 51.98
22 F3 45.80 43.88
32 F4 44.09 54.56 41.87 49.02
42 F5 38.92 42.23 53.45
52 F6 45.50 36.63
62 F7 42.65 61.90 43.21 54.43
72 F8 47.65 64.97 42.52 54.00
4 F9 45.93 42.43 51.35
14 F10 41.55 51.10
24 F11 45.80 63.60 42.78 53.06
34 F12 42.19 60.78 43.28 57.07
44 F13 49.47 43.86 54.38
54 F14 49.08 43.84 51.89
64 F15 44.45 41.32 55.99
74 F16 47.39 62.19 44.08 57.89
6 F17 46.57 43.62 59.65
16 F18 43.79 54.14
26 F19 43.71 43.46 52.83
36 F20 44.70 60.80 44.47 57.83
46 F21 43.21 59.70
56 F22 46.14 43.34 57.99
66 F23 47.72 42.51 58.41
76 F24 42.53 53.51
8 F25 48.01 45.13
18 F26 43.20 57.04 41.51 48.68





Tab.9: Snrpn D1 methylation data, section 6 
 
Run order Mouse No. Tongue Muscles Heart
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
69 M39 50.84 65.13 77.09 43.09 53.10
79 M40 48.02 61.00 67.05 44.62 60.39
81 M41 50.75 61.39 66.81 76.47 45.81 59.93
82 M42 47.38 55.91 40.36
83 M43 47.08 59.72 64.68 77.28 41.04 59.35
84 M44 52.15 64.38 69.91 70.58 41.74 54.78
85 M45 44.57 56.46 64.60 77.33 42.61 56.72
86 M46 49.87 60.63 70.66 78.30 42.66 54.80
87 M47 51.84 63.35 51.85 58.46
88 M48 51.79 65.93 75.92 42.68 55.35
89 M49 46.75 58.18 64.14 75.13 42.21 54.70
90 M50 53.44 66.59 63.25 75.04 42.91 61.37
2 F1 41.87 53.65 66.13 76.42 42.58 54.33
12 F2 45.25 57.16 63.34 75.97 43.76 53.12
22 F3 43.91 56.65 42.54 54.68
32 F4 44.12 70.06 79.14 45.54 56.02
42 F5 41.13 53.71 63.89 73.62 46.57 61.87
52 F6 44.04 54.89 63.21 74.70 43.32 56.49
62 F7 65.13 76.18
72 F8 44.45 55.90 65.92 76.48 42.40 58.85
4 F9 43.67 52.66 70.32 77.04 44.73 53.51
14 F10 44.30 52.64 67.44 77.99 42.86 50.30
24 F11 43.21 55.21 65.32 75.02 41.82 54.87
34 F12 44.60 53.65 68.28 79.15 50.61
44 F13 41.97 58.76 69.25 71.12 40.27 53.88
54 F14 43.84 55.39 65.19 78.19 43.18 52.68
64 F15 43.81 52.96 66.54 78.59 42.87 52.72
74 F16 42.82 54.14 64.78 73.50 42.29 53.84
6 F17 44.21 55.74 41.41 51.17
16 F18 41.82 41.46 51.33
26 F19 40.57 56.38 42.21 50.91
36 F20 41.90 52.88 42.26 52.52
46 F21 41.78 42.04 52.81
56 F22 40.73 52.68 41.65 51.03
66 F23 44.53 64.28 74.70 42.26 52.74
76 F24 46.02 61.80 64.60 73.01 42.31 51.61
8 F25 42.24 55.19 67.59 76.79 41.50 51.05
18 F26 40.77 50.60 62.31 41.36 54.28
28 F27 42.0966 53.5429 66.797 80.3952 41.1773 54.2073




Tab.9: Snrpn D1 methylation data, section 7 
 
Run order Mouse No. Spleen Lungs Skin
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
48 F29 40.12 48.82 42.02 42.47 50.49
58 F30 41.72 60.96 41.07 40.39
68 F31 40.53 49.09 39.42 54.15 43.82
78 F32 41.80 49.32 40.22 42.97
10 F33 41.55 48.55 39.87 51.70 43.92
20 F34 41.05 47.18 40.48 50.63 43.57
30 F35 42.61 50.20 40.18 50.87 43.89
40 F36 41.06 48.35 40.20 50.89 44.37
50 F37 41.01 47.94 39.93 50.11 42.97
60 F38 42.27 49.98 41.86 55.76 37.50 47.99
70 F39 42.53 51.31 39.67 52.81 46.96
80 F40 42.86 51.52 40.34 51.98 46.96
91 F41 40.86 49.56 41.39 58.05 44.47 52.70
92 F42 42.21 50.11 38.43 51.16 44.31
93 F43 43.44 50.36 39.81 51.68 42.85
94 F44 44.12 53.43 40.34 51.88 41.99 47.22
95 F45 37.71 50.70 39.72 51.94 39.41 48.69
96 F46 42.90 50.26 40.08 51.03 42.34 50.79
97 F47 43.96 51.18 37.01 52.77 47.90
98 F48 40.87 47.73 40.35 52.19 43.77 52.42
99 F49 43.26 55.74 39.70 43.76 49.87
100 F50 39.11 51.54 42.01 43.45 49.86
Mean males 42.38 49.97 44.32 55.67 44.26 51.81
SD Males 1.56 1.97 2.02
Mean females 42.29 50.79 41.46 52.79 43.63 50.43
SD Females 2.40 1.80 1.99
Mean both 42.34 50.38 42.55 53.66 43.93 51.21
Total Mean 46.36 48.10 47.57
Control M 43.00 51.00 47.00 42.00




Tab.9: Snrpn D1 methylation data, section 8 
 
Run order Mouse No. Brain Bone marrow Testes
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
48 F29 44.52 58.56 43.62 56.76
58 F30 47.22 45.33
68 F31 45.44 60.80 42.15 58.59
78 F32 43.67 46.73
10 F33 44.33 45.80





70 F39 46.20 43.69
80 F40 42.31 60.31 43.88
91 F41 42.42 58.64
92 F42 44.16 60.27 43.20 55.86
93 F43 39.01
94 F44 42.52






Mean males 44.86 60.00 41.66 53.71 17.83 23.84
SD Males 2.64 1.73 7.77
Mean females 45.08 60.57 43.29 55.01
SD Females 2.46 1.77
Mean both 44.97 60.23 42.50 54.39
Total Mean 52.60 48.44 20.84





Tab.9: Snrpn D1 methylation data, section 9 
 
Run order Mouse No. Tongue Muscles Heart
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
48 F29 42.79 57.92 66.48 72.89 41.37 55.76
58 F30 44.87 55.95 63.20 73.22 40.85 57.06
68 F31 40.60 50.34 63.71 69.39 42.03 54.28
78 F32 42.41 54.29 42.69 52.19
10 F33 45.89 59.52 44.06 52.22
20 F34 40.27 51.07 43.68 53.70
30 F35 40.08 53.71 44.18 53.46
40 F36 40.65 55.20 44.01 54.75
50 F37 41.05 54.85 45.66 55.54
60 F38 43.88 53.38 42.50 51.00
70 F39 40.03 49.71 43.95 52.27
80 F40 42.22 57.24 43.02 52.56
91 F41 41.08 57.14 64.16 68.75 57.59 42.75
92 F42 43.15 53.01 44.41 52.33
93 F43 39.00 59.52 65.60 67.24 44.33 53.90
94 F44 44.40 59.19 42.71 52.78
95 F45 42.76 54.20 62.49 75.62 42.54 54.94
96 F46 42.64 57.97 63.13 74.29 43.71 55.42
97 F47 42.82 56.37 66.59 76.51 45.63 55.92
98 F48 37.52 56.62 66.96 77.94 45.31 58.97
99 F49 41.78 53.57 68.11 78.14 44.19 58.38
100 F50 43.10 53.32 76.39 44.92 56.15
Mean males 50.79 63.02 65.33 75.22 43.77 54.48
SD Males 4.57 2.25 1.84
Mean females 42.57 54.99 65.62 75.21 43.45 53.71
SD Females 1.79 2.19 2.74
Mean both 46.64 58.56 65.45 75.22 43.61 54.10
Total Mean 52.60 70.34 48.85
Control M 42.00 51.00 67.00 78.00 42.00 51.00




Tab.10: IAP methylation data, section 1 
 
Run order Mouse No. Spleen Lungs Skin
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
1 M1 80.59 85.08 83.39 87.01 85.46 88.42
11 M2 74.88 81.13 83.23 87.51 84.72 87.56
21 M3 83.92 86.08 82.49 86.43 83.91 87.28
31 M4 76.61 82.06 83.83 87.31 85.04 87.41
41 M5 84.78 88.04 84.63 88.71 85.21 88.67
51 M6 84.70 87.94 84.27 88.13 84.82 88.33
61 M7 77.24 82.46 83.37 86.55 85.13 87.30
71 M8 78.17 82.72 83.15 86.93 85.78 88.30
3 M9 74.22 80.32 83.13 87.06 85.06 88.00
13 M10 84.66 87.53 83.37 86.98 84.54 87.12
23 M11 74.62 81.35 82.55 87.01 83.85 87.13
33 M12 78.93 84.14 84.25 87.88 84.09 87.50
43 M13 71.83 78.63 82.65 86.32 84.72 87.57
53 M14 78.00 82.99 83.15 87.23 84.72 87.92
63 M15 72.03 78.98 83.63 87.32 84.09 87.01
73 M16 73.67 80.53 83.96 87.24 85.14 87.93
5 M17 75.99 81.75 84.04 87.49 84.65 87.37
15 M18 81.85 86.60 84.04 88.19 84.89 88.62
25 M19 77.72 83.23 82.98 86.98 84.47 87.31
35 M20 81.41 85.81 82.92 87.13 84.22 84.29
45 M21 86.98 89.67 85.20 89.12
55 M22 76.96 82.76 81.97 86.80
65 M23 84.88 88.56 83.90 87.61 85.22 88.26
75 M24 80.07 84.81 84.50 88.29 85.27 88.38
7 M25 78.37 83.46 82.80 86.29 84.91 87.76
17 M26 83.88 87.41 83.85 87.36 84.68 87.91
27 M27 76.58 81.65 81.53 85.77 84.04 87.28
37 M28 77.04 82.34 84.28 87.45 85.33 88.45
47 M29 78.50 83.16 81.31 85.48 83.90 86.77
57 M30 77.95 83.32 81.79 85.98 83.84 87.08
67 M31 85.59 88.49 85.11 88.19
77 M32 80.81 84.41 85.86 88.13
9 M33 80.98 84.88 86.16 88.83
19 M34 85.23 88.07 84.39 87.44
29 M35 78.23 83.08 84.77 87.81
39 M36 82.74 86.55 84.50 87.90
49 M37 82.82 87.28 83.57 87.25




Tab.10: IAP methylation data, section 2 
 
Run orderMouse No.Spleen Lungs Skin
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
69 M39 82.46 86.04 85.08 87.71
79 M40 83.18 86.39 75.41 79.74
81 M41 78.41 84.12 84.62 87.13 83.96 86.30
82 M42 80.39 85.36 85.52 88.48 83.58 86.59
83 M43 80.92 85.37 85.98 88.08 84.28 86.28
84 M44 75.29 81.57 85.34 88.03 84.18 86.64
85 M45 79.04 84.20 86.40 88.90 84.54 86.92
86 M46 77.39 82.94 84.34 87.26 84.42 86.16
87 M47 79.61 84.76 86.40 89.23 83.92 86.54
88 M48 84.53 88.19 85.34 88.14 84.20 86.58
89 M49 82.30 87.21 84.38 87.40 86.52 87.62
90 M50 71.36 79.39 84.12 87.11 83.69 85.95
2 F1 83.91 87.25 84.50 88.04
12 F2 71.90 79.46 83.41 86.75 84.84 88.36
22 F3 85.54 88.75 83.23 86.73 84.64 88.07
32 F4 76.76 83.83 84.53 87.70 85.12 88.39
42 F5 82.18 86.59 84.75 87.73 85.17 88.21
52 F6 81.84 86.69 84.34 87.16 84.64 88.09
62 F7 80.12 85.27 84.75 87.00 85.62 88.33
72 F8 73.25 80.36 83.98 86.84 84.69 88.15
4 F9 73.97 80.96 83.26 86.84 84.34 88.16
14 F10 73.69 80.66 83.36 87.48 83.95 87.43
24 F11 82.79 86.47 83.62 87.20 84.60 87.99
34 F12 79.97 84.78 83.44 86.96 84.82 88.03
44 F13 81.31 85.83 85.15 88.16 85.22 88.60
54 F14 84.33 87.88 84.25 87.45 84.32 87.90
64 F15 86.62 89.27 87.09 88.34 84.10 87.40
74 F16 70.35 78.17 84.73 87.67 84.99 88.31
6 F17 75.31 81.37 84.44 87.27 84.50 87.42
16 F18 83.79 87.51 84.12 87.26 84.40 87.39
26 F19 51.76 83.58 87.50 84.72 87.81
36 F20 83.90 87.22 84.50 87.81 84.37 82.90
46 F21 81.29 85.62 83.84 87.14 84.37 87.63
56 F22 79.84 84.48 84.18 87.38 84.63 87.73
66 F23 70.42 78.46 83.26 87.02 83.24 87.06
76 F24 77.75 83.26 84.54 86.91 85.87 87.94
8 F25 76.71 82.43 84.54 87.01 84.44 87.19
18 F26 77.09 83.28 83.54 87.07 84.85 88.24
28 F27 82.60 86.20 83.83 86.94 84.79 87.59




Tab.10: IAP methylation data, section 3 
 
Run orderMouse No.Spleen Lungs Skin
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
48 F29 68.99 77.04 83.57 86.91 84.54 87.26
58 F30 84.27 87.97 84.10 87.89 84.84 88.33
68 F31 73.69 80.20 83.88 86.82 85.31 87.91
78 F32 71.42 78.72 84.61 87.78 85.42 88.11
10 F33 75.30 81.13 83.73 87.16 85.28 87.59
20 F34 82.01 86.33 84.02 87.72 84.13 87.32
30 F35 84.62 88.28 84.05 88.23 35.30 88.64
40 F36 77.13 82.74 84.55 87.86 85.42 88.27
50 F37 73.69 80.68 83.31 87.46 83.67 87.28
60 F38 83.19 86.48 83.73 87.39 84.01 87.09
70 F39 86.74 89.29 84.61 88.03 84.81 87.77
80 F40 75.74 81.89 84.47 87.74 84.93 88.04
91 F41 80.17 85.95 83.64 87.22 83.71 85.77
92 F42 77.67 84.08 84.46 88.18 84.32 87.10
93 F43 85.38 89.39 83.52 87.21 86.52 87.82
94 F44 84.06 88.16 84.02 87.52 83.60 86.70
95 F45 78.91 84.12 83.18 87.05 83.13 86.98
96 F46 80.64 85.77 82.85 86.20 84.31 86.45
97 F47 80.34 85.71 83.13 86.23 83.74 85.96
98 F48 78.18 84.45 84.93 87.46 84.72 86.82
99 F49 80.84 86.00 83.79 86.45 84.08 86.07
100 F50 79.73 84.96 83.83 87.05 83.44 86.09
Mean males79.62 84.39 83.81 87.38 84.46 87.28
SD Males 3.91 1.23 1.49
Mean females78.47 84.32 84.04 87.30 83.59 87.50
SD Females 6.03 0.70 7.00
Mean both 79.05 84.35 83.94 87.34 84.02 87.39
Total mean 81.70 85.64 85.71
Control M 83.00 86.00 84.00 88.00




Tab.10: IAP methylation data, section 4 
Run orderMouse No.Brain Bone marrow Testes
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
1 M1 88.00 84.49 73.98 81.46 82.68 49.63
11 M2 87.56 84.49 71.32 74.78 0.00
21 M3 87.86 84.44 74.99 82.39 66.10 55.49
31 M4 88.29 84.53 72.94 80.64 72.51 52.65
41 M5 88.56 85.51 72.87 80.66 64.74 55.48
51 M6 88.61 85.00 72.90 80.97 67.74 54.45
61 M7 87.77 83.95 73.50 80.20 81.01 49.75
71 M8 87.93 84.68 74.28 82.15 80.37 50.55
3 M9 88.34 85.11 71.57 79.43 66.50 54.43
13 M10 88.00 84.42 71.61 79.56 77.26 50.73
23 M11 87.41 84.48 69.07 77.50 83.27 48.21
33 M12 88.08 84.96 72.14 79.92 63.13 55.87
43 M13 87.70 84.01 70.18 78.41 66.42 54.14
53 M14 87.63 84.47 70.87 78.70 61.18 56.26
63 M15 87.80 84.28 70.00 77.88 63.23 55.19
73 M16 87.52 84.14 69.86 78.44 74.13 51.41
5 M17 88.20 84.68 70.39 78.75 67.38 53.89
15 M18 88.42 85.17 72.13 80.10 74.34 51.86
25 M19 86.11 83.51 74.09 81.35 62.38 56.60
35 M20 87.50 84.48 69.58 78.63 76.10 50.82
45 M21 87.80 84.97 70.26 78.93 69.27 53.26
55 M22 87.23 84.32 73.55 81.65 66.81 55.00
65 M23 87.07 83.86 72.54 80.02 73.97 51.96
75 M24 71.83 79.59 80.12 49.83
7 M25 87.60 84.11 69.66 78.18 68.82 53.18
17 M26 88.61 85.38 72.95 81.20 58.20 58.25
27 M27 88.15 84.80 70.13 77.80 81.67 48.79
37 M28 91.55 71.23 78.65 73.26 51.77
47 M29 87.51 83.66 70.54 77.48 74.39 51.02
57 M30 86.92 83.90 69.65 77.40 65.59 54.13
67 M31 87.56 84.05 69.10 77.63 85.69 47.53
77 M32 88.77 83.90 69.74 77.17 75.55 50.53
9 M33 87.68 83.85 70.98 79.40 81.76 49.27
19 M34 87.99 84.28 71.74 79.61 79.86 49.92
29 M35 88.21 85.57 70.93 78.60 64.58 54.90
39 M36 89.29 71.01 78.60 74.50 51.34
49 M37 87.44 84.27 71.97 79.84 78.11 50.55




Tab.10: IAP methylation data, section 5 
 
Run orderMouse No.Brain Bone marrow Testes
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
69 M39 87.61 84.19 73.00 80.67 81.06 49.88
79 M40 88.15 84.12 70.88 77.99 72.40 51.86
81 M41 85.00 87.01 68.81 75.72 62.74 54.69
82 M42 85.57 88.30 71.05 77.86 67.61 53.52
83 M43 84.10 86.32 67.14 75.43 81.51 48.06
84 M44 87.12 89.84 72.88 79.79 85.29 48.33
85 M45 84.86 87.16 76.73 83.62 81.12 50.76
86 M46 86.67 88.06 70.42 78.04 70.76 52.45
87 M47 86.74 88.64 72.03 80.37 67.68 54.28
88 M48 86.99 89.13 70.24 77.36 78.79 49.54
89 M49 86.25 88.63 74.52 81.71 82.06 49.89
90 M50 86.09 88.13 73.72 80.22 66.20 54.79
2 F1 88.32 84.22 73.45 81.43
12 F2 88.64 84.65 70.35 78.95
22 F3 87.23 84.54 73.54 81.27
32 F4 87.61 84.36 71.70 79.85
42 F5 80.93 80.79 70.99 79.36
52 F6 87.62 84.44 72.01 79.60
62 F7 88.21 84.55 72.78 80.52
72 F8 87.46 84.56 70.37 78.47
4 F9 86.99 84.28 68.32 77.24
14 F10 87.11 84.64 68.15 77.14
24 F11 87.95 84.77 72.85 80.92
34 F12 87.75 84.12 72.51 80.61
44 F13 88.09 84.43 73.87 80.99
54 F14 87.37 78.96 70.36 78.16
64 F15 87.67 84.17 74.17 81.69
74 F16 87.84 84.30 72.93 80.52
6 F17 88.59 84.33 86.25 91.09
16 F18 88.99 85.01 72.30 80.25
26 F19 88.20 84.71 70.20 78.13
36 F20 88.00 84.29 72.58 80.36
46 F21 88.79 84.53 72.08 80.25
56 F22 88.07 84.25 71.16 79.17
66 F23 88.04 84.63 69.21 78.46
76 F24 71.73 79.67
8 F25 88.25 84.91 73.18 80.48
18 F26 88.18 85.12 68.48 77.49
28 F27 88.32 84.61 70.87 78.54




Tab.10: IAP methylation data, section 6 
 
Run order Mouse No. Brain Bone marrow Testes
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
48 F29 88.85 85.43 70.71 78.45
58 F30 87.81 85.28 71.41 80.28
68 F31 88.01 84.84 71.03 79.27
78 F32 88.25 84.69 72.73 81.29
10 F33 88.12 84.57 73.54 81.18
20 F34 89.19 85.98 73.86 81.41
30 F35 59.86 71.62 79.29
40 F36 88.61 84.77 71.97 79.91
50 F37 87.77 85.17 71.25 80.04
60 F38 87.81 84.52 80.12 87.43
70 F39 87.49 84.81 73.15 81.33
80 F40 87.73 85.09 71.64 79.50
91 F41 87.23 85.21 71.50 78.54
92 F42 87.56 85.23 71.03 78.34
93 F43 86.99 84.29 74.00 80.53
94 F44 88.18 85.19 74.77 80.91
95 F45 86.69 84.85 73.15 80.19
96 F46 89.03 85.39 78.24 84.38
97 F47 88.22 85.27 72.62 79.64
98 F48 89.46 85.94 74.21 81.43
99 F49 88.09 85.55 74.93 80.52
100 F50 88.22 85.42 72.49 78.83
Mean males 87.54 85.21 71.56 79.31 72.84 51.21
SD Males 1.18 1.84 7.33
Mean females 87.20 84.49 72.57 80.26
SD Females 4.20 2.90
Mean both 87.37 84.85 72.07 79.79
Total mean 86.11 75.93 62.03
Control M 85.00 89.00 83.00 87.00 84.00 87.00




Tab.10: IAP methylation data, section 7 
 
Run orderMouse No.Tongue Muscles Heart
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
1 M1 85.96 89.14 83.99 87.03 81.84 86.11
11 M2 86.25 89.00 83.22 86.35 80.69 84.99
21 M3 85.31 88.28 83.47 85.81 81.44 85.33
31 M4 85.43 88.37 83.70 85.83 79.81 84.32
41 M5 85.59 88.82 83.54 86.67 85.24 87.45
51 M6 86.80 90.25 83.42 86.35 83.40 85.62
61 M7 85.10 87.58 83.64 85.98 83.06 85.06
71 M8 86.22 88.98 83.65 86.58 79.86 83.73
3 M9 83.89 86.52 76.28 82.04
13 M10 86.20 88.64 83.84 86.43 78.48 83.41
23 M11 84.62 87.92 83.99 86.68 78.99 83.87
33 M12 84.35 87.47 83.25 86.66 82.42 85.72
43 M13 83.96 87.11 83.60 85.77 80.17 83.78
53 M14 84.76 87.79 82.79 85.87 80.96 85.35
63 M15 84.94 87.88 83.70 86.49 80.52 84.58
73 M16 84.69 87.82 86.18 87.43 80.60 84.49
5 M17 83.62 86.99 84.27 86.64 81.63 85.68
15 M18 84.34 88.05 82.61 86.52 80.77 85.32
25 M19 83.54 87.07 82.70 85.44 77.91 82.78
35 M20 84.75 87.92 83.16 86.55 79.71 84.09
45 M21 83.78 87.83 84.47 86.83 82.02 86.08
55 M22 84.21 87.77 83.89 86.82 79.32 84.07
65 M23 84.47 88.02 83.70 85.98 81.16 84.91
75 M24 85.18 88.44 83.31 86.02 81.00 85.00
7 M25 84.50 87.80 83.66 86.79 80.07 85.34
17 M26 84.89 88.31 82.77 85.76 80.37 84.86
27 M27 84.17 86.85 78.49 83.33
37 M28 85.60 88.71 82.30 85.82 81.07 84.81
47 M29 84.34 87.38 82.71 85.63 80.40 84.49
57 M30 85.49 88.07 82.67 86.40 79.24 83.69
67 M31 85.50 88.29 83.02 85.78 81.43 85.29
77 M32 85.28 87.70 83.55 85.58 80.26 84.67
9 M33 85.16 83.98 80.11 84.49 84.01 87.77
19 M34 86.14 83.06 84.14 87.17 82.23 86.08
29 M35 85.38 83.44 83.04 85.51 80.12 84.55
39 M36 85.55 83.53 83.53 86.46 81.06 85.02
49 M37 85.12 83.45 83.60 86.17 80.40 84.69




Tab.10: IAP methylation data, section 8 
 
Run order Mouse No. Tongue Muscles Heart
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
69 M39 84.86 82.24 84.08 86.29 81.70 85.07
79 M40 85.11 83.49 83.82 86.15 80.33 84.39
81 M41 84.31 82.99 82.33 85.51 80.20 84.63
82 M42 84.68 83.85 83.47 86.19 80.52 84.91
83 M43 85.08 82.96 82.20 85.09 81.34 84.86
84 M44 85.46 83.61 82.88 86.03 81.28 84.41
85 M45 86.11 84.09 83.78 86.63 80.77 84.54
86 M46 85.81 83.38 84.39 86.42 81.07 84.81
87 M47 84.42 82.98 83.47 86.57 82.27 85.80
88 M48 85.70 83.49 83.26 86.29 80.55 85.03
89 M49 83.85 82.79 81.86 85.54 80.02 84.55
90 M50 86.67 83.35 83.16 85.55 81.36 85.74
2 F1 86.68 85.01 85.17 88.25 82.64 87.40
12 F2 86.54 83.84 83.62 86.91 82.43 86.55
22 F3 85.92 83.72 83.50 86.49 82.42 86.33
32 F4 85.68 83.84 84.15 86.98 83.20 86.89
42 F5 86.92 83.67 84.38 86.34 83.78 87.21
52 F6 86.09 83.80 83.95 86.38 83.28 86.42
62 F7 84.95 82.73 83.93 86.10 82.62 85.78
72 F8 86.31 84.03 82.66 85.80 83.14 86.56
4 F9 86.09 84.64 84.17 87.32 81.81 86.46
14 F10 86.75 84.26 82.58 86.19 81.01 85.52
24 F11 86.92 84.35 83.62 87.02 82.07 85.95
34 F12 87.27 84.52 81.81 85.61 81.69 85.52
44 F13 85.82 83.05 85.18 86.85 82.40 86.01
54 F14 86.36 83.44 84.45 86.47 82.58 86.29
64 F15 86.78 83.49 84.66 87.07 81.58 85.62
74 F16 87.01 84.28 83.26 86.58 82.67 86.52
6 F17 85.57 86.04 84.48 87.34
16 F18 87.33 84.08 83.77 86.51 81.66 85.38
26 F19 87.22 84.01 83.67 86.80 81.46 85.73
36 F20 87.25 83.90 83.96 86.78 81.41 85.65
46 F21 86.07 83.73 83.89 86.23 80.95 85.06
56 F22 86.30 83.60 83.85 86.37 80.56 84.23
66 F23 87.60 84.76 82.43 85.32 81.54 85.85
76 F24 86.80 83.95 84.74 86.48 81.70 85.18
8 F25 86.19 84.08 83.22 85.90 81.35 85.58
18 F26 87.11 84.21 83.31 86.62 80.79 84.80
28 F27 86.47 84.36 84.00 86.13 81.16 85.45




Tab.10: IAP methylation data, section 9 
 
Run order Mouse No. Tongue Muscles Heart
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
48 F29 86.61 83.09 83.67 85.72 81.37 85.06
58 F30 86.90 83.88 83.25 86.43 81.65 85.48
68 F31 86.62 84.08 83.03 85.26 81.44 85.38
78 F32 83.65 86.49 82.87 86.54
10 F33 86.40 85.49 85.19 87.00 81.00 84.56
20 F34 86.64 83.78 80.12 84.44
30 F35 86.20 84.17 84.41 87.24 82.39 85.93
40 F36 86.64 83.41 83.54 86.43 82.31 85.56
50 F37 86.34 83.79 83.03 86.51 82.50 86.00
60 F38 85.45 82.87 82.94 85.79 78.15 82.48
70 F39 86.61 83.90 82.46 85.76 81.85 85.31
80 F40 85.04 83.69 83.35 86.08 81.82 85.36
91 F41 84.18 83.72 83.52 86.87 80.75 84.97
92 F42 84.82 83.91 84.62 87.21 82.59 86.17
93 F43 85.69 83.10 83.17 86.14 80.48 84.63
94 F44 85.69 83.03 82.92 86.19 81.80 85.75
95 F45 86.29 83.24 82.68 86.02 82.03 85.79
96 F46 85.95 82.97 83.10 85.83 80.70 84.38
97 F47 85.55 83.20 83.04 85.19 82.26 85.52
98 F48 86.17 84.27 84.92 86.94 83.64 86.21
99 F49 85.48 84.27 84.36 86.76 80.49 84.33
100 F50 85.15 83.80 84.86 86.87 81.77
Mean males 85.08 86.31 83.40 86.15 80.77 84.83
SD Males 0.79 0.87 1.49
Mean females 86.24 83.88 83.70 86.44 81.77 85.59
SD Females 0.73 0.79 1.01
Mean both 85.66 85.10 83.55 86.30 81.26 85.20
Total mean 85.38 84.92 83.23
Control M 85.00 83.00 84.00 87.00 84.00 87.00




Tab.11: Line 1 methylation data, section 1 
 
Run orderMouse No.Spleen Lungs Skin
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
1 M1 80.59 85.08 83.39 87.01 85.46 88.42
11 M2 74.88 81.13 83.23 87.51 84.72 87.56
21 M3 83.92 86.08 82.49 86.43 83.91 87.28
31 M4 76.61 82.06 83.83 87.31 85.04 87.41
41 M5 84.78 88.04 84.63 88.71 85.21 88.67
51 M6 84.70 87.94 84.27 88.13 84.82 88.33
61 M7 77.24 82.46 83.37 86.55 85.13 87.30
71 M8 78.17 82.72 83.15 86.93 85.78 88.30
3 M9 74.22 80.32 83.13 87.06 85.06 88.00
13 M10 84.66 87.53 83.37 86.98 84.54 87.12
23 M11 74.62 81.35 82.55 87.01 83.85 87.13
33 M12 78.93 84.14 84.25 87.88 84.09 87.50
43 M13 71.83 78.63 82.65 86.32 84.72 87.57
53 M14 78.00 82.99 83.15 87.23 84.72 87.92
63 M15 72.03 78.98 83.63 87.32 84.09 87.01
73 M16 73.67 80.53 83.96 87.24 85.14 87.93
5 M17 75.99 81.75 84.04 87.49 84.65 87.37
15 M18 81.85 86.60 84.04 88.19 84.89 88.62
25 M19 77.72 83.23 82.98 86.98 84.47 87.31
35 M20 81.41 85.81 82.92 87.13 84.22 84.29
45 M21 86.98 89.67 85.20 89.12
55 M22 76.96 82.76 81.97 86.80
65 M23 84.88 88.56 83.90 87.61 85.22 88.26
75 M24 80.07 84.81 84.50 88.29 85.27 88.38
7 M25 78.37 83.46 82.80 86.29 84.91 87.76
17 M26 83.88 87.41 83.85 87.36 84.68 87.91
27 M27 76.58 81.65 81.53 85.77 84.04 87.28
37 M28 77.04 82.34 84.28 87.45 85.33 88.45
47 M29 78.50 83.16 81.31 85.48 83.90 86.77
57 M30 77.95 83.32 81.79 85.98 83.84 87.08
67 M31 85.59 88.49 85.11 88.19
77 M32 80.81 84.41 85.86 88.13
9 M33 80.98 84.88 86.16 88.83
19 M34 85.23 88.07 84.39 87.44
29 M35 78.23 83.08 84.77 87.81
39 M36 82.74 86.55 84.50 87.90
49 M37 82.82 87.28 83.57 87.25




Tab.11: Line 1 methylation data, section 2 
 
Run order Mouse No. Spleen Lungs Skin
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
69 M39 82.46 86.04 85.08 87.71
79 M40 83.18 86.39 75.41 79.74
81 M41 78.41 84.12 84.62 87.13 83.96 86.30
82 M42 80.39 85.36 85.52 88.48 83.58 86.59
83 M43 80.92 85.37 85.98 88.08 84.28 86.28
84 M44 75.29 81.57 85.34 88.03 84.18 86.64
85 M45 79.04 84.20 86.40 88.90 84.54 86.92
86 M46 77.39 82.94 84.34 87.26 84.42 86.16
87 M47 79.61 84.76 86.40 89.23 83.92 86.54
88 M48 84.53 88.19 85.34 88.14 84.20 86.58
89 M49 82.30 87.21 84.38 87.40 86.52 87.62
90 M50 71.36 79.39 84.12 87.11 83.69 85.95
2 F1 83.91 87.25 84.50 88.04
12 F2 71.90 79.46 83.41 86.75 84.84 88.36
22 F3 85.54 88.75 83.23 86.73 84.64 88.07
32 F4 76.76 83.83 84.53 87.70 85.12 88.39
42 F5 82.18 86.59 84.75 87.73 85.17 88.21
52 F6 81.84 86.69 84.34 87.16 84.64 88.09
62 F7 80.12 85.27 84.75 87.00 85.62 88.33
72 F8 73.25 80.36 83.98 86.84 84.69 88.15
4 F9 73.97 80.96 83.26 86.84 84.34 88.16
14 F10 73.69 80.66 83.36 87.48 83.95 87.43
24 F11 82.79 86.47 83.62 87.20 84.60 87.99
34 F12 79.97 84.78 83.44 86.96 84.82 88.03
44 F13 81.31 85.83 85.15 88.16 85.22 88.60
54 F14 84.33 87.88 84.25 87.45 84.32 87.90
64 F15 86.62 89.27 87.09 88.34 84.10 87.40
74 F16 70.35 78.17 84.73 87.67 84.99 88.31
6 F17 75.31 81.37 84.44 87.27 84.50 87.42
16 F18 83.79 87.51 84.12 87.26 84.40 87.39
26 F19 51.76 83.58 87.50 84.72 87.81
36 F20 83.90 87.22 84.50 87.81 84.37 82.90
46 F21 81.29 85.62 83.84 87.14 84.37 87.63
56 F22 79.84 84.48 84.18 87.38 84.63 87.73
66 F23 70.42 78.46 83.26 87.02 83.24 87.06
76 F24 77.75 83.26 84.54 86.91 85.87 87.94
8 F25 76.71 82.43 84.54 87.01 84.44 87.19
18 F26 77.09 83.28 83.54 87.07 84.85 88.24
28 F27 82.60 86.20 83.83 86.94 84.79 87.59




Tab.11: Line 1 methylation data, section 3 
 
Run order Mouse No. Spleen Lungs Skin
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
48 F29 68.99 77.04 83.57 86.91 84.54 87.26
58 F30 84.27 87.97 84.10 87.89 84.84 88.33
68 F31 73.69 80.20 83.88 86.82 85.31 87.91
78 F32 71.42 78.72 84.61 87.78 85.42 88.11
10 F33 75.30 81.13 83.73 87.16 85.28 87.59
20 F34 82.01 86.33 84.02 87.72 84.13 87.32
30 F35 84.62 88.28 84.05 88.23 35.30 88.64
40 F36 77.13 82.74 84.55 87.86 85.42 88.27
50 F37 73.69 80.68 83.31 87.46 83.67 87.28
60 F38 83.19 86.48 83.73 87.39 84.01 87.09
70 F39 86.74 89.29 84.61 88.03 84.81 87.77
80 F40 75.74 81.89 84.47 87.74 84.93 88.04
91 F41 80.17 85.95 83.64 87.22 83.71 85.77
92 F42 77.67 84.08 84.46 88.18 84.32 87.10
93 F43 85.38 89.39 83.52 87.21 86.52 87.82
94 F44 84.06 88.16 84.02 87.52 83.60 86.70
95 F45 78.91 84.12 83.18 87.05 83.13 86.98
96 F46 80.64 85.77 82.85 86.20 84.31 86.45
97 F47 80.34 85.71 83.13 86.23 83.74 85.96
98 F48 78.18 84.45 84.93 87.46 84.72 86.82
99 F49 80.84 86.00 83.79 86.45 84.08 86.07
100 F50 79.73 84.96 83.83 87.05 83.44 86.09
Mean males 79.62 84.39 83.81 87.38 84.46 87.28
SD Males 3.91 1.23 1.49
Mean females 78.47 84.32 84.04 87.30 83.59 87.50
SD Females 6.03 0.70 7.00
Mean both 79.05 84.35 83.94 87.34 84.02 87.39
Total mean 81.70 85.64 85.71
Control M 83.00 86.00 84.00 88.00




Tab.11: Line 1 methylation data, section 4 
Run order Mouse No. Brain Bone marrow Testes
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
1 M1 88.00 84.49 73.98 81.46 82.68 49.63
11 M2 87.56 84.49 71.32 74.78 0.00
21 M3 87.86 84.44 74.99 82.39 66.10 55.49
31 M4 88.29 84.53 72.94 80.64 72.51 52.65
41 M5 88.56 85.51 72.87 80.66 64.74 55.48
51 M6 88.61 85.00 72.90 80.97 67.74 54.45
61 M7 87.77 83.95 73.50 80.20 81.01 49.75
71 M8 87.93 84.68 74.28 82.15 80.37 50.55
3 M9 88.34 85.11 71.57 79.43 66.50 54.43
13 M10 88.00 84.42 71.61 79.56 77.26 50.73
23 M11 87.41 84.48 69.07 77.50 83.27 48.21
33 M12 88.08 84.96 72.14 79.92 63.13 55.87
43 M13 87.70 84.01 70.18 78.41 66.42 54.14
53 M14 87.63 84.47 70.87 78.70 61.18 56.26
63 M15 87.80 84.28 70.00 77.88 63.23 55.19
73 M16 87.52 84.14 69.86 78.44 74.13 51.41
5 M17 88.20 84.68 70.39 78.75 67.38 53.89
15 M18 88.42 85.17 72.13 80.10 74.34 51.86
25 M19 86.11 83.51 74.09 81.35 62.38 56.60
35 M20 87.50 84.48 69.58 78.63 76.10 50.82
45 M21 87.80 84.97 70.26 78.93 69.27 53.26
55 M22 87.23 84.32 73.55 81.65 66.81 55.00
65 M23 87.07 83.86 72.54 80.02 73.97 51.96
75 M24 71.83 79.59 80.12 49.83
7 M25 87.60 84.11 69.66 78.18 68.82 53.18
17 M26 88.61 85.38 72.95 81.20 58.20 58.25
27 M27 88.15 84.80 70.13 77.80 81.67 48.79
37 M28 91.55 71.23 78.65 73.26 51.77
47 M29 87.51 83.66 70.54 77.48 74.39 51.02
57 M30 86.92 83.90 69.65 77.40 65.59 54.13
67 M31 87.56 84.05 69.10 77.63 85.69 47.53
77 M32 88.77 83.90 69.74 77.17 75.55 50.53
9 M33 87.68 83.85 70.98 79.40 81.76 49.27
19 M34 87.99 84.28 71.74 79.61 79.86 49.92
29 M35 88.21 85.57 70.93 78.60 64.58 54.90
39 M36 89.29 71.01 78.60 74.50 51.34
49 M37 87.44 84.27 71.97 79.84 78.11 50.55





Tab.11: Line 1 methylation data, section 5 
 
Run order Mouse No. Brain Bone marrow Testes
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
69 M39 87.61 84.19 73.00 80.67 81.06 49.88
79 M40 88.15 84.12 70.88 77.99 72.40 51.86
81 M41 85.00 87.01 68.81 75.72 62.74 54.69
82 M42 85.57 88.30 71.05 77.86 67.61 53.52
83 M43 84.10 86.32 67.14 75.43 81.51 48.06
84 M44 87.12 89.84 72.88 79.79 85.29 48.33
85 M45 84.86 87.16 76.73 83.62 81.12 50.76
86 M46 86.67 88.06 70.42 78.04 70.76 52.45
87 M47 86.74 88.64 72.03 80.37 67.68 54.28
88 M48 86.99 89.13 70.24 77.36 78.79 49.54
89 M49 86.25 88.63 74.52 81.71 82.06 49.89
90 M50 86.09 88.13 73.72 80.22 66.20 54.79
2 F1 88.32 84.22 73.45 81.43
12 F2 88.64 84.65 70.35 78.95
22 F3 87.23 84.54 73.54 81.27
32 F4 87.61 84.36 71.70 79.85
42 F5 80.93 80.79 70.99 79.36
52 F6 87.62 84.44 72.01 79.60
62 F7 88.21 84.55 72.78 80.52
72 F8 87.46 84.56 70.37 78.47
4 F9 86.99 84.28 68.32 77.24
14 F10 87.11 84.64 68.15 77.14
24 F11 87.95 84.77 72.85 80.92
34 F12 87.75 84.12 72.51 80.61
44 F13 88.09 84.43 73.87 80.99
54 F14 87.37 78.96 70.36 78.16
64 F15 87.67 84.17 74.17 81.69
74 F16 87.84 84.30 72.93 80.52
6 F17 88.59 84.33 86.25 91.09
16 F18 88.99 85.01 72.30 80.25
26 F19 88.20 84.71 70.20 78.13
36 F20 88.00 84.29 72.58 80.36
46 F21 88.79 84.53 72.08 80.25
56 F22 88.07 84.25 71.16 79.17
66 F23 88.04 84.63 69.21 78.46
76 F24 71.73 79.67
8 F25 88.25 84.91 73.18 80.48
18 F26 88.18 85.12 68.48 77.49
28 F27 88.32 84.61 70.87 78.54




Tab.11: Line 1 methylation data, section 6 
 
Run order Mouse No. Brain Bone marrow Testes
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
58 F30 88.85 85.43 70.71 78.45
68 F31 87.81 85.28 71.41 80.28
78 F32 88.01 84.84 71.03 79.27
10 F33 88.25 84.69 72.73 81.29
20 F34 88.12 84.57 73.54 81.18
30 F35 89.19 85.98 73.86 81.41
40 F36 59.86 71.62 79.29
50 F37 88.61 84.77 71.97 79.91
60 F38 87.77 85.17 71.25 80.04
70 F39 87.81 84.52 80.12 87.43
80 F40 87.49 84.81 73.15 81.33
91 F41 87.73 85.09 71.64 79.50
92 F42 87.23 85.21 71.50 78.54
93 F43 87.56 85.23 71.03 78.34
94 F44 86.99 84.29 74.00 80.53
95 F45 88.18 85.19 74.77 80.91
96 F46 86.69 84.85 73.15 80.19
97 F47 89.03 85.39 78.24 84.38
98 F48 88.22 85.27 72.62 79.64
99 F49 89.46 85.94 74.21 81.43
100 F50 88.09 85.55 74.93 80.52
88.22 85.42 72.49 78.83
Mean males
SD Males 87.54 85.21 71.56 79.31 72.84 51.21
Mean females 1.18 1.84 7.33
SD Females 87.20 84.49 72.57 80.26
Mean both 4.20 2.90




Control F 85.00 89.00 83.00 87.00 84.00 87.00




Tab.11: Line 1 methylation data, section 7 
 
Run orderMouse No.Tongue Muscles Heart
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
1 M1 85.96 89.14 83.99 87.03 81.84 86.11
11 M2 86.25 89.00 83.22 86.35 80.69 84.99
21 M3 85.31 88.28 83.47 85.81 81.44 85.33
31 M4 85.43 88.37 83.70 85.83 79.81 84.32
41 M5 85.59 88.82 83.54 86.67 85.24 87.45
51 M6 86.80 90.25 83.42 86.35 83.40 85.62
61 M7 85.10 87.58 83.64 85.98 83.06 85.06
71 M8 86.22 88.98 83.65 86.58 79.86 83.73
3 M9 83.89 86.52 76.28 82.04
13 M10 86.20 88.64 83.84 86.43 78.48 83.41
23 M11 84.62 87.92 83.99 86.68 78.99 83.87
33 M12 84.35 87.47 83.25 86.66 82.42 85.72
43 M13 83.96 87.11 83.60 85.77 80.17 83.78
53 M14 84.76 87.79 82.79 85.87 80.96 85.35
63 M15 84.94 87.88 83.70 86.49 80.52 84.58
73 M16 84.69 87.82 86.18 87.43 80.60 84.49
5 M17 83.62 86.99 84.27 86.64 81.63 85.68
15 M18 84.34 88.05 82.61 86.52 80.77 85.32
25 M19 83.54 87.07 82.70 85.44 77.91 82.78
35 M20 84.75 87.92 83.16 86.55 79.71 84.09
45 M21 83.78 87.83 84.47 86.83 82.02 86.08
55 M22 84.21 87.77 83.89 86.82 79.32 84.07
65 M23 84.47 88.02 83.70 85.98 81.16 84.91
75 M24 85.18 88.44 83.31 86.02 81.00 85.00
7 M25 84.50 87.80 83.66 86.79 80.07 85.34
17 M26 84.89 88.31 82.77 85.76 80.37 84.86
27 M27 84.17 86.85 78.49 83.33
37 M28 85.60 88.71 82.30 85.82 81.07 84.81
47 M29 84.34 87.38 82.71 85.63 80.40 84.49
57 M30 85.49 88.07 82.67 86.40 79.24 83.69
67 M31 85.50 88.29 83.02 85.78 81.43 85.29
77 M32 85.28 87.70 83.55 85.58 80.26 84.67
9 M33 85.16 83.98 80.11 84.49 84.01 87.77
19 M34 86.14 83.06 84.14 87.17 82.23 86.08
29 M35 85.38 83.44 83.04 85.51 80.12 84.55
39 M36 85.55 83.53 83.53 86.46 81.06 85.02
49 M37 85.12 83.45 83.60 86.17 80.40 84.69




Tab.11: Line 1 methylation data, section 8 
 
Run orderMouse No.Tongue Muscles Heart
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
69 M39 84.86 82.24 84.08 86.29 81.70 85.07
79 M40 85.11 83.49 83.82 86.15 80.33 84.39
81 M41 84.31 82.99 82.33 85.51 80.20 84.63
82 M42 84.68 83.85 83.47 86.19 80.52 84.91
83 M43 85.08 82.96 82.20 85.09 81.34 84.86
84 M44 85.46 83.61 82.88 86.03 81.28 84.41
85 M45 86.11 84.09 83.78 86.63 80.77 84.54
86 M46 85.81 83.38 84.39 86.42 81.07 84.81
87 M47 84.42 82.98 83.47 86.57 82.27 85.80
88 M48 85.70 83.49 83.26 86.29 80.55 85.03
89 M49 83.85 82.79 81.86 85.54 80.02 84.55
90 M50 86.67 83.35 83.16 85.55 81.36 85.74
2 F1 86.68 85.01 85.17 88.25 82.64 87.40
12 F2 86.54 83.84 83.62 86.91 82.43 86.55
22 F3 85.92 83.72 83.50 86.49 82.42 86.33
32 F4 85.68 83.84 84.15 86.98 83.20 86.89
42 F5 86.92 83.67 84.38 86.34 83.78 87.21
52 F6 86.09 83.80 83.95 86.38 83.28 86.42
62 F7 84.95 82.73 83.93 86.10 82.62 85.78
72 F8 86.31 84.03 82.66 85.80 83.14 86.56
4 F9 86.09 84.64 84.17 87.32 81.81 86.46
14 F10 86.75 84.26 82.58 86.19 81.01 85.52
24 F11 86.92 84.35 83.62 87.02 82.07 85.95
34 F12 87.27 84.52 81.81 85.61 81.69 85.52
44 F13 85.82 83.05 85.18 86.85 82.40 86.01
54 F14 86.36 83.44 84.45 86.47 82.58 86.29
64 F15 86.78 83.49 84.66 87.07 81.58 85.62
74 F16 87.01 84.28 83.26 86.58 82.67 86.52
6 F17 85.57 86.04 84.48 87.34
16 F18 87.33 84.08 83.77 86.51 81.66 85.38
26 F19 87.22 84.01 83.67 86.80 81.46 85.73
36 F20 87.25 83.90 83.96 86.78 81.41 85.65
46 F21 86.07 83.73 83.89 86.23 80.95 85.06
56 F22 86.30 83.60 83.85 86.37 80.56 84.23
66 F23 87.60 84.76 82.43 85.32 81.54 85.85
76 F24 86.80 83.95 84.74 86.48 81.70 85.18
8 F25 86.19 84.08 83.22 85.90 81.35 85.58
18 F26 87.11 84.21 83.31 86.62 80.79 84.80
28 F27 86.47 84.36 84.00 86.13 81.16 85.45




Tab.11: Line 1 methylation data, section 9 
 
Run orderMouse No.Tongue Muscles Heart
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
48 F29 86.61 83.09 83.67 85.72 81.37 85.06
58 F30 86.90 83.88 83.25 86.43 81.65 85.48
68 F31 86.62 84.08 83.03 85.26 81.44 85.38
78 F32 83.65 86.49 82.87 86.54
10 F33 86.40 85.49 85.19 87.00 81.00 84.56
20 F34 86.64 83.78 80.12 84.44
30 F35 86.20 84.17 84.41 87.24 82.39 85.93
40 F36 86.64 83.41 83.54 86.43 82.31 85.56
50 F37 86.34 83.79 83.03 86.51 82.50 86.00
60 F38 85.45 82.87 82.94 85.79 78.15 82.48
70 F39 86.61 83.90 82.46 85.76 81.85 85.31
80 F40 85.04 83.69 83.35 86.08 81.82 85.36
91 F41 84.18 83.72 83.52 86.87 80.75 84.97
92 F42 84.82 83.91 84.62 87.21 82.59 86.17
93 F43 85.69 83.10 83.17 86.14 80.48 84.63
94 F44 85.69 83.03 82.92 86.19 81.80 85.75
95 F45 86.29 83.24 82.68 86.02 82.03 85.79
96 F46 85.95 82.97 83.10 85.83 80.70 84.38
97 F47 85.55 83.20 83.04 85.19 82.26 85.52
98 F48 86.17 84.27 84.92 86.94 83.64 86.21
99 F49 85.48 84.27 84.36 86.76 80.49 84.33
100 F50 85.15 83.80 84.86 86.87 81.77
Mean males85.08 86.31 83.40 86.15 80.77 84.83
SD Males0.79 0.87 1.49
Mean females86.24 83.88 83.70 86.44 81.77 85.59
SD Females0.73 0.79 1.01
Mean both85.66 85.10 83.55 86.30 81.26 85.20
Total mean85.38 84.92 83.23




Tab.12: Long intronic transcript methylation data, section 1 
 
Run order Mouse No. Spleen Lungs Skin
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
1 M1 46.79 38.72 44.78 37.25 49.36 45.12
11 M2 47.32 39.23 46.95 40.72 43.76 43.50
21 M3 48.08 38.82 41.08 35.82 47.99 43.52
31 M4 46.85 39.35 46.59 39.77 42.13 37.55
41 M5 46.94 38.54 46.38 41.06 43.71 39.25
51 M6 43.25 38.62 46.92 42.23
61 M7 44.77 35.34 44.26 37.69 44.04 40.69
71 M8 49.06 40.20 46.54 39.69 34.32
3 M9 49.13 40.72 45.39 36.17 46.79 42.95
13 M10 49.62 41.49 44.53 29.17 44.57 39.23
23 M11 48.51 39.65 42.38 35.82 45.73 40.10
33 M12 49.09 40.42 45.45 39.45 46.69 41.38
43 M13 50.09 40.54 43.96 29.81 46.40 40.51
53 M14 47.04 38.67 44.12 48.33 43.49
63 M15 45.93 37.32 44.93 30.13 47.32 42.27
73 M16 46.75 38.89 45.42 29.69 45.48 40.87
5 M17 48.18 40.48 44.71 37.09 46.28 40.26
15 M18 48.74 40.74 44.36 37.18 48.74 39.72
25 M19 45.94 37.08 43.60 36.45 44.62 40.29
35 M20 48.44 40.61 43.95 29.35 42.22 36.80
45 M21 47.75 39.47 44.84 36.33
55 M22 47.92 39.12 44.52 37.36
65 M23 49.93 41.75 45.28 38.11 47.69 44.63
75 M24 48.87 40.75 44.31 37.98 47.14 42.97
7 M25 47.92 39.25 44.21 38.15 44.08 37.72
17 M26 48.60 39.81 43.03 35.85 42.81 37.67
27 M27 45.91 37.35 40.78 34.65 43.69 37.55
37 M28 48.83 39.79 43.82 38.05 50.91 46.77
47 M29 48.48 39.05 41.92 36.79 44.34 38.31
57 M30 48.00 39.25 43.51 38.37 44.28 39.65
67 M31 47.72 39.26 47.94 43.36
77 M32 48.52 39.50 47.17 47.26
9 M33 48.72 40.10 47.83 43.24
19 M34 46.35 36.93 45.44 41.79
29 M35 47.62 38.52 48.04 43.06
39 M36 48.47 39.13 50.37 44.91
49 M37 48.75 39.22 42.84 39.72





Tab.12: Long intronic transcript methylation data, section 2 
 
Run order Mouse No. Spleen Lungs Skin
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
69 M39 46.86 37.97 43.21 39.50
79 M40 45.78 37.69 44.77 40.43
81 M41 44.34 35.19 61.93 52.05 47.54 46.01
82 M42 44.33 35.67 52.73 43.91 40.37
83 M43 44.86 35.82 46.72 45.87 42.71
84 M44 47.66 39.02 56.35 53.31 47.65 43.25
85 M45 46.73 38.26 48.29 46.36 48.30 46.61
86 M46 48.11 38.03 50.61 47.16 45.43 42.57
87 M47 45.38 35.63 52.52 47.55 48.66 47.59
88 M48 46.79 37.07 54.12 49.08 44.29 41.84
89 M49 44.53 36.20 54.16 50.88 50.62
90 M50 43.27 35.79 58.50 50.56 48.00 45.40
2 F1 46.31 37.51 51.58 42.30 37.53
12 F2 45.86 37.91 42.83 35.61 44.11 40.67
22 F3 46.39 37.45 42.37 36.50 44.06 39.80
32 F4 44.99 38.09 43.27 36.42 43.11 38.71
42 F5 47.99 38.58 41.76 36.08 43.08 37.76
52 F6 47.16 38.37 42.55 36.84 45.63 40.56
62 F7 45.80 38.10 43.56 37.76 45.55 44.19
72 F8 45.84 37.65 42.84 39.75 45.86 44.05
4 F9 48.20 38.29 41.44 35.14 43.06 38.68
14 F10 38.63 33.83 46.44 41.84
24 F11 48.39 39.34 38.06 33.89 45.49 40.76
34 F12 48.64 39.08 42.32 35.36 44.55 39.28
44 F13 47.91 39.10 42.83 37.72
54 F14 47.00 41.35 46.38 43.90 39.67
64 F15 46.31 38.42 39.75 40.89 36.60
74 F16 45.72 35.51 39.11 34.05 42.22 38.31
6 F17 47.95 39.06 46.34 42.81 38.81
16 F18 45.31 36.51 42.28 36.75 42.46 29.59
26 F19 43.23 38.53 42.66 37.14
36 F20 47.80 38.76 43.53 37.60 44.30 38.52
46 F21 47.93 38.49 40.53 33.79 43.41 38.17
56 F22 45.67 37.25 44.05 37.31 43.79 40.60
66 F23 46.02 38.43 41.43 36.55 43.53 38.84
76 F24 46.65 38.68 41.10 36.21 46.56 42.06
8 F25 47.97 39.68 43.32 37.20 44.50 39.46
18 F26 44.07 34.81 42.01 35.68 45.02 40.00
28 F27 49.69 35.92 42.75 36.58 42.36 36.63
38 F28 43.03 35.46 43.85 36.93 44.63 31.95




Tab.12: Long intronic transcript methylation data, section 3 
 
 
Run order Mouse No. Spleen Lungs Skin
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
58.00 F30 43.37 36.93 42.27 36.36 44.03 31.77
68.00 F31 45.25 36.03 41.37 34.67 41.64 37.51
78.00 F32 45.32 36.33 41.95 35.46 42.69 37.83
10.00 F33 48.50 38.94 43.37 36.02 41.27 37.27
20.00 F34 48.12 38.17 44.10 36.66 42.18 38.26
30.00 F35 47.69 38.02 41.99 36.00 42.17 39.53
40.00 F36 47.20 37.25 41.59 35.34 45.28 39.96
50.00 F37 43.83 35.89 44.21 28.51 44.56 40.40
60.00 F38 48.63 40.10 41.37 36.20 43.09 38.68
70.00 F39 45.27 37.12 41.50 34.88 41.96 37.59
80.00 F40 46.22 37.70 43.24 35.88 41.08 38.57
91.00 F41 49.86 40.27 39.88 34.59 42.63 39.48
92.00 F42 46.64 37.84 42.97 36.58 44.17 40.86
93.00 F43 46.31 37.29 42.00 36.26 42.31 38.47
94.00 F44 47.42 37.99 43.42 36.03 41.08 37.22
95.00 F45 46.78 37.31 42.39 26.52 43.25 32.04
96.00 F46 47.69 37.48 41.10 33.64 41.36 37.44
97.00 F47 44.64 35.03 42.49 26.63 43.60 40.73
98.00 F48 46.30 37.78 41.26 25.07 42.02 37.67
99.00 F49 47.52 38.91 42.63 35.66 43.08 38.28
100.00 F50 44.25 37.40 42.23 36.44 41.69 37.20
Mean males 47.40 38.72 46.62 39.18 45.92 41.89
SD Males 1.59 4.80 2.81
Mean females 46.61 37.81 42.47 35.18 43.36 38.48
SD Females 1.58 2.08 1.44
Mean both 47.01 38.27 44.33 37.00 44.62 40.11
Total mean 42.64 40.67 42.37
Control M 48.00 40.00 49.00 43.00 49.00 48.00
Control F 40.00 50.00 43.00 36.00 41.00 36.00
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Tab.12: Long intronic transcript methylation data, section 4 
 
s
Run order Mouse No. Brain Bone marrow Testes
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
1 M1 45.24 38.00 44.93 44.15 11.31
11 M2 42.99 37.47 35.12 32.09
21 M3 44.55 39.99 38.16 12.17 16.94
31 M4 47.02 39.91 37.31 36.95 15.23
41 M5 46.33 39.88 39.36 39.25 17.57
51 M6 43.16 37.60 39.84 41.15 24.84 26.94
61 M7 47.20 39.72 38.41 41.32 58.15
71 M8 44.34 38.34 36.91 25.85
3 M9 43.61 39.47 35.34 37.81 12.23 18.63
13 M10 46.63 39.99 36.23 36.87 10.96
23 M11 44.05 39.08 60.45 33.17 16.25
33 M12 42.51 36.37 40.14 33.60 13.04
43 M13 39.49 32.90 42.46 34.75 21.86
53 M14 39.95 33.14 40.23 39.98 19.90
63 M15 46.57 40.32 36.64 40.90 22.32
73 M16 43.93 37.78 41.98 40.84 16.29
5 M17 39.25 34.85 41.35 31.80 20.38
15 M18 40.16 36.40 40.89 39.85 12.43
25 M19 42.57 36.18 31.72 33.48 12.38
35 M20 40.77 35.68 39.70 32.95 11.15
45 M21 44.73 37.40 39.79 33.35 15.11
55 M22 45.64 38.55 41.11 40.22 13.76
65 M23 39.42 34.76 39.24 38.70
75 M24 41.56 33.96
7 M25 42.49 37.21 40.91 40.30
17 M26 40.47 33.96 41.87 43.92
27 M27 47.96 43.23 39.46 38.75 41.26 32.15
37 M28 40.11 38.72 11.44
47 M29 44.33 37.96 35.04 37.47 11.97
57 M30 45.32 38.22 36.56 28.64 12.01
67 M31 44.30 36.60 40.12 39.22 13.67
77 M32 44.33 38.17 38.64 38.55 13.86
9 M33 45.46 39.11 41.89 40.10 18.78
19 M34 42.92 36.79 40.50 33.70 12.03
29 M35 46.70 39.92 35.35 34.94 15.94
39 M36 39.88 35.22 14.11
49 M37 45.45 37.79 38.67 32.42 12.70




Tab.12: Long intronic transcript methylation data, section 5 
 
Run order Mouse No. Brain Bone marrow Testes
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
69 M39 47.29 39.30 28.33 32.76 41.83 36.88
79 M40 47.13 40.20 39.67 43.01 18.21 20.30
81 M41 44.95 37.92 35.96 36.06 11.55
82 M42 43.66 38.36 41.61 42.51 18.62
83 M43 44.61 37.79 41.74 45.58 46.33 41.79
84 M44 41.95 44.13 50.47 43.09
85 M45 43.77 37.51 44.88 47.28 29.06 27.22
86 M46 46.48 41.60 39.29 39.33 14.41
87 M47 39.10 17.28
88 M48 46.91 41.97 38.82 14.39
89 M49 45.60 39.53 16.24 18.42
90 M50 47.52 41.79 14.78 16.35
2 F1 45.28 38.58 42.58 37.82
12 F2 46.91 42.21 41.00 36.09
22 F3 47.60 40.60 44.22 38.91
32 F4 44.36 38.31 42.50 35.76
42 F5 47.20 41.02 43.24 37.19
52 F6 45.47 41.10 43.19 38.51
62 F7 48.75 41.72 43.58 38.16
72 F8 44.76 39.17 42.64 37.58
4 F9 47.48 41.45 42.55 36.77
14 F10 45.97 45.38 43.00 37.07
24 F11 45.50 39.70 45.69 40.55
34 F12 46.29 39.74 43.77 39.50
44 F13 46.47 39.43 43.49 37.92
54 F14 41.93 39.42 44.96 39.51
64 F15 47.63 41.69 43.24 39.81
74 F16 45.14 38.89 41.96 37.21
6 F17 46.37 40.91 42.94 39.27
16 F18 49.94 48.92 45.11 39.51
26 F19 48.28 42.66 43.51 38.06
36 F20 45.50 39.38 42.99 38.85
46 F21 45.58 42.29 41.81 36.99
56 F22 47.24 41.77 41.82 38.36
66 F23 48.64 43.14 44.19 39.78
76 F24 41.29 37.08
8 F25 42.32 36.25 39.79 37.77
18 F26 47.28 39.90 39.84 35.80
28 F27 43.99 38.37 44.06 38.72




Tab.12: Long intronic transcript methylation data, section 6 
 
 
Run order Mouse No. Brain Bone marrow Testes
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
48 F29 47.62 40.44 41.89 38.70
58 F30 46.03 39.29 41.09
68 F31 44.89 39.51 41.67 38.44
78 F32 44.15 38.45 40.23
10 F33 44.88 37.96 37.54 40.92
20 F34 52.10 46.58 36.26 38.15
30 F35 38.12 38.43
40 F36 45.51 38.65 36.39 38.48
50 F37 40.78 33.98 41.13 39.18
60 F38 45.94 39.67
70 F39 44.42 39.50 39.57 40.96
80 F40 43.71 38.48 41.76 41.34
91 F41 47.78 39.80 40.35 41.76
92 F42 47.03 41.16 42.32 40.81
93 F43 41.80 35.83 41.87 43.92
94 F44 45.53 40.57 41.71 43.82
95 F45 45.94 39.25 40.31 41.84
96 F46 51.58 46.00 37.14 40.63
97 F47 47.02 41.73 42.42 46.00
98 F48 49.78 46.45
99 F49 48.40 46.18 39.74 42.47
100 F50 47.69 46.51 40.93 43.44
Mean males 44.31 38.19 39.61 37.88 19.83 27.57
SD Males 2.39 4.31 11.22
Mean females 46.26 40.81 41.70 39.27
SD Females 2.30 2.17
Mean both 45.31 39.53 40.67 38.60




Tab.12: Long intronic transcript methylation data, section 7 
 
Run order Mouse No. Tongue Muscles Heart
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
1 M1 74.67 68.09 38.26 39.39 42.54 41.53
11 M2 54.78 45.35 37.55 39.12
21 M3 68.05 53.23 42.48 31.68 40.40 41.22
31 M4 58.33 46.77 41.41 38.66 39.30 39.33
41 M5 63.61 53.09 42.17 38.21
51 M6 61.71 51.99 41.70 38.08 39.24 39.38
61 M7 59.98 51.44 39.93 38.83 38.67 38.85
71 M8 66.13 53.97 41.31 38.47 35.71 38.69
3 M9 35.91 30.21 37.25 38.00
13 M10 67.04 57.51 38.67 36.72 31.46 33.74
23 M11 60.78 51.82 43.59 42.03 34.17 36.49
33 M12 58.73 48.03 40.96 38.85 33.52 34.83
43 M13 50.41 42.62 40.69 35.30 37.92
53 M14 54.35 41.46 42.68 39.26 34.29 37.87
63 M15 53.38 43.18 41.81 39.01 32.97 36.35
73 M16 49.87 42.33 45.96 27.17 30.62 34.15
5 M17 34.61 22.21 40.76 40.42
15 M18 58.49 46.09 32.43 24.70 35.47 36.74
25 M19 54.37 42.65 41.54 35.87 37.51 37.83
35 M20 54.60 43.41 41.51 39.18 39.89 40.10
45 M21 57.66 47.36 38.86 32.22 38.56 39.43
55 M22 63.60 45.98 39.49 37.12 33.87 42.30
65 M23 62.40 52.87 41.31 34.62 28.80 34.23
75 M24 55.76 41.80 41.88 33.54 28.86 31.80
7 M25 57.29 45.80 32.03 22.87 30.12 31.51
17 M26 53.01 42.06 42.65 40.69 32.28 34.53
27 M27 52.80 41.04 44.96 35.62 37.29
37 M28 63.66 46.56 41.55 33.57 31.29 35.33
47 M29 56.79 48.10 38.34 37.58 23.75 28.47
57 M30 40.26 40.09 25.79 28.74
67 M31 53.34 42.15 43.15 42.10 22.85 25.63
77 M32 52.85 41.40 43.82 33.39 26.99 29.77
9 M33 56.99 45.73 39.06 33.84 30.71 30.25
19 M34 56.81 55.72 45.32 39.14 27.99 28.00
29 M35 67.53 56.52 48.65 34.80 21.87 26.46
39 M36 46.86 39.92 43.45 37.55 27.13 31.17
49 M37 56.04 46.85 43.74 35.86 27.11 29.20




Tab.12: Long intronic transcript methylation data, section 8 
 
Run order Mouse No. Tongue Muscles Heart
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
69 M39 50.28 44.64 36.77 23.31 27.10
79 M40 49.66 40.29 45.92 35.40 31.05 40.29
81 M41 53.64 42.86 36.12 32.08 36.44 32.38
82 M42 52.65 54.77 37.25 16.21 48.86 46.75
83 M43 47.92 46.14 36.62 29.92 38.73 32.03
84 M44 55.87 46.33 43.54 45.31 34.18 31.85
85 M45 50.83 41.91 34.23 32.58 35.38 32.05
86 M46 51.62 42.37 36.83 36.08 37.54 32.88
87 M47 55.95 39.71 32.22 24.35 32.60 31.06
88 M48 56.40 49.15 34.57 29.33 36.94 33.14
89 M49 49.28 40.97 36.97 30.44 35.24 31.92
90 M50 55.47 44.94 47.60 43.90
2 F1 48.42 40.26 35.87 27.10 34.37 37.18
12 F2 45.01 38.13 39.17 29.83 35.44 37.80
22 F3 52.35 43.36 68.30 39.67 34.14 37.89
32 F4 53.55 42.45 46.41 35.93 37.27 38.08
42 F5 43.68 35.16 50.02 38.59 27.27 32.02
52 F6 46.74 37.09 44.79 37.86 31.17 37.84
62 F7 43.94 35.10 42.88 36.94 27.56 31.68
72 F8 48.24 38.42 43.14 39.56 40.78 41.79
4 F9 44.14 35.70 36.35 26.20 35.81 36.55
14 F10 45.33 36.97 39.99 34.13 28.79 29.84
24 F11 48.05 38.66 50.82 42.52 28.41 29.85
34 F12 47.10 38.22 44.26 39.02 28.76 31.96
44 F13 46.42 37.98 45.79 43.73
54 F14 45.32 38.61 48.81 48.71 34.10 35.11
64 F15 50.60 40.67 42.85 34.03 27.49 31.40
74 F16 48.45 40.32 44.03 40.64
6 F17 44.86 37.02 40.86 32.81 33.33 36.49
16 F18 46.86 38.86 43.92 39.00 31.80 32.82
26 F19 42.91 34.27 30.56 34.34
36 F20 41.85 33.21 44.09 41.40 30.07 33.63
46 F21 49.28 41.70 42.84 38.71 27.86 32.71
56 F22 44.74 36.11 43.37 41.43 25.49 29.40
66 F23 44.40 39.42 41.78 38.83 30.26 33.66
76 F24 51.25 40.87 41.58 39.82 27.65 30.67
8 F25 48.53 36.56 36.60 27.85 29.70 30.82
18 F26 42.24 34.95 44.91 36.45 30.85 33.65
28 F27 44.87 35.96 42.22 33.81 34.05 36.55




Tab.12: Long intronic transcript methylation data, section 9 
 
 
Run order Mouse No. Tongue Muscles Heart
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
48 F29 48.20 39.17 42.92 39.34 26.52 31.81
58 F30 49.01 39.95 41.68 38.79 27.64 33.73
68 F31 47.36 35.20 41.87 33.99 31.00 34.47
78 F32 44.95 37.49 30.57 34.38
10 F33 49.87 39.50 37.49 34.25 36.07 37.46
20 F34 44.64 37.26 37.65 37.20 39.71
30 F35 51.02 39.46 42.00 36.26 37.85 38.06
40 F36 49.51 39.34 40.45 33.78 32.26 34.94
50 F37 48.88 40.89 39.70 32.97 38.77 38.87
60 F38 49.48 39.52 39.62 34.02 35.70 36.41
70 F39 44.79 35.06 41.75 34.52 37.17 37.35
80 F40 47.97 38.81 38.73 30.51 35.82 38.35
91 F41 46.17 39.23 34.65 29.79 39.58 33.23
92 F42 45.32 37.32 32.43 30.48 37.48 31.83
93 F43 45.09 39.74 33.04 31.57 45.02 41.90
94 F44 52.07 44.89 35.73 32.39 38.46 33.67
95 F45 47.00 36.01 31.68 37.24 41.71 36.67
96 F46 55.47 48.89 32.51 28.21 53.04 31.44
97 F47 48.64 44.28 41.08 40.71 37.09 32.20
98 F48 49.01 43.25 38.81 34.03 40.21 37.04
99 F49 43.67 33.94 37.80 36.89 40.98 38.19
100 F50 45.19 38.04 40.38 41.14 43.52 38.43
Mean males 56.56 46.91 40.30 35.03 33.78 34.94
SD Males 6.38 3.84 5.94
Mean females 47.26 38.70 41.65 36.24 34.10 34.93
SD Females 3.00 5.95 5.66




Tab.13: Myosin methylation data, section 1 
 
Run order Mouse No. Spleen Lungs Skin
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
1 M1 76.37 81.14 45.38 46.87 63.81 73.15
11 M2 67.57 75.67 52.28 52.29 66.68 71.34
21 M3 79.48 82.99 46.69 47.98 63.93 70.32
31 M4 68.29 75.67 48.63 49.84 67.43 71.24
41 M5 80.17 83.84 54.07 55.89 69.08 76.41
51 M6 76.71 80.72 47.30 50.05 66.56 74.43
61 M7 71.81 78.36 45.07 50.56 63.62 69.99
71 M8 74.12 78.86 43.31 50.03 61.81 76.69
3 M9 66.22 74.62 50.38 49.97 67.0931 72.8725
13 M10 78.36 83.00 51.05 51.84 68.4433 73.0447
23 M11 65.80 74.80 45.82 47.10 66.6024 70.3282
33 M12 72.08 79.14 45.95 49.19 66.608 75.1965
43 M13 64.07 74.21 48.61 50.27 68.4934 72.6328
53 M14 70.19 78.02 38.24 50.59 65.0446 72.5621
63 M15 65.06 74.04 46.15 51.19 65.8693 70.4517
73 M16 65.93 73.21 43.0898 47.3127 65.6894 69.3178
5 M17 76.09 78.79 45.8513 49.2692 66.2675 69.764
15 M18 73.23 78.79 47.851 49.2005 67.8219 72.3358
25 M19 71.15 78.94 47.4478 48.6116 64.8098 76.19
35 M20 74.93 81.38 45.7841 45.3064 64.8956 67.5365
45 M21 82.37 88.18 54.7857 55.312
55 M22 68.63 78.15 47.6208 55.9553
65 M23 79.59 83.47 43.5617 49.2242 66.2417 73.2391
75 M24 72.82 80.07 45.375 50.463 66.6413 72.4294
7 M25 71.40 78.80 46.2872 47.5565 65.0572 71.1539
17 M26 76.73 82.35 49.343 49.3387 67.7911 68.6024
27 M27 73.52 80.39 45.9456 47.6137 67.339 70.8856
37 M28 71.05 79.47 48.2314 52.2911 62.1071 73.2077
47 M29 72.15 80.21 45.27 47.5516 65.7693 70.2266
57 M30 71.60 80.16 47.9704 53.608 65.9795 68.8202
67 M31 81.69 84.72 67.7996 73.7524
77 M32 74.92 79.69 67.4043 65.902
9 M33 74.29 80.61 65.264 71.5685
19 M34 80.08 85.30 64.9362 68.2333
29 M35 71.77 79.34 69.7918 71.8457
39 M36 77.10 83.74 68.744 75.7735
49 M37 72.56 82.12 66.1598 69.4645




Tab.13: Myosin methylation data, section 2 
 
Run order Mouse No. Spleen Lungs Skin
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
69 M39 77.10 82.58 67.04 71.29
79 M40 79.09 82.94 69.80 74.16
81 M41 73.58 79.72 66.95 72.31
82 M42 76.87 82.79 44.40 51.58 66.37 71.22
83 M43 74.49 80.65 45.19 54.61 67.06 71.55
84 M44 71.00 76.81 47.49 69.08 65.26 70.08
85 M45 77.52 82.57 41.12 55.08 66.64 70.87
86 M46 73.91 80.88 51.05 54.25 64.94 73.78
87 M47 79.03 82.50 51.32 58.26 69.19 76.29
88 M48 81.20 84.90 47.80 57.71 62.67 74.83
89 M49 75.42 80.35 45.55 55.93 61.57 76.40
90 M50 74.60 79.77 43.04 52.54 69.96 75.13
2 F1 81.06 87.58 64.27 73.22
12 F2 63.45 76.55 47.98 47.89 64.40 71.08
22 F3 81.24 82.36 44.69 49.20 68.20 76.61
32 F4 69.54 77.66 42.89 55.08 68.32 72.70
42 F5 77.41 83.16 46.93 52.09 69.35 72.57
52 F6 79.88 83.41 41.56 48.56 63.75 69.83
62 F7 71.76 82.40 47.31 54.00 64.96 72.76
72 F8 66.95 76.17 39.51 48.98 64.09 74.87
4 F9 66.51 77.44 45.62 50.22 68.45 67.15
14 F10 65.51 80.30 46.80 51.52 66.22 67.02
24 F11 74.84 78.82 43.06 45.43 66.01 66.10
34 F12 74.02 81.03 47.84 50.82 65.12 66.18
44 F13 74.22 81.62 62.67 63.55
54 F14 46.95 60.52 62.83 62.93
64 F15 82.61 86.67 37.40 58.18 65.55 70.05
74 F16 58.15 73.66 41.14 50.72 63.95 70.93
6 F17 68.55 76.36 50.07 56.75 69.38 74.12
16 F18 77.68 82.52 45.10 49.41 71.73 74.83
26 F19 46.07 49.47 73.24 75.64
36 F20 74.09 87.25 45.05 45.46 67.31 71.26
46 F21 74.56 81.86 43.71 46.96 68.44 69.63
56 F22 69.51 80.59 46.14022 51.7838 69.75 69.78
66 F23 58.79 72.07 45.78097 53.6503 68.59 72.94
76 F24 70.43 82.16 43.04 49.44 66.68 72.12
8 F25 67.41 77.91 48.73 49.86 66.89 71.73
18 F26 63.71 77.09 44.47 47.25 67.62 72.78
28 F27 75.38 84.29 45.25 48.53 65.50 73.54




Tab.13: Myosin methylation data, section 3 
 
 
Run orderMouse No. Spleen Lungs Skin
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
48 F29 60.59 72.26 51.90 57.85 68.32 71.24
58 F30 76.78 85.12 46.48 53.92 67.56 72.21
68 F31 64.86 73.80 40.61 46.16 67.63 74.00
78 F32 63.17 73.67 40.46 47.74 65.46 71.90
10 F33 50.28 53.19 66.77 69.17
20 F34 75.16 84.95 49.51 50.61 63.69 69.62
30 F35 77.61 82.54 47.18 48.55 67.31 71.83
40 F36 66.48 75.81 47.10 49.72 67.10 69.81
50 F37 43.37 45.44 65.08 68.54
60 F38 76.69 80.81 50.19 58.35 67.84 69.17
70 F39 81.27 83.82 41.15 47.12 63.40 69.43
80 F40 67.62 76.01 66.45 71.87
91 F41 75.37 79.66 43.83 49.40 68.37 72.13
92 F42 72.37 78.84 67.14 69.55
93 F43 81.02 82.25 45.52 52.43 65.92 72.30
94 F44 80.41 82.87 42.24 51.30 66.79 72.52
95 F45 62.40 67.10 45.59 51.14 66.51 70.54
96 F46 75.63 82.41 44.87 51.77 68.05 73.77
97 F47 75.98 84.93 39.72 48.27 66.84 70.34
98 F48 71.72 78.77 40.15 49.13 68.48 72.24
99 F49 78.50 82.67 38.98 46.83 67.30 70.88
100 F50 63.28 71.29 45.07 53.97 67.49 68.75
Mean males 73.89 80.23 46.93 51.57 66.26 72.05
SD Males 4.55 3.31 2.01
Mean females71.80 79.81 44.84 50.73 66.83 71.01
SD Females 6.65 3.31 2.14
Mean both 72.89 80.03 45.80 51.11 66.55 71.52
Total mean 76.46 48.46 69.04
Control M 48.00 50.00 52.00 53.00




Tab.13: Myosin methylation data, section 4 
 
Run order Mouse No. Brain Bone marrow Testes
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
1 M1 73.02 80.77 70.95 79.29 74.54 75.97
11 M2 69.27 78.47 69.19 70.50
21 M3 65.98 74.12 70.64 81.34 68.25 73.28
31 M4 72.61 82.30 66.06 78.37 71.41 74.19
41 M5 74.13 82.50 69.56 73.79 68.90 71.54
51 M6 73.21 81.27 66.18 75.88 69.97 72.12
61 M7 67.87 81.33 69.27 77.17 65.23 72.03
71 M8 66.82 78.23 66.55 73.96 71.71 73.26
3 M9 69.77 80.40 63.41 77.40 69.48 73.10
13 M10 72.98 84.01 67.09 75.90 70.37 74.62
23 M11 68.32 77.91 64.84 74.18 70.87 73.43
33 M12 73.17 81.61 67.13 75.95 68.37 73.89
43 M13 66.12 77.64 64.89 73.39 70.08 74.36
53 M14 64.31 79.54 65.03 74.07 69.99 71.51
63 M15 69.40 79.25 60.24 72.74 68.08 71.91
73 M16 71.27 79.43 62.15 72.76 67.87 67.69
5 M17 72.90 82.06 66.64 75.59 68.60 71.93
15 M18 63.13 77.79 65.94 76.26 68.99 71.39
25 M19 72.00 81.87 69.15 81.34 77.80 77.93
35 M20 70.48 81.08 70.06 73.68
45 M21 72.11 80.33 66.23 74.68 71.06 72.52
55 M22 70.75 79.51 70.80 80.26 65.47 68.50
65 M23 71.02 78.38 67.57 76.09
75 M24 69.08 81.00
7 M25 69.52 79.70 64.53 75.24
17 M26 65.49 77.99 65.20 78.80
27 M27 66.69 75.61 72.97 75.62
37 M28 64.21 75.65 73.24 75.38
47 M29 72.68 81.26 66.75 77.17 72.77 75.52
57 M30 71.02 79.38 64.42 71.34 71.44 71.79
67 M31 73.29 80.28 65.50 76.46 70.92 72.92
77 M32 73.94 81.77 65.64 75.75 72.57 71.86
9 M33 72.04 81.96 65.66 76.25 76.15 80.49
19 M34 69.97 81.92 66.4547 76.8067 76.77 78.77
29 M35 73.95 81.48 63.8455 75.9144 78.61 77.59
39 M36 63.63 74.85 75.77 77.36
49 M37 70.49 81.74 66.58 75.48 76.68 76.76




Tab.13: Myosin methylation data, section 5 
 
Run order Mouse No. Brain Bone marrow Testes
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
69 M39 71.16 81.32 64.33 74.75 73.68 75.96
79 M40 71.93 81.59 68.58 79.21 63.69 68.70
81 M41 71.35 82.07 66.67 75.57 77.20 79.12
82 M42 70.92 82.53 65.97 75.29 72.86 75.13
83 M43 72.65 81.85 64.52 76.28 74.88 76.78
84 M44 65.33 76.98 76.53 79.06
85 M45 71.48 82.10 67.09 79.02 72.70 73.93
86 M46 65.66 76.00 72.90 76.47
87 M47 69.74 79.87 67.14 79.97 73.34 73.71
88 M48 64.58 74.78 72.02 75.54
89 M49 65.28 79.30 68.18 80.25 77.07 79.17
90 M50 64.68 72.08 68.32 78.72 73.28 76.51
2 F1 62.13 76.77 67.87 78.24
12 F2 68.90 80.15 63.86 73.69
22 F3 68.58 80.82 67.22 78.44
32 F4 60.86 74.10 65.99 75.52
42 F5 66.83 74.89 62.42 74.92
52 F6 68.94 82.03 65.82 76.05
62 F7 70.78 81.83 65.95 73.18
72 F8 66.59 79.06 63.91 75.27
4 F9 70.06 81.76 62.20 73.25
14 F10 69.67 78.77 61.10 73.51
24 F11 72.15 81.97 66.18 76.96
34 F12 73.38 82.80 65.26 76.81
44 F13 66.83 75.01 68.63 78.86
54 F14 68.89 79.13 64.42 73.78
64 F15 68.98 76.77 68.96 77.41
74 F16 70.71 80.94 66.74 78.86
6 F17 65.07 78.49 65.11 76.07
16 F18 67.99 77.41 66.76 76.93
26 F19 65.39 80.51 64.67 74.48
36 F20 72.71 81.30 67.25 77.25
46 F21 64.01 66.62 77.92
56 F22 67.87 79.39 65.18316 75.06875
66 F23 70.02 79.38 60.97543 74.27797
76 F24 63.82 75.92
8 F25 68.00 79.77 68.57 78.72
18 F26 72.06 82.61 62.39 73.37
28 F27 65.11 79.50 62.04 75.81




Tab.13: Myosin methylation data, section 6 
 
 
Run order Mouse No. Brain Bone marrow Testes
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
48 F29 68.45 79.91 66.02 74.20
58 F30 71.74 82.68 65.10 74.41
68 F31 69.65 80.00 64.72 75.16
78 F32 69.75 79.63 69.42 78.20
10 F33 73.38 81.52 63.95 78.50
20 F34 66.50 77.97 66.34 80.91
30 F35 65.76 73.79
40 F36 71.95 82.80 65.80 75.97
50 F37 62.72 75.29 68.16 77.90
60 F38 70.78 81.35 65.68 70.36
70 F39 62.62 71.77 66.81 76.82
80 F40 71.86 80.44 64.88 77.52
91 F41 69.57 80.04 65.95 78.47
92 F42 72.57 82.27 65.84 76.12
93 F43 69.95 82.10 67.04 75.24
94 F44 69.98 82.38 70.51 81.56
95 F45 71.98 81.08 68.85 77.26
96 F46 68.97 80.98 69.09 80.62
97 F47 73.10 82.36 66.32 77.88
98 F48 62.50 67.94 78.68
99 F49 62.94 77.26 67.50 77.55
100 F50 68.14 80.65 47.51 50.96
Mean males 70.31 80.28 66.23 76.42 71.91 74.35
SD Males 2.89 2.18 3.46
Mean females 68.55 79.73 65.49 75.92
SD Females 3.32 3.37
Mean both 69.39 80.00 65.85 76.16
Total mean 74.69 71.01 73.13
Control M 47.00 49.00 46.00 47.00




Tab.13: Myosin methylation data, section 7 
 
Run order Mouse No. Tongue Muscles Heart
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
1 M1 64.18 72.80 65.99 76.46 58.55 63.72
11 M2 65.02 74.44 64.04 76.16 55.03 60.07
21 M3 66.44 76.48 63.70 74.48 55.92 67.26
31 M4 64.03 78.92 66.50 74.64 53.62 60.37
41 M5 65.55 78.80 64.89 76.47 73.53 76.99
51 M6 62.42 76.22 66.13 76.70 66.94 71.79
61 M7 69.22 79.76 68.08 79.54 68.65 72.82
71 M8 62.73 75.57 63.94 75.68 46.85 54.42
3 M9 63.67 73.48 53.44 56.91
13 M10 65.69 77.87 68.78 79.16 54.64 62.62
23 M11 59.44 76.44 66.82 78.16 51.50 61.22
33 M12 60.30 72.42 68.85 77.80 57.46 62.73
43 M13 61.73 78.52 66.54 74.38 48.34 55.10
53 M14 64.19 77.60 65.83 76.18 54.92 64.27
63 M15 72.62 75.61 63.64 75.69 50.73 56.92
73 M16 65.05 74.74 64.06 75.46 48.14 53.68
5 M17 61.77 61.20 75.08 53.75 58.60
15 M18 69.00 76.27 64.53 53.67 58.34
25 M19 63.20 62.01 69.42 51.58 57.52
35 M20 66.15 77.27 64.54 74.80 49.58 60.08
45 M21 61.76 73.50 50.50 54.42
55 M22 63.99 76.13 52.31 63.51
65 M23 58.88 64.11 70.79 49.89 58.05
75 M24 66.49 73.52 64.50 64.86 46.25 53.64
7 M25 59.55 48.71 54.62
17 M26 67.82 76.87 65.24 75.37 46.79 51.81
27 M27 63.94 80.01 46.59 56.72
37 M28 65.99 72.37 64.92 73.87 47.93 54.60
47 M29 63.20 77.88 61.04 75.74 44.63 51.25
57 M30 62.05 41.80 46.45
67 M31 65.09 76.80 66.01 76.64 46.46 53.59
77 M32 66.49 76.90 50.21 55.69
9 M33 67.92 74.10 58.09 64.01
19 M34 70.07 72.44 63.6855 76.4901 49.32 53.10
29 M35 68.23 70.7687 46.36 52.06
39 M36 72.49 73.91 64.66 69.01 36.47 50.14
49 M37 68.69 73.08 62.58 43.01 48.00




Tab.13: Myosin methylation data, section 8 
 
Run order Mouse No. Tongue Muscles Heart
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
69 M39 66.91 67.91 65.13 77.09 46.69 52.83
79 M40 67.97 71.94 67.05 51.77 60.08
81 M41 68.34 73.50 53.26 61.96
82 M42 70.30 73.70 50.03 66.06
83 M43 72.52 75.68 64.68 77.28 50.91 59.38
84 M44 72.26 69.64 69.91 70.58 51.40 58.38
85 M45 70.75 70.42 64.60 77.33 49.95 59.05
86 M46 69.08 74.57 70.66 78.30 50.54 58.59
87 M47 71.71 74.05 65.93 75.92 51.23 59.79
88 M48 63.86 64.14 62.75 47.05 56.41
89 M49 65.73 70.12 64.14 75.13 50.94 58.32
90 M50 69.15 73.55 63.25 75.04 47.89 56.91
2 F1 64.21 70.21 66.13 76.36 51.42 56.12
12 F2 65.21 67.37 63.34 75.97 51.20 60.72
22 F3 66.57 71.23 44.35 54.63
32 F4 68.33 70.80 70.06 79.14 53.72 60.11
42 F5 68.15 71.03 63.89 73.62 47.51 60.81
52 F6 67.36 68.12 63.21 74.70 45.68 57.32
62 F7 68.23 72.84 65.13 76.18 51.17 60.59
72 F8 66.50 69.48 65.92 76.48 44.96 61.48
4 F9 67.60 69.65 70.32 77.04 52.52 56.56
14 F10 68.84 71.73 67.44 77.99 50.05 55.13
24 F11 64.57 68.51 65.32 75.02 49.34 60.09
34 F12 64.43 68.45 76.25 79.15 49.85 51.76
44 F13 68.32 69.61 69.25 70.83 53.55 57.54
54 F14 69.56 69.80 65.19 78.19 49.52 56.32
64 F15 67.67 69.64 66.54 78.59 48.35 57.26
74 F16 68.78 73.04 64.78 73.50 58.27 61.51
6 F17 68.12 70.74
16 F18 70.00 72.20
26 F19 70.06 66.89
36 F20 70.73 71.43
46 F21 65.49 75.34
56 F22 70.86 71.68
66 F23 70.91 73.67 64.27932 74.7049
76 F24 70.50 76.63 64.60 73.01
8 F25 65.15 67.95 67.59 76.79 48.58 54.49
18 F26 71.51 68.46 62.31 46.72 53.49
28 F27 69.22 69.38 66.80 80.40 49.44 59.79




Tab.13: Myosin methylation data, section 9 
 
 
Run order Mouse No. Tongue Muscles Heart
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
48 F29 70.08 71.07 66.48 72.89 46.18 56.52
58 F30 68.33 72.02 63.20 73.22 48.71 55.41
68 F31 66.13 67.25 63.71 69.39 49.57 56.10
78 F32 69.97 72.46 49.98 57.15
10 F33 47.11 52.41
20 F34 50.56 57.87
30 F35 49.30 54.52
40 F36 46.02 56.69
50 F37 50.52 57.91
60 F38 52.17 58.87
70 F39 49.29 53.15
80 F40 47.66 52.61
91 F41 63.84 67.26 64.16 68.75 48.28 53.50
92 F42 66.37 69.69 49.35 52.59
93 F43 68.62 71.73 65.60 67.24 50.01 54.34
94 F44 67.17 68.20 49.65 57.03
95 F45 69.06 71.95 62.49 75.62 47.96 53.29
96 F46 70.88 71.32 63.13 74.29 47.25 50.51
97 F47 72.12 71.50 66.59 76.51 45.99 50.95
98 F48 67.01 71.36 66.96 77.94 44.49 48.52
99 F49 63.13 72.31 68.11 78.14 48.02 51.84
100 F50 67.43 70.18 69.06 76.39 50.16 56.42
Mean males 66.32 74.85 65.19 74.84 51.17 58.27
SD Males 3.77 2.27 6.34
Mean females 67.95 70.74 65.97 75.20 49.15 55.94
SD Females 2.25 2.88 2.67
Mean both 67.09 72.77 65.53 75.00 50.25 57.21
Total mean 69.93 70.26 53.73
Control M 50.00 49.00 67.00 78.00 48.00 49.00




Tab.14: Paternally expressed gene 3 methylation data, section 1 
 
Run order Mouse No. Spleen Lungs Skin
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
1 M1 44.20 49.08 37.79 45.72 44.76 51.38
11 M2 43.45 48.55 39.49 51.33 44.64
21 M3 49.04 53.78 38.49 49.63 42.15 50.73
31 M4 42.62 48.98 39.85 46.92 38.95 48.17
41 M5 42.84 49.59 40.61 51.11 42.13 52.01
51 M6 42.69 49.13 40.05 50.78 46.37 53.57
61 M7 43.88 49.32 38.80 53.70 40.76 51.32
71 M8 43.15 50.03 38.49 48.06 46.28
3 M9 42.44 48.05 41.43 55.12 44.60 53.23
13 M10 44.27 49.54 37.30 51.68 42.85 48.74
23 M11 42.83 48.27 39.11 51.35 41.89 49.33
33 M12 44.16 50.15 37.50 47.10 41.88 46.71
43 M13 42.23 48.19 38.35 49.65 46.01 53.47
53 M14 42.55 47.88 41.23 81.77 47.53 54.46
63 M15 42.49 48.74 39.91 51.08 43.05 51.33
73 M16 43.92 48.85 39.66 51.57 42.47 50.85
5 M17 40.82 44.62 38.30 42.22 42.97 50.39
15 M18 43.08 49.29 37.73 48.44 44.36 52.20
25 M19 42.60 47.76 37.17 46.88 44.29 52.35
35 M20 42.80 48.19 37.73 48.65 44.36 51.27
45 M21 43.51 49.63 80.71 50.62
55 M22 44.97 50.93 37.70
65 M23 43.40 49.43 38.53 45.48 55.58
75 M24 42.40 48.32 41.27 44.81 53.58
7 M25 42.56 47.25 37.42 40.71 47.89
17 M26 43.39 48.63 37.41 42.66 50.35
27 M27 43.07 48.70 37.60 43.56 50.91
37 M28 41.93 47.40 38.95 53.94 44.19 53.56
47 M29 43.05 48.52 38.21 53.84 42.43 51.24
57 M30 43.49 49.23 37.82 41.28 49.75
67 M31 43.98 50.71 70.12 46.73 57.50
77 M32 42.55 49.05 74.56 44.58 56.52
9 M33 43.54 49.35 43.54 46.64
19 M34 44.06 48.85 45.91 54.64
29 M35 44.34 49.84 68.65 44.34 51.91
39 M36 42.34 48.53 46.30 57.34
49 M37 41.50 48.76 70.48 40.26 49.94




Tab.14: Paternally expressed gene 3 methylation data, section 2 
 
Run order Mouse No. Spleen Lungs Skin
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
69 M39 43.34 49.06 55.93 42.42 51.58
79 M40 42.45 48.80 44.27 54.54
81 M41 42.92 46.23 52.40 49.00 55.77
82 M42 41.40 48.09 38.61 45.86 50.96
83 M43 41.81 46.02 46.25 46.27 51.98
84 M44 40.45 47.03 51.21 56.92
85 M45 41.35 47.55 46.16 54.10
86 M46 42.53 47.73 46.77 48.64 57.37
87 M47 40.95 47.36 46.57 48.08 57.01
88 M48 41.95 48.26 44.21 50.52 58.97
89 M49 40.96 46.56 47.17 47.62 59.38
90 M50 41.56 47.97 52.79 45.76 53.83
2 F1 46.75 53.98 38.24 45.68 40.73 47.47
12 F2 46.82 50.42 38.21 43.73 44.13 51.15
22 F3 48.94 55.65 39.37 49.53 41.87 51.40
32 F4 45.75 50.64 36.04 45.79 43.14 51.17
42 F5 46.74 52.26 36.21 47.70 40.96 51.69
52 F6 48.06 54.08 37.04 52.31 45.56 55.93
62 F7 47.01 36.61 52.46 44.25 55.41
72 F8 45.16 50.66 35.82 53.15 41.45 52.40
4 F9 47.33 52.96 37.63 53.60 41.71 47.18
14 F10 48.08 53.52 39.76 69.66 45.93 51.21
24 F11 46.04 51.59 41.06 48.76 41.51 49.79
34 F12 45.27 51.51 38.30 48.62 45.72 53.10
44 F13 43.71 50.23 37.97 73.44 45.09 50.79
54 F14 54.93 39.16 44.23 45.23 53.49
64 F15 43.21 50.23 39.15 52.66 43.58 51.39
74 F16 41.77 39.20 48.06 42.90 50.34
6 F17 42.16 46.96 45.03 79.68 44.41 52.04
16 F18 43.23 48.24 40.46 47.14 43.10 51.12
26 F19 36.91 45.71 42.76 50.18
36 F20 42.85 40.75 50.09 42.39 49.32
46 F21 44.70 49.71 38.47 50.83 42.72 46.92
56 F22 42.31 40.50 49.81 42.35 49.28
66 F23 41.62 46.23 42.22 54.01 44.64 50.78
76 F24 40.73 38.90 47.94 44.83 52.76
8 F25 43.04 47.35 39.52 46.85 44.00 50.56
18 F26 38.71 45.55 36.92 45.34 42.80 51.07
28 F27 41.8701 50.19005 40.19207 48.67804 42.10312 49.3933




Tab.14: Paternally expressed gene 3 methylation data, section 3 
 
Run order Mouse No. Spleen Lungs Skin
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
48 F29 41.53 37.57 50.58 43.03 50.86
58 F30 43.19 49.87 39.25 50.22 43.37 51.61
68 F31 41.12 47.57 37.54 48.59 41.11 49.82
78 F32 41.04 47.94 40.64 42.23 50.04
10 F33 34.69 37.12 41.06 53.12
20 F34 40.87 38.02 45.80 41.88 50.89
30 F35 42.41 48.28 38.50 48.17 43.30 51.89
40 F36 42.67 47.77 37.13 43.76 42.35 48.71
50 F37 41.38 36.98 45.31 41.34 48.09
60 F38 43.44 50.07 37.09 52.18 41.15 49.27
70 F39 43.09 50.31 36.34 52.14 41.54 49.90
80 F40 41.64 47.84 36.08 42.31 41.49 49.55
91 F41 42.35 46.80 37.85 40.93 49.58
92 F42 41.42 46.37 39.05 42.38 50.51
93 F43 42.37 47.07 37.55 46.91 41.37 48.07
94 F44 43.01 48.03 35.81 44.42 40.41 47.57
95 F45 43.16 46.00 40.93 46.11
96 F46 43.36 54.21 37.15 43.46 39.99 48.46
97 F47 44.52 35.86 42.15 42.20 49.72
98 F48 41.48 46.16 36.21 40.40 49.74
99 F49 41.96 46.97 39.51 41.34 51.02
100 F50 41.99 46.91 37.93 42.70 51.18
42.90 48.63 45.28 51.36 44.58 52.74
1.34 12.05 2.60
43.69 49.48 38.35 49.83 42.59 50.45
2.82 2.02 1.52
43.29 49.00 41.63 50.36 43.57 51.55
46.14 45.99 47.56
42.00 49.00 49.00 57.00 39.00 46.00












Tab.14: Paternally expressed gene 3 methylation data, section 4 
 
Run order Mouse No. Brain Bone marrow Testes
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
1 M1 42.83 50.80 40.49 47.51 17.28 24.75
11 M2 43.39 51.06 33.23 41.67
21 M3 41.76 50.13 41.94 16.66 24.70
31 M4 43.97 50.04 41.02 11.22
41 M5 42.11 48.98 37.75 19.19 24.90
51 M6 39.03 45.69 38.79 27.57 34.24
61 M7 43.48 49.64 40.62 41.83 53.05
71 M8 39.37 46.58 49.00 24.05 31.49
3 M9 45.37 54.33 42.31 17.17 24.19
13 M10 43.73 50.90 39.15 45.49 16.68 22.78
23 M11 47.61 39.77 47.95 18.01 25.53
33 M12 39.95 48.10 18.03 25.41
43 M13 56.96 61.88 40.81 49.14 16.50 27.93
53 M14 53.20 58.75 41.93 47.53 17.16 25.82
63 M15 42.00 50.03 38.72 44.94 17.73 26.08
73 M16 45.32 51.94 38.62 46.83 18.99 26.68
5 M17 45.02 52.65 41.19 46.84 18.15 25.11
15 M18 52.12 59.70 41.87 46.68 16.39 21.79
25 M19 44.28 50.74 42.03 16.86 24.48
35 M20 41.00 47.78 38.04 47.83 15.96 22.47
45 M21 43.17 50.60 40.66 47.71 21.97 28.73
55 M22 44.75 51.34 40.55 46.96 20.15 27.74
65 M23 44.03 50.75 39.78 46.47 16.41 23.20
75 M24 40.17 46.53 14.83 22.08
7 M25 45.23 52.54 40.84 45.14 14.59 73.02
17 M26 47.73 53.46 39.37 16.09 22.88
27 M27 49.23 57.38 38.56 46.23 49.64 56.74
37 M28 39.34 45.54 11.37 22.99
47 M29 42.88 49.03 38.44 46.21 12.34 22.41
57 M30 44.54 50.01 40.39 46.08 15.73 23.64
67 M31 42.41 48.75 38.01 13.48 21.37
77 M32 40.59 46.37 39.05 45.71 15.19 21.90
9 M33 40.14 46.06 13.89 21.00
19 M34 44.03 51.43 40.30 48.09 12.62 21.45
29 M35 43.26 49.33 39.14 45.86 16.78 23.76
39 M36 38.53 44.43 14.38 21.62
49 M37 41.87 49.14 38.81 44.13 14.12 21.13




Tab.14: Paternally expressed gene 3 methylation data, section 5 
Run order Mouse No. Brain Bone marrow Testes
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
69 M39 43.52 50.52 39.43 38.40 45.18
79 M40 43.88 49.76 38.18 21.08 28.39
81 M41 43.79 50.77 40.73 45.60 13.89 25.17
82 M42 41.87 49.65 42.29 47.96 15.03 22.77
83 M43 45.40 52.71 42.14 48.90 37.89 55.13
84 M44 43.39 52.02 41.95 50.65
85 M45 42.28 47.81 40.56 46.61 29.94 35.74
86 M46 43.46 51.63 45.33 51.07 16.01 23.44
87 M47 48.12 55.71 42.51 18.12 25.61
88 M48 54.27 16.16 24.04
89 M49 44.10 51.87 14.20 22.61
90 M50 43.50 51.94 38.58 44.24 17.61 26.77
2 F1 50.35 59.24 38.78 44.66
12 F2 39.56 48.67 41.57 46.84
22 F3 46.37 53.15 39.97 46.79
32 F4 38.91 47.31
42 F5 41.61 50.25 40.38 48.23
52 F6 52.72 58.01 39.30 46.64
62 F7 43.73 49.31 40.11 45.93
72 F8 53.10 59.32 40.01 47.09
4 F9 45.34 51.79 40.15 45.96
14 F10 51.26 61.01 40.96 46.72
24 F11 47.88 54.76 39.78 46.49
34 F12 46.18 52.91 42.54 49.47
44 F13 54.48 60.64 41.15 47.74
54 F14 48.20 41.85 48.05
64 F15 51.00 41.55 48.26
74 F16 53.11 57.53 42.16 48.83
6 F17 45.38 37.38 46.37
16 F18 52.30 61.74 41.95 48.44
26 F19 44.50 51.60 40.60 48.07
36 F20 45.13 52.75 40.21 48.23
46 F21 54.04 40.60 47.52
56 F22 50.63 56.49 39.91 45.94
66 F23 45.85 51.59 39.38 45.37
76 F24 40.81 47.05
8 F25 56.24 63.11 41.08 46.33
18 F26 44.59 52.04 39.82 47.20
28 F27 56.97 62.96 40.62 48.10
38 F28 39.82 47.42




Tab.14: Paternally expressed gene 3 methylation data, section 6 
Run order Mouse No. Brain Testes
48 F29 Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
58 F30 45.78 53.12 39.70
68 F31 46.55 53.14 40.60 46.09
78 F32 46.65 52.04 42.36
10 F33 41.92 50.34 42.83 46.73
20 F34 54.76 61.50 42.14 50.01
30 F35 42.02
40 F36 44.63 49.80 44.27 54.19
50 F37 51.34 56.75 41.73
60 F38 37.62 51.45
70 F39 48.28 40.14 47.65
80 F40 39.64 45.76 42.74 47.12
91 F41 42.84 51.08
92 F42 43.50 51.06
93 F43 41.63 49.35
94 F44 42.83 49.02




99 F49 49.72 58.61
100 F50 42.14
Mean males 51.33 40.67 46.81 19.89 29.04
SD Males 3.42 2.85 8.63
Mean females 54.22 40.76 47.38
SD Females 4.87 1.34
Mean both 52.69 40.71 47.10
Total Mean 26.34 43.91 24.46
Control M 45.00 54.00 41.00 48.00 39.00 55.00




Tab.14: Paternally expressed gene 3 methylation data, section 7 
 
Run order Mouse No. Tongue Muscles Heart
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
1 M1 77.02 51.98 57.96 47.41 57.62
11 M2 65.27 49.31 54.31 42.22 58.60
21 M3 73.22 46.12 50.48 48.50 61.70
31 M4 62.33 42.72 49.77 50.40 59.61
41 M5 73.61 82.16 45.53 51.48 46.85 55.07
51 M6 60.79 45.49 51.79 47.24 55.09
61 M7 56.86 46.29 53.43 46.19 54.76
71 M8 64.95 52.43 57.60 53.26 65.26
3 M9 50.15 54.54 45.54 54.15
13 M10 65.93 47.89 52.34 45.85 55.88
23 M11 64.99 47.22 51.87 49.49 59.89
33 M12 72.21 48.15 54.02 46.34 56.22
43 M13 65.21 46.17 54.10 46.39 57.37
53 M14 69.96 51.85 58.96 50.74 60.64
63 M15 61.11 49.31 58.77 45.33 53.40
73 M16 55.85 56.94 46.36 60.46
5 M17 54.12 47.74 57.26
15 M18 67.37 50.85 46.36 53.37
25 M19 74.63 53.04 49.44 58.27
35 M20 73.36 52.16 58.97 47.87 55.51
45 M21 58.07 49.88 47.56 57.44
55 M22 52.62 65.97 50.53 64.91
65 M23 52.15 51.24 45.10 55.91
75 M24 63.80 55.46 44.29 56.43
7 M25 73.60 47.69 44.42 55.35
17 M26 67.81 52.22 58.79 47.06 58.19
27 M27 68.90 51.06 61.00
37 M28 72.63 53.27 62.04 47.23 57.38
47 M29 71.33 53.79 58.63 45.00 61.72
57 M30 52.68 54.66 48.13 59.62
67 M31 58.59 50.96 39.84 51.59
77 M32 56.62 45.07 54.23
9 M33 66.39 48.56 56.18 41.80 49.42
19 M34 64.70 52.96 58.32 44.46 51.35
29 M35 63.57 50.19 46.55 60.54
39 M36 53.31 43.48 53.32
49 M37 52.53 50.55 45.20 54.62




Tab.14: Paternally expressed gene 3 methylation data, section 8 
 
Run order Mouse No. Tongue Muscles Heart
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
69 M39 53.99 60.64 40.95 51.65
79 M40 56.53 56.26 41.96
81 M41 70.85 51.14 57.35 56.87 69.10
82 M42 67.70 80.82 52.94 51.38
83 M43 52.67 57.53 64.33 42.34
84 M44 72.30 48.23 49.58 62.20
85 M45 71.83 78.15 53.00 49.92 64.73
86 M46 68.47 51.21 55.85 44.51
87 M47 67.40 48.02 43.99 63.10
88 M48 57.55 54.29 60.97 42.80 61.01
89 M49 68.12 75.33 52.33 61.17 45.60 62.92
90 M50 78.40 85.33 59.71 67.46 48.31
2 F1 64.36 41.70 59.17
12 F2 53.76 50.44 54.55 71.29
22 F3 51.50 50.08 46.97
32 F4 61.65 67.50 53.03 60.44
42 F5 53.77 63.17 58.10 60.36 53.75
52 F6 60.84 69.69 47.01 55.94
62 F7 57.38 67.52 46.68 60.13 43.69 56.26
72 F8 57.03 66.70 49.43 56.74 44.60
4 F9 52.37 62.89 62.74 47.68 55.96
14 F10 55.83 50.09 55.57 47.59 54.29
24 F11 51.57 54.45 47.35 61.16
34 F12 59.58 47.37 56.05 48.66
44 F13 64.26 47.70 57.74 45.71 57.31
54 F14 54.15 52.79 58.65 46.41 55.92
64 F15 52.49 47.80 48.31 57.59
74 F16 56.28 41.59 46.46 45.68 59.19
6 F17 56.28 46.35 53.21 40.61
16 F18 55.79 59.38 44.59 55.38
26 F19 57.55 47.94 53.38 47.14 55.46
36 F20 53.28 51.92 57.99 44.97 53.79
46 F21 59.68 43.74 49.01 45.32 54.79
56 F22 50.60 48.91 54.63 44.08 52.99
66 F23 48.95 55.17 44.11 52.36
76 F24 61.14 46.82 55.36 44.36 52.55
8 F25 60.51 46.85 53.43 44.50 54.42
18 F26 44.74 51.69 64.11
28 F27 57.22 42.11 47.44 48.20 60.61




Tab.14: Paternally expressed gene 3 methylation data, section 9 
 
Run order Mouse No. Tongue Muscles Heart
Primer 1 Primer 2 Primer 1 Primer 2 Primer 1 Primer 2
48 F29 51.81 45.48 52.71 42.55 55.08
58 F30 56.07 44.92 51.52 49.63 60.19
68 F31 51.41 49.97 43.90 55.08
78 F32 58.49 47.08 48.39 57.40
10 F33 69.58 50.70 57.70 44.47 52.07
20 F34 59.36 46.40 59.53
30 F35 43.45 49.22 48.95 57.59
40 F36 46.56 51.59 49.37 58.33
50 F37 48.91 56.41 48.73 56.67
60 F38 51.43 44.86 50.35 46.70 54.09
70 F39 49.57 47.36 53.64 45.78 54.82
80 F40 48.47 55.78 47.27 56.28
91 F41 55.85 45.60 58.81 47.50 57.31
92 F42 46.14 46.46 55.78 45.34 54.86
93 F43 57.34 51.20 61.19 45.45 56.64
94 F44 60.52 43.34 45.35 57.13
95 F45 51.12 46.69 55.22 46.49 58.36
96 F46 53.51 50.73 42.50 53.21
97 F47 58.02 48.10 53.96 46.00 56.75
98 F48 52.54 55.25 62.24 42.97 62.93
99 F49 48.17 54.49 61.65 48.62 63.54
100 F50 49.42 50.01 56.42 43.51 57.81
64.67 80.36 51.39 56.86 46.58 57.81
7.51 4.13847 3.25
55.54 66.72 47.11 57.00
4.29 3.98
60.31 72.40 46.84 57.42
66.36 52.13
46.00 54.00 41.00 51.00























11 Appendix 2, Correlation of methylation between different loci within 
one tissue, complete data 
 
Analysed data has been compiled into Excel tables. It is all presented in Tab.14.1-22.2. 
While the raw data was sorted by the fragment analysed, the end result is sorted by the 
tissue. In these tables, the Pearson correlation coefficient, mean deviation and number 
of samples analysed for each sex is presented (males and females were analysed 
separately). 
172 
Tab.15 and 16: Male bone marrow. Correlation observed between: LINE-1-MyLC (both 
primers) 
 15 
Males MYC LIT1 PEG3
SN1 SN2 SN1 SN2 SN1 SN2
A Actin -0.1183 0.26209 0.28854 0.22727 -0.2189 0.0587
0.4336 0.082 0.0575 0.1427 0.1534 0.7456
46 45 44 43 44 33
MYC 0.10046 0.36704 0.09888 0.03857
0.5165 0.0168 0.5181 0.8312








Male SNRPND1 IAP L1
A Actin SN1 SN2 SN1 SN2 SN1 SN2
0.31677 0.24223 0.04568 -0.0778 -0.1494 0.09929
0.0494 0.2332 0.7631 0.6156 0.3162 0.5115
39 26 46 44 47 46
MYC 0.20285 0.13757 0.25232 0.41157 0.606 0.55107
0.2219 0.512 0.0907 0.005 <.0001 <.0001
38 25 46 45 48 48
LIT1 0.12008 0.38968 0.12891 0.23556 0.08899 0.25157
0.479 0.0491 0.41 0.1332 0.561 0.1037
37 26 43 42 45 43
PEG3 -0.067 -0.1236 0.24168 0.29867 0.07514 -0.0143
0.6852 0.5562 0.1097 0.0913 0.6197 0.936
39 25 45 33 46 34
SNRPND1 0.32027 -0.1201 0.28886 0.41274
0.0468 0.5589 0.0745 0.0361







Tab.17 and 18: Female bone marrow. Correlation observed between Iap-MyLC (both 
primers) and Iap-LINE-1 (both primers)  
17 
Female MYC LIT1 PEG3
SN1 SN2 SN1 SN2 SN1 SN2
A Actin 0.00246 0.09272 0.22446 0.16496 -0.1893 -0.2449
0.9869 0.5354 0.1251 0.2733 0.2485 0.1563
47 47 48 46 39 35
MYC -0.1814 0.27025 0.06298 0.28895
0.2223 0.0726 0.7033 0.0923







Female SNRPND1 IAP L1
SN1 SN2 SN1 SN2 SN1 SN2
A Actin -0.1496 0.24452 -0.0864 0.2458 0.0379 0.11163
0.3506 0.2098 0.5594 0.0922 0.8003 0.455
41 28 48 48 47 47
MYC 0.30871 0.28016 0.70082 0.59966 0.64942 0.25718
0.0467 0.1487 <.0001 <.0001 <.0001 0.0776
42 28 49 48 48 48
LIT1 -0.2146 0.2919 -0.1263 0.58577 -0.2867 0.2059
0.1779 0.1318 0.3922 <.0001 0.0507 0.1748
41 28 48 46 47 45
PEG3 0.3457 0.10271 -0.0007 0.09555 0.1694 0.21518
0.0311 0.6176 0.9965 0.585 0.3093 0.2216
39 26 39 35 38 34
SNRPND1 0.25365 0.02291 0.28589 0.14074
0.105 0.9079 0.07 0.4838






Tab.19 and 20: Male brain: Correlation observed between: Peg3-A Actin (both primers), 
SnrpnD1-A Actin (primer 1), SNPRD1-MyLC (primer 1), SNPRND1-Peg3 (primer 1)  
19 
Male MYC LIT1 PEG3
SN1 SN2 SN1 SN2 SN1 SN2
A Actin -0.5239 -0.3416 -0.483 -0.2513 0.73014 0.75344
0.0003 0.025 0.0009 0.0998 <0.0001 <.0001
43 43 44 44 43 42
MYC - 0.26833 0.04429 -0.5226 -0.311
0.0858 0.7806 0.0005 0.0508







Male SNRPND1 IAP L1
SN1 SN2 SN1 SN2 SN1 SN2
A Actin 0.75479 0.28035 0.17475 0.11446 0.24946
<.0001 0.2312 0.2566 0.454 0.0984
37 20 44 45 45
MYC -0.7045 -0.3247 -0.1839 -0.0011 -0.0495
<.0001 0.1625 0.2436 0.09943 0.7526
37 20 42 43 43
LIT1 -0.7045 -0.3521 0.5157 0.05444 0.23387
<.0001 0.1279 0.0003 0.7225 0.122
37 20 44 45 45
PEG3 0.70027 0.41589 0.11895 -0.0189 0.20687
<.0001 0.0766 0.4589 0.9043 0.1887
35 19 41 43 42





Tab.21 and 22: Female brain: Correlation observed between: A-Actin-MYC (Primer 2), A 
Actin-Peg3 (primer 2), Peg3-SnrpnD1 (primer 1) 
21 
Female A Actin MYC LIT1 PEG3
SN1 SN2 SN1 SN2 SN1 SN2 SN1 SN2
A Actin -0.4963 -0.6102 -0.2432 -0.0764 0.47698 0.70936
0.0005 <.0001 0.1074 0.6177 0.0011 <.0001
45 44 45 45 44 36
MYC -0.0182 -0.0479 -0.3443 -0.4651
0.9035 0.7546 0.0191 0.00037







Female SNRPND1 IAP L1
SN1 SN2 SN1 SN2 SN1 SN2
A Actin 0.42094 0.12843 0.04904 -0.0612 0.18368
0.0118 0.6483 0.749 0.6897 0.2271
35 15 45 45 45
MYC -0.2497 0.32187 0.03146 -0.0288 0.09864
0.142 0.242 0.8374 0.8478 0.5192
36 15 45 47 45
LIT1 -0.063 -0.1021 0.50545 0.17759 0.26377
0.7152 0.7174 0.0003 0.2324 0.0732
36 15 47 47 47
PEG3 0.65868 0.52023 0.40183 0.2783 0.29167
<.0001 0.0565 0.0137 0.0611 0.0798
35 14 37 46 37








Tab.23 and 24: _Male heart: Correlation observed between MyLC-Lit1 (primer 2), MyLC-
LINE-1 (primer 1)  
23 
Male MYC LIT1 PEG3
SN1 SN2 SN1 SN2 SN1 SN2
A Actin 0.21843 -0.0171 0.28205 -0.2249 -0.0407 0.50092
0.1275 0.9518 0.0496 0.4395 0.7812 0.0005
50 15 49 14 49 45
MYC 0.48272 14 0.08095 0.11772
0.0004 0.57195 0.5803 0.4412
49 <.0001 49 45







Male SNRPND1 IAP L1
SN1 SN2 SN1 SN2 SN1 SN2
A Actin 0.27003 -0.0316 0.23942 0.64879 0.13716 0.32901
0.0606 0.9109 0.094 0.0089 0.3422 0.2311
49 15 50 15 50 15
MYC 0.23762 -0.0142 0.45165 0.25373 0.55408 0.28047
0.1002 0.3306 0.001 0.0754 <.0001 0.0485
49 49 50 50 50 50
LIT1 0.172 0.10334 0.20466 0.17872 0.07015 -0.0833
0.2424 0.4846 0.1584 0.2192 0.632 0.5691
48 48 49 49 49 49
PEG3 0.20212 0.50092 -0.1748 -0.176 -0.2328 -0.3188
0.1683 0.0005 0.2297 0.2474 0.1074 0.0328
48 45 49 45 49 45
SNRPND1 0.04364 0.06374 -0.0549 -0.1953
0.7659 0.6635 0.7077 0.1786






Tab.25 and 26: Female heart: Correlation observed between Peg3-SnrpnD1 (primer 2) 
 
25 
Female MYC LIT1 PEG3
SN1 SN2 SN1 SN2 SN1 SN2
0.07085 0.21108 0.10606 0.22972 0.21344 0.18608
0.664 0.6881 0.483 0.6202 0.1544 0.6895
40 6 46 7 46 7
MYC 0.18892 0.10593 -0.1449 0.23444
0.243 0.5153 0.3723 0.1752










Female SNRPND1 IAP L1
SN1 SN2 SN1 SN2 SN1 SN2
A Actin 0.02792 -0.218 0.12057 0.04575 0.00425 0.25413
0.8539 0.6782 0.4143 0.9224 0.9774 0.5824
46 6 48 7 47 7
MYC 0.00712 0.2248 0.14669 0.18707 -0.0585 0.43557
0.9657 0.1689 0.3539 0.2355 0.7127 0.0044
39 39 42 42 42 41
LIT1 0.45314 0.25378 0.09616 0.43176 -0.184 0.12509
0.0018 0.0925 0.5156 0.0022 0.2156 0.4075
45 45 48 48 47 46
PEG3 0.3313 0.60354 0.27379 -0.0614 0.3181 0.22766
0.0262 <.0001 0.0597 0.6991 0.0293 0.1523
45 40 48 42 47 41
SNRPND1 0.30716 0.25434 0.21125 0.34004
0.0357 0.0845 0.1588 0.0223










Male MYC LIT1 PEG3
SN1 SN2 SN1 SN2 SN1 SN2
A Actin 0.38756 0.37505 0.21278 0.37954 0.16083 -0.0723
0.0259 0.0709 0.2678 0.0674 0.4136 0.7828
33 24 29 24 28 17
MYC 0.25173 0.33272 0.11503 0.13431
0.1796 0.0778 0.545 0.5512









Male SNRPND1 IAP L1
SN1 SN2 SN1 SN2 SN1 SN2
A Actin -0.138 0.38214 0.04215 -0.006 0.24929 0.71332
0.4838 0.3101 0.8158 0.9779 0.1618 <.0001
28 9 33 24 33 24
MYC -0.1814 -0.0492 0.10373 0.09022 0.34125 0.4509
0.3463 0.9 0.5297 0.5849 0.0335 0.004
29 9 39 39 39 39
LIT1 0.17236 -0.2217 -0.099 0.04416 0.4551 0.31936
0.3713 0.5664 0.6029 0.8201 0.0115 0.0913
29 9 30 29 30 29
PEG3 0.49079 -0.4885 -0.0712 -0.0623 0.27137 -0.265
0.008 0.3256 0.7086 0.7832 0.1469 0.2333
28 6 30 22 30 22
SNRPND1 -0.3925 0.07454 0.10801 0.35138
0.0352 0.8489 0.577 0.3538










Female MYC LIT1 PEG3
SN1 SN2 SN1 SN2 SN1 SN2
A Actin 0.13525 -0.164 0.02498 0.13023 0.0086 0.07505
0.3757 0.3466 0.8676 0.449 0.9537 0.6934
45 35 47 36 48 30
MYC 0.31851 0.31817 0.0039 0.15224
0.031 0.04 0.9797 0.3684









Female SNRPND1 IAP L1
SN1 SN2 SN1 SN2 SN1 SN2
A Actin -0.1999 0.38938 0.01987 -0.2426 -0.0289 -0.0502
0.1731 0.1102 0.9032 0.2048 0.8439 0.7647
48 18 40 29 49 38
MYC -0.1192 0.19114 0.20474 0.0329 -0.1976 0.1702
0.4353 0.4331 0.2242 0.8489 0.1881 0.2581
45 19 37 36 46 46
LIT1 -0.1188 0.13552 0.17541 0.00756 -0.0514 0.21585
0.4265 0.5581 0.2855 0.9661 0.7284 0.1594
47 21 39 34 48 44
PEG3 0.1781 0.65216 -0.1545 -0.3111 0.05895 0.04791
0.2259 0.0084 0.3412 0.0831 0.6874 0.7721
48 15 40 32 49 39
SNRPND1 -0.198 -0.3894 0.28842 -0.1419
0.2207 0.1688 0.0445 0.5396






Tab.31 and 32: Male skeletal muscle: Correlation observed between: MyLC-SnrpnD1 




Male MYC LIT1 PEG3
SN1 SN2 SN1 SN2 SN1 SN2
A Actin -0.0396 0.04384 -0.135 -0.1594 -0.0111 0.29352
0.8059 0.8503 0.3765 0.4786 0.9444 0.2091
41 21 45 22 42 20
MYC 0.25266 0.13286 -0.4117 -0.1954
0.111 0.4398 0.0092 0.3387









Male SNRPND1 IAP L1
SN1 SN2 SN1 SN2 SN1 SN2
A Actin -0.0541 0.21014 0.00294 0.18902 -0.0142 -0.4994
0.7405 0.3479 0.9845 0.3995 0.9244 0.0153
40 22 46 22 47 23
MYC 0.98645 0.67349 0.05843 -0.1204 0.0623 0.25795
<.0001 <.0001 0.7132 0.4777 0.6915 0.1179
41 36 42 37 43 38
LIT1 0.2586 0.04666 -0.0055 -0.2219 0.17751 -0.0706
0.1071 0.7839 0.9713 0.1383 0.2326 0.6373
40 37 46 46 47 47
PEG3 -0.3782 -0.1726 -0.3021 0.45033 -0.0259 -0.2214
0.0192 0.3894 0.0463 0.0162 0.8674 0.2575
38 27 44 28 44 28
SNRPND1 0.0395 -.0.05784 0 -0.0445
0.8063 0.7301 1 0.788






Tab.33 and 34: Female skeletal muscle: Correlation observed between MyLC and 




Female MYC LIT1 PEG3
SN1 SN2 SN1 SN2 SN1 SN2
A Actin 0.23251 0.36067 0.28008 -0.1772 0.10694 0.4155
0.2003 0.226 0.0594 0.4303 0.4694 0.0769
32 13 46 22 48 19
MYC 0.02349 0.0477 0.11813 -0.0694
0.8985 0.7989 0.5268 0.759









Female SNRPND1 IAP L1
SN1 SN2 SN1 SN2 SN1 SN2
A Actin 0.03959 0.36067 0.17996 0.36067 0.0418 0.25919
0.8325 0.226 0.216 0.226 0.7755 0.2324
31 13 49 13 49 23
MYC 0.86849 1 0.1214 -0.303 0.08005 0.09426
<.0001 <.0001 0.508 0.0976 0.6632 0.614
31 31 32 31 32 31
LIT1 -0.035 0.0477 0.00497 -0.0549 0.007 -0.2292
0.8518 0.7989 0.9739 0.714 0.9632 0.1213
31 31 46 47 46 47
PEG3 0.17531 -0.0694 0.12122 0.24071 0.12549 0.16762
0.3541 0.759 0.4118 0.1637 0.3954 0.3358
30 22 48 35 48 35
SNRPND1 0.01237 -0.303 0.27692 0.09426
0.9473 0.0976 0.1315 0.614










Male SN1 SN2 SN1 SN2 SN1 SN2
A Actin -0.0426 -0.4358 0.21129 -0.346 0.25877 -0.4871
0.781 0.2081 0.1686 0.3274 0.0861 0.1534
45 10 44 10 45 10
MYC -0.0847 0.25239 -0.0991 0.32961
0.5714 0.0906 0.5027 0.0253











Male SN1 SN2 SN1 SN2 SN1 SN2
A Actin 0.15343 -0.3015 0.09528 0.16048 0.35472 0.42252
0.3259 0.4681 0.5384 0.6579 0.0181 0.2572
43 8 44 10 44 9
MYC -0.1323 0.39836 -0.1356 -0.2107 -0.2653 0.31264
0.381 0.1016 0.3634 0.1598 0.0715 0.0324
46 18 47 46 47 47
LIT1 0.47415 0.49975 0.07625 0.23804 0.29484 0.25629
0.0009 0.0347 0.6145 0.1153 0.0467 0.0892
46 18 46 45 46 45
PEG3 0.28966 0.21591 0.01471 0.04782 0.01032 0.18245
0.0509 0.3895 0.9218 0.7579 0.9451 0.2303
46 18 47 44 47 45
SNRPND1 0.13008 0.03359 0.02845 -0.1403
0.3944 0.8947 0.8528 0.5911






Tab.37 and 38: Female skin. No correlation observed. 
37 
MYC LIT1 PEG3
Female SN1 SN2 SN1 SN2 SN1 SN2
A Actin 0.05313 0.10294 -0.1617 -0.108 -0.0024 -0.0919
0.7199 0.6485 0.2724 0.6324 0.9869 0.6841
48 22 48 22 48 22
MYC -0.1152 -0.1611 -0.2 0.00862
0.4257 0.2636 0.1637 0.9526











Female SN1 SN2 SN1 SN2 SN1 SN2
A Actin 0.26697 0.49811 0.07777 -0.0956 0.11346 -0.426
0.0666 0.1724 0.5993 0.6722 0.4477 0.048
48 9 48 22 47 22
MYC -0.2921 0.14644 -0.0037 0.03165 -0.1364 -0.0753
0.0396 0.6174 0.9799 0.8273 0.3502 0.6032
50 14 50 50 49 50
LIT1 0.12371 0.08765 -0.0862 0.04826 0.18852 0.10789
0.392 0.7657 0.5515 0.7393 0.1945 0.4558
50 14 50 50 49 50
PEG3 0.2232 0.22768 0.11011 0.23597 0.12275 0.15083
0.1192 0.4337 0.4465 0.099 0.4008 0.2958
50 14 50 50 49 50
SNRPND1 0.01702 -0.056 0.22893 -0.056
0.9066 0.8493 0.1136 0.8491






Tab.39 and 40: Male spleen. Correlation observed between: MyLC-Iap (primer 1), 





Male SN1 SN2 SN1 SN2 SN1 SN2
A Actin 0.27323 0.14417 0.26855 0.23212 0.19925 0.21837
0.0549 0.3878 0.0621 0.1668 0.1699 0.1878
50 38 49 37 49 38
MYC -0.0548 -0.1373 0.07083 0.27261
0.7082 0.3468 0.6287 0.0554









Male SN1 SN2 SN1 SN2 SN1 SN2
A Actin 0.30653 0.19455 0.31087 0.04019 0.4526 0.12419
0.0341 0.2486 0.0297 0.8133 0.001 0.4576
48 37 49 37 50 38
MYC 0.41864 0.33787 0.88058 0.35375 0.80881 0.83874
0.0031 0.0176 <.0001 0.0126 <.0001 <.0001
48 49 49 49 50 50
LIT1 0.30121 0.24379 -0.0628 0.12932 0.18845 0.07034
0.0396 0.095 0.6714 0.381 0.1947 0.631
47 48 48 48 49 49
PEG3 0.0994 0.14103 0.31714 0.17283 0.24514
0.5062 0.339 0.0264 0.235 0.0862
47 48 49 49 50
SNRPND1 0.53271 0.26091 0.58886 0.51953
0.0001 0.0733 <.0001 0.0001






Tab.41 and 42: Female spleen. Correlation observed between MyLC-SnrpnD1 (primer 
1), MyLC-Iap (primer 1), MyLC-LINE-1 (both primers), SnrpnD1-Iap (primer 1),SnrpnD1-





Female SN1 SN2 SN1 SN2 SN1 SN2
A Actin 0.14683 0.226 0.08649 0.03397 0.17778 0.58816
0.3416 0.2998 0.5767 0.8777 0.2427 0.0032
44 23 44 23 45 23
MYC 0.27008 0.09327 0.31496 0.48993
0.0728 0.5422 0.033 0.0018










Female SN1 SN2 SN1 SN2 SN1 SN2
A Actin 0.143 0.19506 0.22573 0.1548 0.19193 0.0636
0.3603 0.3724 0.1407 0.4915 0.212 0.7731
43 23 44 22 44 23
MYC 0.6426 0.35418 0.83195 0.38112 0.90428 0.75517
<.0001 0.017 <.0001 0.0107 <.0001 <.0001
44 45 45 44 45 45
LIT1 0.02568 -0.0288 0.2536 0.28194 0.27244 0.2739
0.8655 0.8477 0.0928 0.0637 0.0639 0.0625
46 47 45 44 47 47
PEG3 0.01631 -0.0086 0.42768 0.24839 0.17962 0.24397
0.9153 0.9594 0.003 0.1441 0.2323 0.1456
45 38 46 36 46 37
SNRPND1 0.60696 0.24293 0.61539 0.43357
<.0001 0.1121 <.0001 0.0023







Tab.43 and 44: Male tongue. Correlation obserwed between Peg3 and SnrpnD1 in 
primer 1.  
43 
MYC LIT1 PEG3
Males SN1 SN2 SN1 SN2 SN1 SN2
A Actin 0.06528 -0.1215 0.29446 0.50829 0.26265
0.6664 0.722 0.0496 0.0915 0.0745
46 11 45 12 47
MYC -0.3785 0.03756 0.11049 0.95975
0.0103 0.818 0.4597 0.0096









Males SN1 SN2 SN1 SN2 SN1 SN2
A Actin 0.31275 0.21698 -0.0234 0.18518 0.31659
0.0323 0.4982 0.8758 0.5645 0.0302
47 12 47 12 47
MYC 0.13986 0.28897 -0.0336 0.32032 0.29875
0.3485 0.1087 0.8224 0.0412 0.0414
47 32 47 41 47
LIT1 -0.0765 0.29545 0.04873 -0.0647 0.12503
0.6134 0.0849 0.7477 0.673 0.4077
46 35 46 45 46
PEG3 0.97609 0.65545 0.17151 -0.0202 0.0334
<.0001 0.2298 0.2438 0.9743 0.8198
50 5 48 5 49








Tab.45 and 46: Female tongue. Correlation obserwed between: Lit1 and SnrpnD1 in 
primer 2.  
45 
MYC LIT1 PEG3
Female SN1 SN2 SN1 SN2 SN1 SN2
A Actin 0.11563 0.42615 0.07417 0.17506 0.36341
0.4716 0.0267 0.6125 0.3462 0.4789
41 27 49 31 6











Female SN1 SN2 SN1 SN2 SN1 SN2
A Actin 0.06313 -0.3431 -0.208 -0.3926
0.7544 0.017 0.2614 0.0058
27 48 31 48
MYC 0.32142 0.18182 0.26203 0.41362
0.0524 0.2552 0.0937 0.0072
37 41 42 41
LIT1 0.59557 -0.1089 -0.0272 -0.1891
<.0001 0.4564 0.8512 0.1932












Tab.47 and 48: Testes: Correlation obserwed between: A Actin-Lit1 (both primers), A 
Actin-Peg3 (both primers), A Actin-SnrpnD1 (both primers), A Actin-Iap (primer 1),  Lit1-
Peg3 (both primers), Lit1-SnrpnD1 (both primers), Lit1-Iap (primer 1), SnrpnD1-Peg3 
(bothprimers), SnrpnD1-Iap (primer1). Most likely due to general unspeciffic 
hypomethylation in the testis. 
47 
MYC LIT1 PEG3
SN1 SN2 SN1 SN2 SN1 SN2
A Actin 0.14162 0.00307 -0.9444 -0.9263 -0.9676 -0.7591
0.3478 0.9839 <.0001 <.0001 <.0001 <.0001
46 46 46 12 50 49
MYC -0.0941 0.31703 -0.1383 0.00441
0.5341 0.3154 0.3595 0.9771








SN1 SN2 SN1 SN2 SN1 SN2
A Actin -0.967 -0.975 -0.7799 -0.3152 -0.3492 -0.4122
<.0001 <.0001 <.0001 0.0329 0.0129 0.0029
50 50 48 46 50 50
MYC -0.1158 0.0038 0.13959 0.12422 0.18425 0.27494
0.4433 0.98 0.3662 0.4332 0.2203 0.0644
46 46 44 42 46 46
LIT1 0.90987 0.94838 0.83128 0.10713 0.38361 0.68777
<.0001 <.0001 <.0001 0.7539 0.0085 0.0134
46 12 44 11 46 12
PEG3 0.97609 0.76286 0.76277 0.16785 0.33446 0.27345
<.0001 <.0001 <.0001 0.2704 0.0176 0.0573
50 49 48 45 50 49
SNRPND1 0.78227 0.29634 0.35985 0.41107
<.0001 0.0455 0.0103 0.003
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